Resotech Polymer Solutions (RPS) — Medical-grade bioresorbable polymers and semi-finished resorbable forms (B2B materials supply) Opportunity Dossier

§01

Executive Summary

The binding constraint on RPS is not money movement but goods origin: the Dubai and Delaware entities let the company be paid and contract almost anywhere, yet every kilogram still originates in Ulyanovsk, which is what customs, tariffs, origin declarations and ISO 13485 site audits actually test. That single fact closes the two markets the blended scores flatter most — Ireland/EU, where Reg. (EU) 833/2014 Art. 3i and Annex XXI Part B prohibit the buyer from importing these CN codes with no medical carve-out, and the United States, where Column 2 duty of 15.4c/kg + 45% (vs 6.5% MFN) and 40% on sterile absorbable suture material erase the price wedge for an LTV/CAC of 2.0 and a 3-year ROI of -120%. The credible strategy is therefore to win where origin does not disqualify: the Russian home market (210 realistic buyers, no origin barrier, the four highest-scoring country x segment cells), Kazakhstan inside the EAEU (~$45k entry, 7-month payback, no customs border), and the research, veterinary, aesthetics and domestic-only-filing niches that sit outside the Western regulatory machinery. Sequence: fund Kazakhstan first because it is the only entry a company with ~1.6M RUB revenue and a -24M RUB result can write unaided, run Russia concurrently as home ground with its $400k staged across the 12-30-month qualification cycle, and defer India's $300k until cash exists. The biggest caveat is concentration risk on both flanks: Kazakhstan's case rests on a single account (TOO RuMa Farm), and Russia is not an empty field — NPK Novokhim sells the identical import-substitution pitch with Russian excipient certification and there is no evidence Western supply ever stopped.

Markets ranked — best first

#	Market	Verdict
1	🇮🇳 India	Consider
2	🇰🇿 Kazakhstan	Go
3	🇷🇺 Russia	Go
4	🇺🇸 United States	Avoid
5	🇮🇪 Ireland	Avoid
6	🇨🇳 China	Avoid
7	🇹🇷 Turkey	Consider

The market in four numbers

Total market worldwide

$1.9B

what everyone spends on this per year ("TAM")

Market growth per year

11%

expected yearly growth ("CAGR")

Part we could serve

$660M

buyers matching this product and model ("SAM")

Best market to enter

🇮🇳 India

55 / 100

§02

Global Market Overview

Medical-grade bioresorbable polymers and semi-finished resorbable forms (B2B materials supply). The market for synthetic bioresorbable (absorbable) polymers made from cyclic esters — PLLA, P(D,L)LA, PGA, PGLA/PLGA, PCL, PLCL — manufactured to medical/pharmaceutical grade and sold business-to-business as an input to someone else's product. Buyers are medical device OEMs, pharmaceutical and CDMO formulators, aesthetic injectable makers and research groups; they buy resin/granulate to a specified molecular weight, L/D ratio, inherent viscosity, end-group chemistry and degradation window (roughly 6 months to 5 years), or they buy the same chemistry already converted into a semi-finished form (fibre and surgical thread, extruded tubing, cast film, microspheres, 3D-printing filament). Fee-based contract R&D and device-development work sold alongside the material sits inside this market when it is a route to a material supply agreement. Commercially the market is quotation-based with no public pricing, long qualification cycles, and purchase decisions driven by regulatory documentation (GMP/ICH Q7, ISO 13485, ISO 10993 biocompatibility, drug/device master files) as much as by price. Incumbent supply is concentrated in a small number of Western producers — Evonik (RESOMER, LACTEL), Corbion (PURASORB), Poly-Med, Ashland (Viatel) and catalogue resellers such as Merck/Sigma-Aldrich — which makes second-source qualification and regional supply security a live buyer concern. Resotech Polymer Solutions has evidenced commercial presence in Russia only, a market where medical-grade polymer supply has historically been almost entirely imported (Russian trade press reported in late 2024 that under a third of the polymer grades the medical industry needs are produced domestically); separately, market digests citing 2020 customs data report no domestic commodity polylactide capacity and imports led by Germany. That import dependence is the specific gap RPS occupies. No market-size figure is asserted here: published estimates for this niche differ by roughly fivefold between vendors and several conflate medical resorbables with industrial PGA and commodity bioplastics.

What counts as this market

Medical- and pharmaceutical-grade bioresorbable polyester resins from cyclic esters: PLLA, P(D,L)LA, PDLA, PGA, PLGA/PGLA, PCL, PLCL and related copolymers
Custom synthesis to specified molecular weight / inherent viscosity, lactide-to-glycolide and L/D ratio, and terminal group chemistry (acid- vs ester-terminated)
Semi-finished converted forms sold as inputs to device and pharma makers: multifilament and monofilament fibre and undyed surgical thread, extruded tubing for stents and scaffolds, cast or extruded anti-adhesion and barrier film, drug-loaded or blank microspheres, and 3D-printing filament
GMP / ISO 13485 grade material supplied with the regulatory dossier a customer needs (CoA, biocompatibility data, master-file or equivalent support)
Research and pilot-scale lots, including small custom batches sold to academic and corporate R&D groups
Fee-based contract R&D, formulation and device-development services sold by the polymer producer as a route to material supply
Regional and second-source supply of these polymers where the incumbent supply is imported

What does not

Finished, sterile, registered medical devices sold to hospitals, distributors or end users — packaged absorbable sutures, hernia meshes, screws and anchors, stents, anti-adhesion sheets. The boundary is: semi-finished forms sold as an input are IN; anything sterile, registered and sold to a care setting is OUT
Finished pharmaceutical products and finished aesthetic injectables (the marketed depot, the boxed filler), as distinct from the polymer that goes into them
Non-resorbable medical polymers: polyethylene, PEEK, silicone, polyurethane, PTFE/ePTFE, polypropylene mesh, PVC and other permanent implant or disposables materials
Commodity and industrial bioplastics: packaging and 3D-printing PLA, compostable food service and agricultural film, and industrial polyglycolic acid for oil-and-gas downhole tools — chemically adjacent, entirely different buyer, specification and price point
Non-polymer resorbable implant materials that compete for the same device slots: magnesium and zinc alloys (e.g. magnesium coronary scaffolds), calcium phosphate, hydroxyapatite and bioactive glass ceramics
Natural and non-polyester biopolymers: collagen, gelatin, chitosan, alginate, hyaluronic acid fillers, oxidised regenerated cellulose haemostats, silk and PHA/PHB
Polydioxanone (PDO/PDS) and other resorbable chemistries outside the cyclic-ester portfolio described here — notably PDO monofilament thread-lift and suture products
Upstream monomer and feedstock supply: lactic acid, lactide, glycolide and caprolactone production sold as chemicals (RPS polymerises from cyclic esters; the monomer market is a separate upstream business)
Standalone contract manufacturing services with no polymer supply attached: device CDMO assembly, contract sterilisation, fill-finish and packaging
Bioresorbable metal or ceramic powders for additive manufacturing

Market state

Life stage

Growing

Direction

Growing

Neighboring markets

What customers use it for

Problems this market exists to solve

Single-source dependence on a small group of Western producers, with no qualified second source if supply, logistics, export control or sanctions interrupt it
For Russian and other non-Western buyers specifically: medical-grade resorbable polymer has been almost entirely imported, with foreign-exchange, payment, customs and lead-time exposure on every lot
Catalogue grades do not match the required degradation window; buyers need a specific molecular weight, L/D or lactide:glycolide ratio and end-group chemistry that no standard product offers
Batch-to-batch variability in inherent viscosity, residual monomer or end groups shifts a validated release profile or strength-retention curve and can force re-validation
Regulatory documentation burden: without GMP/ICH Q7 manufacture, ISO 13485, ISO 10993 biocompatibility data and master-file support, a material cannot be designed into a filing at all
Very long and expensive qualification cycles, which raise switching costs and make buyers reluctant to change supplier once designed in
High minimum order quantities and long lead times from incumbents, which block small developers and early-stage R&D
Cost of imported GMP polymer as a share of finished-device cost, especially in price-regulated or tender-driven procurement markets
Processing difficulty: resorbable polyesters are hydrolytically and thermally sensitive, so drying, melt processing, sterilisation and shelf-life all need supplier know-how the buyer often lacks
Sterilisation compatibility — gamma and EtO both affect molecular weight and degradation behaviour and must be validated with the specific grade
Clinical risk from mismatched resorption: late inflammatory response, sterile sinus, osteolysis or premature loss of strength if the polymer profile is wrong for the indication
Small buyers cannot access development support, so they need a supplier that will do formulation and device R&D as a paid service
Traceability and supply-chain audit requirements imposed by device notified bodies and pharma quality systems on every raw-material supplier

§03

Global Market Size & Growth

Total market worldwide

$1.9B

if every potential buyer bought — analysts call this "TAM"

our estimate · medium confidence^{[gm-01] [gm-02] [gm-03] [gm-04] [gm-05]}

Part we could serve

$660M

buyers that match this product and business model ("SAM")

our estimate · low confidence^{[gm-01] [gm-06] [gm-08] [gm-09]}

Realistic 3-year target

$5M

what's obtainable given budget and presence ("SOM")

our estimate · low confidence^{[gm-01] [gm-06] [gm-10]}

Market size, history and forecast

USD; the dashed part of the line is the forecast — later years are estimates

What pushes the market up

Long-acting injectable pharmaceuticals: PLGA and PLA microsphere and implant depots have moved from experimental excipient to clinically validated platform for oncology, CNS, hormonal and infectious-disease therapies, pulling merchant demand for high-purity, tightly specified copolymer grades (PLGA excipient market growing at ~12% CAGR).
Ageing populations and rising surgical volumes worldwide, particularly orthopaedic trauma, spine and sports-medicine fixation, where resorbable screws, pins, anchors and interference devices displace metal and avoid removal surgery.
Shift to minimally invasive procedures, which favours resorbable meshes, tacks, staple-line reinforcements and knotless closure devices over permanent implants.
Boom in aesthetic collagen-stimulating injectables based on PLLA and PCL microspheres, a segment with far shorter regulatory cycles than implants and rapidly growing volumes in Asia, Latin America and the Middle East.
Regenerative medicine and tissue-engineering scaffolds, plus medical 3D printing / bioprinting, creating demand for resorbable filament, custom-molecular-weight resins and small development lots.
Substitution away from non-resorbable polymers driven by clinician preference for implants that leave nothing behind, and by post-market pressure on permanent mesh and fixation hardware.
Healthcare infrastructure build-out and domestic medtech manufacturing programmes in Asia-Pacific (China, India, South Korea) and the Gulf, expanding the manufacturing base that buys these resins.
Fragmented supply base (Mordor rates concentration only 'medium'), leaving room for specialist and regional suppliers alongside Evonik, Corbion, Ashland, Foster and Poly-Med.

What could hold it back

Very high cost versus conventional non-degradable medical polymers, driven by ultra-pure lactide/glycolide monomer, controlled-atmosphere ring-opening polymerisation and implant-grade QA - a persistent brake on adoption in price-sensitive markets and high-volume applications.
Supplier requalification burden: changing resorbable resin supplier forces re-validation of biocompatibility and degradation profile and often a regulatory file change, so incumbent grades (RESOMER, PURASORB) are locked in for years and new entrants face long design-in cycles.
Regulatory intensity - EU MDR, FDA implantable pathways, NMPA - raising the cost and time of qualifying both new polymer grades and the devices made from them; master-file support (DMF/MAF) is effectively table stakes for suppliers.
Setbacks in bioresorbable coronary scaffolds after the Absorb withdrawal, which removed the single largest anticipated volume driver and continues to depress the cardiovascular sub-segment relative to mid-2010s forecasts.
Technical limitations of the chemistry itself: hydrolytic instability requiring cold-chain and moisture-controlled storage, limited shelf life, acidic degradation products and inflammatory response, and mechanical strength below metals for load-bearing fixation.
Narrow, concentrated upstream supply of implant-grade lactide and glycolide monomer, exposing polymer producers to raw-material availability and price volatility.
Capital and know-how barriers to entry: implant-grade polymerisation, residual-monomer and residual-solvent control, ISO 13485 quality systems and cleanroom converting are expensive to stand up and slow to qualify.
Geopolitical and trade barriers specific to a Russian supplier: sanctions and export controls, restricted access to Western analytical, sterilisation and notified-body services, payment and logistics friction, and customer risk aversion to a Russia-domiciled supplier of an implantable-grade material.

Growth per year

11% est.^{[gm-01] [gm-02] [gm-04] [gm-05] [gm-06] [gm-07]}

Biggest markets today

Growing fastest

Hottest segments

§04

Country Ranking

All bars are 0–100 scores; higher is always better. Hover a bar or dot for details; click a column to sort.

Market	Size	Growth	Verdict
🇮🇳 India South Asia	$28M est.^{[in-01] [in-05] [in-06] [in-08] [in-11] [in-12] [in-15] [in-20]}	14% est.^{[in-01] [in-11] [in-12] [in-13]}	Consider
🇰🇿 Kazakhstan Central Asia	$0.6M est.^{[kz-03] [kz-04] [kz-10] [kz-11] [kz-12] [kz-18]}	12 percent est.^{[kz-05] [kz-06] [kz-18]}	Go
🇷🇺 Russia Eastern Europe & CIS	$8M^{[ru-03] [ru-09] [ru-11] [ru-12] [ru-18] [ru-19] [ru-20]}	13% est.^{[ru-19] [ru-20]}	Go
🇺🇸 United States North America	$560M est.^{[us-01] [us-02] [us-14]}	9% est.^{[us-01] [us-02] [us-13] [us-14]}	Avoid
🇮🇪 Ireland Western Europe	$30M est.^{[ie-06] [ie-13] [ie-14] [ie-15] [ie-16]}	11%^{[ie-06] [ie-13] [ie-15]}	Avoid
🇨🇳 China East Asia	$250M est.^{[cn-01] [cn-02] [cn-03] [cn-11] [cn-21] [cn-06]}	13% est.^{[cn-01] [cn-02] [cn-03] [cn-24]}	Avoid
🇹🇷 Turkey Middle East & Turkey	$8.5M est.^{[tr-01] [tr-04] [tr-05] [tr-06] [tr-14] [tr-18]}	10 pct est.^{[tr-01] [tr-18]}	Consider

Yearly market size by country

USD, biggest first — deep-dive countries only

Screening — all 30 candidates we considered

Every candidate was rated on quick directional signals; the top 7 got full research.

Country	Score	Size	Growth	Language	Buying power	Outcome
🇷🇺 Russia						Researched in full
🇮🇳 India						Researched in full
🇨🇳 China						Researched in full
🇺🇸 United States						Researched in full
🇰🇿 Kazakhstan						Researched in full
🇹🇷 Turkey						Researched in full
🇮🇪 Ireland						Researched in full
🇧🇾 Belarus						screened out
🇧🇷 Brazil						screened out
🇦🇪 United Arab Emirates						screened out
🇸🇦 Saudi Arabia						screened out
🇰🇷 South Korea						screened out
🇩🇪 Germany						screened out
🇦🇲 Armenia						screened out
🇰🇬 Kyrgyzstan						screened out
🇩🇴 Dominican Republic						screened out
🇯🇵 Japan						screened out
🇨🇷 Costa Rica						screened out
🇲🇾 Malaysia						screened out
🇮🇷 Iran						screened out
🇷🇸 Serbia						screened out
🇺🇿 Uzbekistan						screened out
🇨🇭 Switzerland						screened out
🇬🇧 United Kingdom						screened out
🇮🇱 Israel						screened out
🇻🇳 Vietnam						screened out
🇮🇩 Indonesia						screened out
🇪🇬 Egypt						screened out
🇵🇱 Poland						screened out
🇲🇽 Mexico						screened out

§05

Country Deep Dives

Every researched market in full detail, best first. Click a country to expand.

▶🇮🇳 India

South Asia · English, Hindi, Gujarati, Marathi, Telugu, Tamil

Consider

CONSIDER — The top-ranked market on blended score and genuinely a lawful distribution route, but downgraded to CONSIDER on funding and on the size of the actually winnable pool. The DMF gate excludes a Ulyanovsk SME from US/EU-bound filings, leaving only domestic-only filings, research and pre-filing R&D - roughly a quarter to a third of the market - and a $300k entry is not fundable from ~1.6M RUB revenue and a -24M RUB result until Kazakhstan and Russia produce cash.

Highest overall score at 55.1 with demand 82.2 and weak-competition 70.6, and healthy unit economics: ACV $35k, LTV/CAC 6.4, 10-month payback.
But 3-year ROI is only 15% on a $300k entry, the weakest return of any market we are not calling AVOID.
The DMF gate shrinks ~75 realistic buyers to the domestic-filing, research and pre-filing R&D slice - roughly a quarter to a third of the market.
Payments clear through the RBI rupee vostro route but leave hard-to-repatriate INR, and Nomisma Healthcare (Vadodara) offers the identical custom-spec pitch with no freight, duty, FX or origin friction.

Market attractiveness

Growth momentum

Customer demand

Buying power

Weak competition

Profit potential

Ease of entry

Regulatory safety

Ease of winning customers

Springboard value

All bars 0–100, higher is always better.

The market here

Yearly market size

$28M est.^{[in-01] [in-05] [in-06] [in-08] [in-11] [in-12] [in-15] [in-20]}

Growth per year

14% est.^{[in-01] [in-11] [in-12] [in-13]}

Size in ~3 years

$42M^{[in-01] [in-11] [in-12]}

Life stage / how crowded

Growing · saturation

Who buys

Ideal customer: An Indian formulation-development or device-R&D team at a mid-size pharma/CDMO or suture-mesh manufacturer, starting a NEW resorbable programme aimed at the domestic or non-US/EU export market, buying 2-50 kg/yr of custom-spec PLGA/PLLA/PCL and needing molecular-weight, L/D-ratio and end-group tailoring plus responsive technical support at a price meaningfully below Evonik/Corbion list.
Who signs the contract: Head of Procurement / VP Supply Chain for commercial volumes; for development lots the Head of Formulation Development (pharma) or R&D Director / Head of Materials (device OEM) signs off directly out of a project budget.

Potential customers

75 companies est.^{[in-01] [in-11] [in-12] [in-15] [in-17] [in-18]}

Readiness to pay

How badly they want it

Typical yearly budget

$35k est.^{[in-05] [in-06] [in-07] [in-08]}

What hurts them today

What buyers search for — demand is Growing

Search phrase	Searches /mo	Ad cost per click	Why they search
PLGA supplier India (en)	~90/mo est.^[in-23]	$2.5 est.^[in-23]	Comparing products
bioresorbable polymer manufacturer (en)	~210/mo est.^[in-23]	$3.2 est.^[in-23]	Comparing products
PLGA 50:50 price (en)	~140/mo est.^[in-23]	$2.1 est.^[in-23]	Ready to buy
polyglycolic acid suture raw material (en)	~70/mo est.^[in-23]	$1.4 est.^[in-23]	Comparing products
medical grade polycaprolactone PCL India (en)	~60/mo est.^[in-23]	$1.8 est.^[in-23]	Comparing products
biodegradable polymer for controlled release drug delivery (en)	~330/mo est.^[in-23]	$2.8 est.^[in-23]	Just researching

Searches nobody answers well yet

Who we'd compete with — 6 companies est.^{[in-02] [in-03] [in-05] [in-06] [in-07]} serious vendors, moderate market

Competitor	Local or global	Share of market	Price level	Good at / weak at
Evonik Health Care (RESOMER) ↗ The default safe choice: 30+ years of commercial use, the deepest regulatory dossier in the category, US FDA excipient DMF coverage, multi-site supply security, and formulation-development services alongside the resin.	Global player	30%	Premium. Catalogue observations put RESOMER PLGA 50:50 at roughly USD 1,200/kg, with bulk contract prices reported 20-40% below list; research-scale pack sizes sold through Merck/Sigma-Aldrich at far higher per-gram rates.	+ Referenceable regulatory files that de-risk an ANDA or MDR submission+ Broadest grade portfolio including PEG-PLGA and specialty end-groups+ Supply-security narrative (multiple plants) that matters enormously once a product is filed+ In-house formulation development and toll manufacturing that pulls customers in early− Price is the single most common complaint from Indian buyers− MOQ and lead time are unattractive for small development lots− Limited appetite for genuinely bespoke small-volume grades− Slow, committee-driven response to a small Indian startup
Corbion Biomaterials (PURASORB) ↗ The lactide-chemistry specialist — backward integrated into its own lactide/glycolide monomer, which underwrites a purity and consistency story, with a very wide PURASORB grade matrix across PLLA, PDLLA, PLGA, PCL, PDO and copolymers.	Global player	22%	Premium, broadly comparable to Evonik. Catalogue observation: PURASORB PLGA 85:15 at roughly USD 750 per 500 g, i.e. ~USD 1,500/kg at catalogue pack size.	+ Monomer backward integration gives a genuine consistency and traceability argument+ Very broad grade matrix, including fibre-grade and high-IV PLLA that suture and scaffold makers need+ Established regulatory support documentation− Same price objection as Evonik in an Indian cost structure− Less India-local technical field presence than Evonik− Custom synthesis for small accounts is not the commercial model
Nomisma Healthcare Pvt. Ltd. ↗ The domestic Indian PLGA/PLA producer. Vadodara, Gujarat, founded 2017/2018, ~11-25 employees. Supplies lyophilised, tin-free, sterilised PLGA and PLA (21 PLGA variants listed) plus L-lactide and DL-lactide monomer, with grades varied by molecular weight, molar ratio and end group (hydroxy, ester, carboxylic acid, PEG). Claims IPEC GMP and 21 CFR compliance, ISO 9001 and WHO-GMP certification, clean-room manufacture, and use in FDA-approved commercial formulations.	Local player	—	Not published; sells by quotation via IndiaMART/TradeIndia enquiry and direct contact. Positioned as the affordable Indian alternative to imported RESOMER/PURASORB — the same value proposition RPS intends to make.	+ Domestic supplier — no import duty, no forex, no sanctions question, no 30-45 day sea leg, and it counts as local content under Make-in-India preferences+ Offers exactly the custom MW / molar-ratio / end-group tailoring that is RPS's differentiator, at Indian prices+ Physically close to the Vadodara-Ahmedabad-Mumbai pharma cluster, so a formulation scientist can visit+ Sells small development lots without European MOQ friction− Very small company (est. 11-25 staff) — supply-security and business-continuity risk is a real objection once a product is filed− Thin regulatory dossier relative to Evonik/Corbion; no comparable long commercial track record− Marketplace-led sales presence signals a small operation to a large buyer− Limited or no converted semi-finished forms (spun fibre, extruded tubing, cast film) — resin only
Chinese suture-grade PGA / PGLA and PLA producers (Jinan Daigang, BMG-class and similar) Volume, price and short lead times to India. Sells resin and, importantly, finished PGA yarn, which lets an Indian suture maker skip polymer purchase and qualification entirely.	Global player	15%	The price floor of the category. Suture-grade PGA/PGLA resin and spun yarn is transacted at roughly USD 100-300/kg — an order of magnitude below pharma-grade PLGA — which is why the tonnage line and the dollar line in India point at different suppliers.	+ Unbeatable landed price at tonnage+ Short and reliable shipping into Indian west-coast ports+ Willing to sell yarn as well as resin, removing a processing step for the customer+ Payment is routine — no bank will refuse a China-India invoice− Documentation and biocompatibility dossiers are often thin or inconsistent− Batch-to-batch variability is the standing complaint− Not credible for a regulated-market pharma filing− Little to no custom-synthesis or technical-development capability
Merck / Sigma-Aldrich (RESOMER and catalogue biodegradable polymers) ↗ Instant availability of named research grades with a published price, an Indian entity to invoice, and next-week delivery — the default for anyone starting a project.	Global player	—	Catalogue per-gram pricing at a very large premium to bulk — the convenience channel. Buyers accept it for grams, never for kilos.	+ Owns the moment of first purchase, which is exactly where a new supplier could otherwise win+ Frictionless procurement inside Indian institutional purchasing rules+ Brand trust in the lab− Prohibitively expensive above ~100 g, so it never converts into the commercial account− No custom synthesis− Distributes others' polymer rather than tailoring it
Ashland (Viatel bioresorbable polymers) ↗ The third Western catalogue option, leaning on Ashland's existing pharmaceutical-excipient relationships in India to cross-sell bioresorbables into formulators that already buy its cellulosics.	Global player	—	Premium, positioned with Evonik and Corbion; sold by quotation.	+ Existing Indian excipient customer relationships and supply-chain trust to build on+ Full regulatory documentation package expected of a Western excipient supplier+ Bundled technical service− Smaller bioresorbable share of mind than RESOMER or PURASORB− Narrower grade portfolio− Same price and MOQ objections as the other Western suppliers

Customers they leave behind

Rules & barriers to enter

Foreign companies allowed

Yes

Needs a local company set up

How hard to enter

Tax paperwork

Licenses needed

Importer-Exporter Code (IEC) — held by the Indian buyer or the appointed distributor, not by RPS, GST registration for the Indian importing entity, No CDSCO import licence is required for the polymer itself: Form MD-14/MD-15 applies to finished medical devices, and a raw material or semi-finished component imported for local manufacture falls under the Indian manufacturer's own CDSCO manufacturing licence (Form MD-5 for Class A/B, MD-9 for Class C/D) rather than a separate material registration, The Indian customer's device or drug licence is what carries the material: absorbable sutures, meshes, resorbable fixation and bioresorbable scaffolds are Class C/D under the Medical Device Rules 2017, requiring an MD-9 manufacturing licence and central-licensing-authority scrutiny of the material specification, For a pharmaceutical use, the polymer is an excipient characterised inside the customer's CDSCO application under the New Drugs and Clinical Trials Rules 2019 — India has no standalone excipient DMF register equivalent to the US Type IV DMF, If RPS were to sell a finished converted form as a device rather than a material, an Indian Authorised Agent holding Form MD-42 registration plus MD-14/MD-15 import licensing would become mandatory — a strong argument for selling material, not devices, BIS registration is not applicable to these polymers; no product-specific Indian standard licence exists for resorbable resin

Data protection rules

Digital Personal Data Protection Act 2023 (DPDP Act) governs personal data of Indian data principals, with consent, purpose-limitation and breach-notification duties and government power to restrict transfers to notified countries. For a B2B materials business the exposure is limited to CRM contact data and sampling records, but a Russian-domiciled data controller should assume that Russia could in principle be a notified restricted destination and keep Indian contact data in a documented, minimal, consent-backed form. Separately, customers will require confidentiality agreements covering their formulation and grade specifications, which is the more commercially material data question.

Culture & language hurdles

How we'd win customers

Sellable remotely

Yes

How hard to win customers

Cost to win one customer

$15k est.^{[in-20] [in-21] [in-23]}

Time from contact to deal

15 mo est.^{[in-13] [in-14] [in-23]}

Needs a local office

Channels that work

An appointed Indian technical distributor or agent carrying stock and acting as importer of record — the single highest-leverage move, since it solves the IEC/GST, customs, credit-terms, physical-presence and (with the right partner) payment-routing problems at once; the consolidated specialty-excipient distributors (IMCD India post-Signet, Barentz post-Anshul, Azelis) are the obvious targets but are also the most likely to decline a Russian principal on their own compliance policy, so a mid-size independent Indian distributor is the realistic partner, Direct technical business development to formulation-development heads and device R&D directors at NEW programmes — the only door that avoids change-control lock-in, and the one that rewards RPS's actual differentiator (custom MW, L/D ratio, end group, stated degradation window), CPHI India and PMEC India (the pharma ingredient and machinery show) for the drug-delivery segment; Medical Fair India and the India MedTech Expo for the device segment — in a cluster-based market these are where a new supplier gets a hearing, A structured academic sampling programme with SCTIMST, IIT polymer and biomaterials groups, NIPERs, CSIR labs and CIPET: small revenue, near-zero qualification burden, publications that cite the material, and the students who become tomorrow's formulation heads, Contract R&D sold as the entry product rather than the polymer — a paid degradation-profile or release-matching study creates a commercial relationship, generates data on RPS's own grade, and sidesteps the price comparison entirely, IndiaMART and TradeIndia B2B marketplace listings — unglamorous but demonstrably where Indian buyers of exactly this material transact (Nomisma's primary shopfront), English-language technical content SEO: grade-selection guides, degradation-profile comparisons, RESOMER/PURASORB equivalence tables, CoA parameter explainers — cheap, durable, and matched to how Indian technical buyers research, LinkedIn outbound to named formulation scientists and QA/RA heads in the Gujarat, Hyderabad, Mumbai and Bengaluru clusters, A UAE-based commercial and logistics presence used as the customer-facing invoicing, stocking and settlement entity — the standard structure for this trade lane and a material de-risking of the bank-refusal problem

The money math

Revenue per customer /yr

$35k^{[in-05] [in-06] [in-08]}

Cost to win one customer

$15k est.^{[in-20] [in-21] [in-23]}

Return ratio (LTV/CAC)

6.4 ratio^[in-23]

Gross margin

55% est.^{[in-05] [in-06] [in-08] [in-23]}

Months to earn back a sale

10 mo^[in-23]

Year-1 cost to enter

$300k est.^{[in-13] [in-14] [in-20] [in-23]}

3-year return

15%^[in-23]

Months until profitable

30 mo est.^[in-23]

What could go wrong here

Risk	How bad if it happens	How likely
regulatoryThe US FDA Type IV excipient DMF gate. India's pharmaceutical industry is export-led, and any formulation destined for a US ANDA or an EU filing requires a polymer supplier whose manufacturing detail is referenceable through a DMF — a credential Evonik, Corbion and Ashland hold and a Ulyanovsk SME cannot realistically obtain (estimated USD 150,000-400,000 plus facility qualification, and exposed to the same political risk as everything else). The equivalent applies on the device side through EU MDR notified-body scrutiny. This removes the highest-value slice of Indian demand — export-oriented depot and implant programmes — from RPS's reach before any technical or commercial conversation begins, and reduces the honest addressable pool to perhaps a quarter to a third of the USD 28M market. What we'd do: Stop selling to the segment that cannot buy. Target domestic-market-only Indian filings, products exported to Africa/LatAm/SE Asia/CIS where the file is lighter, research and custom-synthesis buyers where the qualification burden is near zero, and early-stage R&D programmes years away from a filing decision. Build the strongest non-DMF dossier available — ISO 13485, full ISO 10993 and USP Class VI packages on the lead grades, IPEC-PQG-style GMP statements, complete CoA parameter sets — and offer to place the full manufacturing detail under a direct confidentiality agreement with the customer, which some Indian buyers will accept where a DMF is not legally required. Treat a future third-country (UAE or Indian) toll-manufacturing or repacking partner able to file in its own name as the long-term structural answer.
competitiveNomisma Healthcare, a domestic Indian PLGA/PLA manufacturer in Vadodara, already occupies RPS's exact positioning — custom molecular weight, molar ratio and end-group tailoring, tin-free, small lots, Indian prices, IPEC GMP and 21 CFR claims — with none of the freight, duty, FX, banking or country-of-origin friction, and it counts as domestic content under Make-in-India preferences. Below it, Chinese suture-grade PGA/PGLA producers set a price floor at roughly USD 100-300/kg that a Russian supplier shipping 30-45 days cannot approach on tonnage. RPS is squeezed from both sides in the one market where its central pitch is 'the quality of Evonik at a price you can afford'. What we'd do: Do not compete on being the cheap alternative to Evonik — that seat is taken locally. Compete on the two things Nomisma visibly lacks: converted semi-finished forms (spun fibre and yarn, extruded stent tubing, cast anti-adhesion film, microspheres, 3D-printing filament), which no small Indian producer supplies and which carry a large step-up in value over resin; and genuine contract R&D depth on degradation-window and release-profile engineering, sold as a paid service. Concede the suture-grade tonnage line to China rather than bleeding on it. Where price comparison against Nomisma is unavoidable, shift the argument to supply security and scale — an 11-25 person supplier is a real business-continuity objection once a product is filed — but expect that argument to cut both ways given RPS's own country risk.
operationalPayment and banking execution. The rupee settlement route works at the regulatory level — nine Indian banks hold Russia-linked SRVA approvals and the August 2025 liberalisation widened access — but individual Indian banks decline Russia-linked transactions on their own compliance policy, with some Indian-origin multinational banks reportedly refusing Russian payments and refusing to issue electronic Bank Realisation Certificates. Separately, roughly USD 60bn of rupees has already accumulated in vostro accounts because Russia sells far more to India than it buys, so RPS would be paid in INR that is easy to receive and hard to repatriate or convert, at a 2-4% cross-rate spread with no direct INR/RUB market. US SDN designation of RPS's Russian bank is not itself disqualifying under Indian law — designated banks including VTB operate the rupee vostro channel — but it materially raises the probability that the customer's Indian bank, which is the actual gatekeeper, refuses the leg. What we'd do: Qualify the customer's bank before qualifying the polymer — make it the second question in the sales process, not the last. Prefer a non-designated Russian bank and be able to name it early in the commercial conversation, because the Indian bank's own compliance policy — not Indian law — decides whether the transaction clears. Stand up a UAE invoicing, stocking and settlement vehicle so the Indian customer contracts with a Gulf counterparty and the dirham route is available alongside the SRVA route. Decide the end use of rupee proceeds in advance — Indian raw materials, laboratory services, analytical testing, equipment or permitted investment — so revenue does not become trapped cash. Structure early orders with partial advance payment and accept that this costs some price-sensitive accounts.
regulatorySwitching-cost and change-control lock-in. Once an Indian device is filed under a CDSCO MD-9 licence or a drug product under the New Drugs and Clinical Trials Rules 2019 with a named polymer supplier and grade, changing supplier is a formal change-control exercise requiring re-characterisation, re-testing of degradation and release behaviour, and in implantable Class C/D cases a regulatory submission — an 18-36 month cycle nobody undertakes to save money on a material that is a small fraction of finished-product cost. Every account RPS wants is either already locked to an incumbent or will lock to whoever is present when the programme is filed. What we'd do: Treat displacement as out of scope for the first three years and hunt exclusively for programmes at the pre-filing stage: new depot formulations in feasibility, second-tier suture makers developing a new absorbable line, aesthetics and thread-lift entrants, scaffold and 3D-printing R&D, and every academic project that will spin out into one. Instrument the pipeline by programme stage rather than by account size, and walk away from a filed product quickly rather than spending a sales cycle on it. Use free grade-screening kits and paid feasibility studies to be physically present in the laboratory at the moment the grade is chosen, because that moment is the entire commercial opportunity.
operationalLogistics and working capital. There is no direct container service between Russia and India; routings run via UAE/Jebel Ali transhipment, the INSTC through Iran, or a 30-45 day sea leg, each adding a counterparty who must be comfortable with the cargo's origin. Bioresorbable polyesters are moisture- and temperature-sensitive with limited shelf life, so a delayed or heat-exposed container can arrive out of specification. Layered on top, Indian buyers expect 60-90 day credit terms while letters of credit naming a Russian beneficiary are hard to obtain and trade credit insurance is effectively unavailable, producing a 3-4 month cash-conversion cycle with no recourse if a customer does not pay. What we'd do: Ship through a UAE stocking point so the Indian customer sees short, predictable lead times from a Gulf warehouse rather than a 45-day Russian origin; this also fixes the transhipment counterparty question once rather than per shipment. Qualify packaging and cold-chain integrity with temperature loggers on every consignment and build stability data supporting the actual transit profile. Pre-agree HSN classification with the importer's customs broker to avoid clearance holds on a specialty polymer. On credit, hold advance or partial-advance terms for the first two or three orders of any account, extend terms only against demonstrated payment history, and cap total India receivables exposure explicitly rather than discovering it.

▶🇰🇿 Kazakhstan

Central Asia · Kazakh, Russian

GO — A GO on bounded risk rather than on market attractiveness. Demand scores 27.0, the weakest of the seven, and the entire commercial case rests on one company - but the downside is capped at roughly $45k, entry friction is near zero inside the EAEU, and a single win pays back in seven months. For a four-person company this is the only market it can fund unaided, and the chemistry match is exact.

Best unit economics in the set: LTV/CAC 11.8, 7-month payback, 3-year ROI 38%, ACV $45k against CAC $12k and a ~$45k entry cost.
Frictionless entry: no customs border, Russian as the working language, no product registration for a raw material, and EAEU-only device registration deferred to 01.01.2028.
Concentration risk is the whole story: TOO RuMa Farm (Almaty) and its registered Rumacryl suture at glycolide 90 / L-lactide 10 is an exact chemistry match; if it declines, the residual market is roughly $50k of academic sales against ~6 realistic buyers.
Structuring note: Dubai invoicing fixes bank de-risking but forfeits EAEU indirect-tax treatment, so both routes should be quoted.

Market attractiveness

Growth momentum

Customer demand

Buying power

Weak competition

Profit potential

Ease of entry

Regulatory safety

Ease of winning customers

Springboard value

All bars 0–100, higher is always better.

The market here

Yearly market size

$0.6M est.^{[kz-03] [kz-04] [kz-10] [kz-11] [kz-12] [kz-18]}

Growth per year

12 percent est.^{[kz-05] [kz-06] [kz-18]}

Size in ~3 years

$0.9M est.^{[kz-05] [kz-18]}

Life stage / how crowded

Emerging · saturation

Who buys

Ideal customer: A Kazakh manufacturer that already holds a registration certificate for a resorbable medical device and currently imports the polymer or the braided yarn it converts — in practice today this describes exactly one company, RuMa Farm: an ISO 13485-certified suture converter in the Almaty area running clean rooms, braiding/coating and needle attachment, selling into hospital tenders and the state guaranteed-benefit package, and therefore under permanent cost pressure and local-content pressure. Secondary ICP: a university or state research institute doing tissue-engineering, 3D bioprinting or drug-carrier work that needs 50 g to 5 kg of specified-molecular-weight PLLA/PLGA/PCL with a certificate of analysis, in Russian, on a short lead time and without an EU import procedure. Tertiary and currently hypothetical ICP: an entrepreneur setting up domestic conversion of aesthetic PDO/PLLA lifting threads or resorbable dental membranes as an import-substitution play under the local-content regime.
Who signs the contract: At the converter: the owner or general director. Kazakh medical-device manufacturers of this size are owner-managed, and a change of a critical registered raw material is an owner-level decision because it carries re-registration and revalidation cost. The production/technical director and the QA/regulatory manager (responsible for the registration dossier) hold the effective veto. At a university: the principal investigator holds the technical decision, but the purchase is executed by the procurement office against a state grant or programme-targeted funding line, which imposes competitive-procurement formalities on anything above a low threshold.

Potential customers

6 organisations est.^{[kz-03] [kz-04] [kz-11] [kz-15] [kz-16] [kz-17]}

Readiness to pay

How badly they want it

Typical yearly budget

$150k est.^{[kz-03] [kz-12] [kz-18]}

What hurts them today

What buyers search for — demand is Flat

Search phrase	Searches /mo	Ad cost per click	Why they search
полигликолид купить (Russian)	20 searches_per_month est.^[kz-19]	$0.5 est.^[kz-19]	Ready to buy
рассасывающийся шовный материал производство (Russian)	40 searches_per_month est.^[kz-19]	$0.6 est.^[kz-19]	Comparing products
биорезорбируемые полимеры медицинского назначения (Russian)	25 searches_per_month est.^[kz-19]	$0.4 est.^[kz-19]	Just researching
PLGA полимер купить Казахстан (Russian)	10 searches_per_month est.^[kz-19]	$0.8 est.^[kz-19]	Ready to buy
полилактид PLLA медицинский сырье поставщик (Russian)	15 searches_per_month est.^[kz-19]	$0.5 est.^[kz-19]	Comparing products
медициналық сіңетін жіп полимер (Kazakh)	5 searches_per_month est.^[kz-19]	$0.2 est.^[kz-19]	Just researching

Searches nobody answers well yet

Who we'd compete with — 4 competitors est.^{[kz-12] [kz-18]} serious vendors, moderate market

Competitor	Local or global	Share of market	Price level	Good at / weak at
Chinese medical-grade PLGA/PGA resin and yarn producers (cluster: Jinan Daigang Biomaterial, Huizhou Foryou Medical, Shenzhen Polymtek and similar) ↗ [Home base: China. No entity, distributor or technical presence in Kazakhstan.] Cost-equivalent material with adequate paperwork. Sells on landed price per kilogram and on willingness to supply the exact converted form (braided, coated, ready for needle attachment) rather than raw resin.	Global player	45%	Price leader by a wide margin. Medical-grade PLGA and PGA resin and braided yarn from Chinese producers is commonly quoted at a small fraction of Evonik and Corbion levels, with negotiable minimum order quantities and willingness to sell small trial lots.	+ Lowest landed cost of any credible source, which is decisive for a converter selling into state tenders+ Sells the converted form the customer actually wants — braided coated yarn, not just resin+ Flexible minimum order quantities and willingness to run trial lots+ Long-established supply relationships with exactly this class of converter+ No sanctions or payment-compliance friction for a Kazakh buyer− Long lead times and sea or long-haul rail transit into landlocked Kazakhstan, with customs clearance at the external EAEU border− Documentation frequently thin or English-only, and not written for a Russian-language regulatory dossier− Batch-to-batch inherent-viscosity variability is a recurring complaint and directly affects braiding and strength retention− No technical support in Russian and no realistic prospect of a plant visit− Cannot do genuine custom synthesis to a specified molecular weight and end-group chemistry for small volumes
Evonik Health Care (RESOMER, LACTEL) ↗ [Home base: Germany. No entity, distributor or technical presence in Kazakhstan.] The reference standard. Sells regulatory certainty — the drug and device master files, the audit history and the name that regulators and partners already recognise.	Global player	12%	Premium. Roughly USD 800-1,200/kg for medical-grade PLGA 75/25 in bulk [src-kz-12], with high minimum order quantities and separate research-only grades sold through Sigma-Aldrich. Product line and grade range per the company's own healthcare site [src-kz-22].	+ Deepest regulatory documentation and master-file support in the industry+ Widest grade range across L/D ratio, molecular weight and end-group chemistry+ Reputation that de-risks a customer's own registration and partnering+ Proven supply reliability and capacity− Price far above what a tender-constrained Kazakh converter can absorb− Minimum order quantities and commercial process built for large OEMs, not for a plant buying a few hundred kilograms− No local entity, no Russian-language technical service, no realistic account attention in Kazakhstan− EU export procedure, external-border customs clearance and long lead times into a landlocked market− Reluctance to take on small Central Asian accounts with Russian-linked supply chains
Corbion (PURASORB) ↗ [Home base: Netherlands. No entity, distributor or technical presence in Kazakhstan.] The specialist alternative to Evonik, with particular strength in high-purity monomer integration and in fibre-grade polymers suited to suture and textile conversion.	Global player	10%	Premium. Roughly USD 950-1,100/kg for PURASORB grades [src-kz-12]. PURASORB portfolio and positioning per the company's own biomedical-polymers page [src-kz-23].	+ Backward integration into implant-grade lactide and glycolide monomer+ Strong fibre-grade portfolio directly applicable to braided absorbable suture+ Full biocompatibility and master-file documentation+ Established name in the exact segment that matters in Kazakhstan− Price and minimum order quantities out of reach for the one Kazakh account that matters− No local presence or Russian-language support− Export, customs and lead-time burden into Central Asia− Compliance caution about Central Asian accounts with Russian-adjacent supply chains
Merck KGaA / Sigma-Aldrich ↗ [Home base: Germany / United States. No entity, distributor or technical presence in Kazakhstan.] Convenience and availability for laboratory quantities. Sells the catalogue, the existing procurement relationship and next-week delivery rather than a supply partnership.	Global player	15%	Catalogue pricing per gram, an order of magnitude above bulk cost per kilogram. Research-and-development use only — RESOMER grades sold through this channel are explicitly not for clinical or production use [src-kz-12].	+ Already embedded in Kazakh university procurement through existing reagent suppliers+ No minimum order quantity — a lab can buy 5 g+ Fast, predictable, low-friction ordering with no compliance questions+ Trusted brand in academic purchasing− Research-grade only, explicitly excluded from clinical or production use, so it can never follow a customer into manufacturing− Extremely high cost per gram once quantities exceed laboratory scale− No custom synthesis, no molecular-weight or end-group tailoring, no technical partnership− No path from a research account to a commercial supply agreement
Poly-Med Inc. ↗ [Home base: United States. No entity, distributor or technical presence in Kazakhstan.] Absorbable-fibre specialist — sells finished absorbable yarn, braid and monofilament as much as resin, and co-develops device-specific fibre with customers.	Global player	—	Not published; quotation-based, positioned as a premium technical supplier. No Kazakh price point found.	+ Sells the converted fibre form rather than raw resin — the closest structural analogue to what RPS offers+ Deep absorbable-fibre and textile expertise+ Strong custom-development capability− No presence, distribution or awareness in Kazakhstan or the wider CIS− US export and compliance posture makes a Central Asian account with Russian-adjacent trade unattractive− Small scale and premium positioning inappropriate for a tender-constrained buyer
Ashland (Viatel bioresorbable polymers) ↗ [Home base: United States / Ireland. No entity, distributor or technical presence in Kazakhstan.] Broad specialty-chemicals house with a bioresorbable polymer line sold alongside pharmaceutical excipients, leaning on existing pharma-formulation relationships.	Global player	—	Not published; quotation-based premium positioning. No Kazakh price point found.	+ Established pharmaceutical excipient relationships and regulatory documentation practice+ Breadth of adjacent product lines that can be sold together− No Kazakh presence and no route to the one converter that matters− The pharma-formulator entry point is worthless here because no Kazakh plant runs depot or microsphere manufacture− Premium price against a price-capped buyer

Customers they leave behind

Rules & barriers to enter

Foreign companies allowed

Yes

Needs a local company set up

How hard to enter

Tax paperwork

Licenses needed

None for the polymer itself. Medical-grade bioresorbable polymer sold as a raw material to a manufacturer is neither a medical device nor a medicinal product, so it requires no registration certificate (регистрационное удостоверение) in Kazakhstan and no EAEU device registration. The registration burden sits entirely with the customer that makes a device from it. This is the single most under-appreciated fact about this market entry: RPS's regulatory deliverable in Kazakhstan is documentary, not licensing., Registration IS required if RPS sells a finished or sterile form that is itself presented as a medical device — for example sterile packaged suture thread, a sterile anti-adhesion film or a stent tube supplied as a device. Selling non-sterile bulk yarn, resin, film stock or filament as an intermediate to a licensed manufacturer avoids this entirely, and that is the correct commercial structure for entry., Standard EAEU intra-union trade documentation: contract, invoice, CMR/transport documents, safety data sheet in Russian, and the statistical form of goods movement. No customs declaration and no import duty on movement from Russia to Kazakhstan., Sanitary-epidemiological documentation for a chemical substance may be requested at the customer's or the regulator's initiative depending on how the material is classified; a Russian-language SDS and composition declaration should be prepared in advance., No Kazakh business licence, accreditation or local representative is legally required to export and sell B2B into Kazakhstan from Russia.

Data protection rules

Kazakhstan's Law on personal data and its protection (2013, as amended) is modelled on the same lineage as Russian law and includes a data-localisation requirement: personal data of Kazakh citizens must be stored in databases located on Kazakh territory. Practical exposure for RPS is minimal, because this is a business-to-business materials sale with no consumer data and no processing of patient information. The only touchpoints are contact details of customer employees in a CRM and any website analytics or lead forms serving Kazakh visitors. Prudent handling is to keep Kazakh customer contact records inside the ordinary contractual relationship, avoid building a marketing database of Kazakh individuals, and add a Russian-language privacy notice to any lead form. This is a hygiene item, not a barrier to entry.

Culture & language hurdles

How we'd win customers

Sellable remotely

Yes

How hard to win customers

Cost to win one customer

$12k est.^[kz-18]

Time from contact to deal

12 mo est.^{[kz-01] [kz-18]}

Needs a local office

Channels that work

Direct named-account outbound to a target list of fewer than ten organisations — with a buying base this small, there is no funnel to build, only a list to work. RuMa Farm is target number one and the entire commercial case for the country largely rests on it., In-person technical visits to Almaty and Astana. A plant visit with a materials scientist who can discuss braiding behaviour and inherent-viscosity control is worth more than any amount of digital activity, and it is precisely what no incumbent supplier offers., Trade exhibitions — KIHE (Kazakhstan International Healthcare Exhibition) in Almaty and Astana Zdorovie — which function less as lead generation than as the accepted venue for a first face-to-face meeting in this business culture., Academic and research partnerships: joint work, free or subsidised sample material, and co-authorship with Nazarbayev University, KazNU, Satbayev and the medical universities. These accounts are small in revenue but generate published references, train the next generation of specifiers, and can pull RPS into state-funded programme grants., Russian-language technical content — datasheets, degradation and strength-retention data, comparison guidance and regulatory-documentation explainers. This works as sales-enablement and credibility material rather than as a traffic channel, because search volume is negligible., Industry associations and professional bodies in Kazakh pharma and medical devices, which provide the warm introductions that cold outreach cannot., A local agent or laboratory-supply distributor for research quantities, which solves university procurement formalities and small-shipment logistics without requiring RPS to establish anything in-country., Jurisdictional flexibility used as a sales instrument: opening the commercial conversation by asking whether the customer's bank and accountant would prefer a UAE or a Russian-entity invoice [src-kz-24] converts the single most awkward topic in the relationship into evidence that RPS has thought about the customer's problem. No Chinese, German or Dutch competitor can offer that choice.

The money math

Revenue per customer /yr

$45k est.^{[kz-03] [kz-12] [kz-18]}

Cost to win one customer

$12k est.^[kz-18]

Return ratio (LTV/CAC)

11.8 ratio^[kz-18]

Gross margin

45 percent est.^{[kz-12] [kz-18]}

Months to earn back a sale

7 mo^[kz-18]

Year-1 cost to enter

$45k est.^[kz-18]

3-year return

38 percent^{[kz-03] [kz-12] [kz-18]}

Months until profitable

18 mo est.^[kz-18]

What could go wrong here

Risk	How bad if it happens	How likely
demandThe entire commercial case for Kazakhstan rests on one company. Exactly one domestic manufacturer of absorbable surgical suture was identified — TOO RuMa Farm, whose registered Rumacryl product is a glycolide 90 / L-lactide 10 braided copolymer, an exact match to RPS's chemistry [src-kz-03, src-kz-04] — and it accounts for the large majority of estimated national demand. Everything else is four or five academic laboratories buying grams to kilograms. There is no domestic depot or microsphere pharmaceutical manufacture [src-kz-15, src-kz-16, src-kz-17], no domestic resorbable orthopaedic or cardiovascular manufacture, and no domestic aesthetic-thread conversion [src-kz-14]. If RuMa Farm declines, is already locked to an incumbent, or is smaller than modelled, Kazakhstan's addressable market falls to roughly USD 50,000 a year and the country ceases to be a revenue proposition. The frequently cited '166 domestic medical-device producers' [src-kz-05] is a registration count covering gauze, syringes and hospital furniture and provides no comfort whatsoever. What we'd do: Do not underwrite Kazakhstan as a revenue market. Underwrite it as a bounded-cost reference and EAEU bridgehead play with entry capped near USD 45,000 — roughly one trade show — and an explicit go/no-go gate at month 12. Before committing any spend, resolve the one cheap decisive unknown: contact RuMa Farm and establish whether it buys resin or braided yarn, from whom, at what price, and what it would take to requalify. Run the academic accounts in parallel from day one so that even a negative answer yields citable references and regional credibility. Treat any decision to expand spend as conditional on a signed qualification agreement, not on optimism.
economicREVISED DOWN after the corporate-structure correction. The original concern was that RPS could only present as a Russian counterparty into a market whose banks are actively de-risking Russian flows: the EU's 19th sanctions package (adopted 23 October 2025, effective 12 November 2025) placed banks in Kazakhstan and Belarus under a transaction ban for using the Bank of Russia's SPFS messaging system [src-kz-08, src-kz-09], VTB Bank Kazakhstan was named effective 2 December 2025 on top of its 2024 OFAC listing [src-kz-07], the National Bank of Kazakhstan's stated position is that other Kazakh banks 'independently decide' whether to transact 'taking into account possible secondary sanctions risks' [src-kz-07], and the same over-compliance pattern is visible in the withdrawal of Halyk, ForteBank, Nurbank, Freedom Bank and Bank CenterCredit from Russian Mir card servicing ahead of any legal requirement [src-kz-20]. That environment is real and unchanged. What has changed is RPS's exposure to it: the company publishes a UAE free-zone address in Dubai and a Delaware registered-agent address, with no Russian entity on its contact page [src-kz-24], so a Kazakh buyer can be invoiced by an Emirati company in USD or AED through ordinary correspondent banking. The residual risk is therefore not 'RPS cannot get paid' but a narrower and more manageable set: that the jurisdiction chosen to solve the payment problem forfeits the EAEU tax and customs simplicity that is Kazakhstan's main attraction; that a customer objecting to Russian ORIGIN rather than Russian PAYMENT is not helped by a Dubai invoice, since the manufacturing site is named in its registration dossier either way; and that a third-country invoice against goods shipping from Russia draws its own compliance attention if run opaquely. Note also that medical-grade bioresorbable polymer is not dual-use and medical goods sit under humanitarian carve-outs, so the underlying legal position was always clean — the problem was bank behaviour, not law. What we'd do: Offer both routes explicitly at the quotation stage and let the customer's own bank and chief accountant decide: Route A, a UAE free-zone invoice in USD or AED for a customer whose banking relationship is the binding constraint; Route B, a Russian invoice in tenge or roubles for a customer whose accountant wants the routine EAEU indirect-tax treatment (self-assessed 12% import VAT, form 328.00, statistical form only). Never price Route B in USD or EUR — it is the correspondent-bank leg that attracts de-risking. Treat the Delaware entity as a last resort and take US legal advice before using it for Russian-origin goods. Establish before contracting which bank the customer uses and avoid any counterparty banking with VTB Kazakhstan or another institution named under the EU 19th package. Run the third-country structure transparently with consistent documentation, matching transport papers and an explicit end-use statement identifying the material as a medical intermediate for absorbable surgical suture — the aim is to give a compliance officer an easy approval, not to obscure anything. Confirm internally, before any customer conversation, which entity actually invoices and from which warehouse goods ship, since that is unverified here and determines everything above.
operationalThe commercial barrier that most likely decides this deal is neither customs nor price. The polymer is named in the customer's registered device dossier, so replacing it triggers a registration variation or re-registration plus process revalidation on the braiding and coating line — a cost measured in months of calendar time and real cash, borne entirely by the customer, for a benefit that accrues mostly to the new supplier. This protects whoever supplies RuMa Farm today and is a rational reason for a small manufacturer with tender-capped margins to do nothing at all. The forthcoming transition to EAEU-only registration from 1 January 2028 [src-kz-01] cuts both ways: it raises the eventual dossier burden, which argues for acting inside the national-rules window that runs to 31 December 2027, but it also makes any customer nervous about disturbing a registration while the regime is changing. What we'd do: Pay for the switch rather than asking the customer to. Supply free qualification and pilot lots, fund or co-fund the revalidation work, and provide a complete Russian-language documentation package — ISO 10993 dossier, material master file, per-batch certificates with inherent viscosity and residual monomer, full lot traceability — in a form the customer's regulatory manager can drop straight into a dossier without translation. Target a new product line or a planned registration renewal rather than substitution into a stable existing one, since the marginal cost of naming a new supplier at registration is near zero. Move inside the national-rules window that closes 31 December 2027 [src-kz-01], when the dossier burden is lighter. Frame the case around five-country EAEU market access rather than around price per kilogram.
regulatoryKazakhstan's role as a re-export corridor is a real compliance hazard for RPS, and the usual framing gets the direction wrong. The familiar circumvention story is Western goods transiting Kazakhstan into Russia; RPS runs the opposite way, exporting Russian material outward. The sharper exposures are therefore two. First, inbound: RPS's own supply chain for implant-grade lactide and glycolide monomer, catalysts and analytical instrumentation may route through Kazakh intermediaries, which creates the exposure rather than removes it. Second, outbound counterparty risk: a Kazakh buyer whose order volume exceeds any plausible conversion capacity is not a customer but a transshipment front, and doing business with one would put RPS, and any Kazakh bank touching the payment, into a category neither can afford. Kazakhstan operates its own traceability and export-control measures on goods moving onward to Russia and has stated repeatedly that it will not allow its territory to be used for circumvention; the controlled lists focus on dual-use and electronic items rather than medical polymers, but the regime means unusual order patterns attract scrutiny. The precise current scope of those lists could not be verified in this research and is not asserted here. What we'd do: Name the risk and design against it rather than relying on the fact that the product is not dual-use. Run documented KYC on every Kazakh counterparty including beneficial ownership, verify that declared conversion capacity is consistent with order volume, and refuse orders that are not — a suture converter that suddenly wants ten times its plausible annual intake is a red flag, not an upside. Require end-use certificates and no-re-export undertakings in the contract. Keep a written compliance policy that can be shown to a bank compliance officer, since it is as much a sales asset as a control. Map RPS's own inbound monomer and equipment supply chain and avoid routing it through the same corridor. Do not pursue, structure around, or accept revenue from re-export volume: it is excluded from the market sizing in this file deliberately, and it should be excluded from the commercial plan for the same reason.
competitiveThe realistic incumbent at the one account that matters is Chinese braided PGA and PGLA yarn competing purely on landed cost, at a price well below Western levels of roughly USD 800-1,200/kg [src-kz-12]. The customer's own selling price is set inside hospital tenders and the state guaranteed-benefit package, so cost pressure is transmitted straight through to the input polymer and there is little room to pay a premium. If RPS attempts to win on price it enters a fight it cannot profitably sustain against a cost structure it does not have; if it prices as a Western-equivalent it will not be affordable. Compounding this, the structural alternative for the Kazakh healthcare system is simply to keep importing finished suture from Ethicon, Covidien, B. Braun, Lintex or Futberg [src-kz-13, src-kz-21], in which case no polymer is bought in Kazakhstan by anyone. What we'd do: Compete on everything except price per kilogram. The differentiators no incumbent can match are specific and cheap to deliver: no customs border and days rather than weeks of transit; Russian-language technical service from a named engineer who visits the plant; documentation written for a Russian-language dossier rather than translated into one; custom molecular weight, L/D ratio and end-group chemistry at volumes the majors will not quote; small-lot flexibility that suits a single-plant converter's storage and shelf-life constraints; and consistent certified inherent viscosity, which is the recurring complaint against low-cost yarn and directly affects braiding and strength retention. Price below Western list but clearly above commodity, and hold that line. Use fee-based contract R&D as the wedge — co-developing a specification that is then written into the customer's dossier converts a price comparison into a partnership the incumbent cannot bid against.

▶🇷🇺 Russia

Eastern Europe & CIS · Russian

GO — Ranked third on blended score but first in practice, because it is the only market where Russian goods origin costs nothing: no tariff wedge, no origin declaration problem, no foreign site audit, and the ISO 13485 manufacturing site is in the same jurisdiction as the customer. It carries the largest realistic buyer pool and four of the top eight computed country x segment cells. The trade is low ACV and slow qualification, which is survivable only because the company is already here.

Weak-competition 77.6 (highest of the seven) and ~210 realistic buyers, against ~75 in India and ~6 in Kazakhstan.
Holds computed cells #1 RU x aesthetic-injectables 79.9, #3 RU x absorbable-sutures-meshes 72.7, #5 RU x drug-delivery 64.6 and #6 RU x research-custom-synthesis 64.6.
Economics are thin and slow: ACV $9k, payback 28 months, 3-year ROI 35% on a $400k entry that must be staged across a 12-30-month dossier qualification cycle, not written as one cheque.
Competitive reality check: NPK Novokhim (Tomsk) already runs the same import-substitution pitch with Russian excipient certification, and parallel import of Western material is a live competitor.

Market attractiveness

Growth momentum

Customer demand

Buying power

Weak competition

Profit potential

Ease of entry

Regulatory safety

Ease of winning customers

Springboard value

All bars 0–100, higher is always better.

The market here

Yearly market size

$8M^{[ru-03] [ru-09] [ru-11] [ru-12] [ru-18] [ru-19] [ru-20]}

Growth per year

13% est.^{[ru-19] [ru-20]}

Size in ~3 years

$11.5M^{[ru-19] [ru-20]}

Life stage / how crowded

Emerging · saturation

Who buys

Ideal customer: A Russian manufacturer or formulator that has an existing or planned product whose active component is a resorbable aliphatic polyester, is currently buying (or has lost access to) Evonik RESOMER / Corbion PURASORB grades through an intermediary, and needs 5-500 kg/yr of a specified molecular weight, L/D ratio and end-group with a full batch documentation package in Russian. Two sub-profiles: (1) pharma development groups formulating PLGA microsphere or implant depot forms, where the polymer is a registered excipient and documentation depth matters more than price; (2) suture, mesh, thread and film converters who need fibre-grade PGA/PGLA or PLLA in kilogram lots at a price that survives comparison with Chinese resin. A third, lower-value but faster-closing profile is the university/NMITs laboratory buying 5-100 g for a grant-funded programme.
Who signs the contract: Technical director or production director at converters; head of pharmaceutical development (руководитель отдела фармразработки) or R&D director at pharma; for state institutes, the head of the contract service (контрактная служба) executing under 44-ФЗ/223-ФЗ. Final sign-off on a material change at a manufacturer with a registered product usually sits with the general director because it touches the registration dossier.

Potential customers

210 organisations est.^{[ru-09] [ru-11] [ru-12] [ru-18] [ru-20] [ru-21]}

Readiness to pay

How badly they want it

Typical yearly budget

$25k est.^{[ru-07] [ru-08] [ru-11] [ru-20]}

What hurts them today

What buyers search for — demand is Growing

Search phrase	Searches /mo	Ad cost per click	Why they search
полилактид медицинского назначения купить (ru)	~40/mo est.	$0.9 est.	Ready to buy
PLGA микросферы поставщик (ru)	~30/mo est.	$1.2 est.	Comparing products
биорезорбируемые полимеры производитель Россия (ru)	~70/mo est.	$0.8 est.	Comparing products
сополимер лактида и гликолида купить (ru)	~50/mo est.	$1 est.	Ready to buy
поликапролактон медицинский купить PCL (ru)	~60/mo est.	$0.7 est.	Ready to buy
аналог Resomer Purasorb российский (ru)	~20/mo est.	$1.5 est.	Comparing products

Searches nobody answers well yet

Who we'd compete with — 6 competitors est.^{[ru-03] [ru-07] [ru-08] [ru-10] [ru-20]} serious vendors, fragmented market

Competitor	Local or global	Share of market	Price level	Good at / weak at
НПК «Новохим» (Tomsk) - biopolymers division ↗ The domestic import-substitution supplier, stated explicitly: the site markets its polymers as alternatives to Evonik, Corbion, Ashland, Mitsui and Merck under the slogan «Замените биополимеры без повторной регистрации» (replace biopolymers without re-registration), and states the products are certified in Russia as вспомогательные вещества for prolonged-release dosage forms.	Local player	—	No published prices; quotation-based. Positions on availability and regulatory continuity rather than on being cheaper than imports.	+ Product matrix overlaps RPS almost exactly: PLGA at 50:50, 75:25, 90:10 and custom X:100-X, PLA in L and DL isomers, PGA, with published inherent-viscosity ranges (PLGA 50:50 0.15-0.9 dL/g; PLGA 75:25 0.15-1.5 dL/g; PLA 0.25-2.2 dL/g) and custom viscosity «под ваши требования»+ Has already solved the regulatory framing that gates pharma sales - Russian certification as an excipient for prolonged-release forms+ Owns the exact positioning the brief treats as RPS's core structural advantage, and says it in the customer's own words+ Real production site in Tomsk with a chemical-industry base around it− No published capacity, scale or customer references; could not verify revenue or headcount (no Tomsk «Новохим» entity surfaced in company-registry search)− Resin only - no evidence of converted semi-finished forms (fibre, extruded tubing, film, microspheres, filament), which is where RPS's differentiation would sit− No PCL or PLCL evidenced in the published range, unlike RPS− No public prices, so buyers cannot self-qualify without a sales conversation
НПО «ЭкоТек» ↗ Catalogue reagent and biomedical-materials house: research-scale biodegradable polymers sold alongside screening kits for drug-form development (PEG-PLGA offered as part of a nanoparticle screening kit).	Local player	—	Published e-commerce prices: PLLA listed at 11,430 RUB and PEG-PLGA (PEG-PLGA-50H) at 28,104 RUB. The quantity selector offers grams/kg/tonnes/ml with no stated package size, so the per-unit basis is ambiguous and these are not directly comparable to a per-kg resin price. Orders accepted only from legal entities and sole traders.	+ Published prices and an ordering path - the only competitor found that lets a buyer self-serve+ Adjacent reagent catalogue creates recurring contact with exactly the research tail RPS wants as lead flow+ Serves gram-scale demand fast, without qualification− Research/reagent scale; not evidenced as a kilogram-scale supply-chain partner for a registered product− Unclear whether it synthesises or repackages, which matters for batch traceability and dossier support− No device-grade quality system or converted forms evidenced
АО «ВНИИСВ» (Tver) Synthetic-fibre research-production institute listed in Russian polymer supplier directories as a polylactide producer; reported to have run medical high-purity PLA capacity since around 2015.	Local player	—	Not published; institutional quotation.	+ Fibre-spinning competence, which is exactly the conversion step suture makers need+ Industrial-scale infrastructure and state-institute standing− PLA only - no PGA, PLGA, PCL or PLCL breadth evidenced− No web-visible commercial offer, price list or specification sheet; institute-paced responsiveness− The directory listing carries no medical-grade claim, so the medical PLA capability could not be confirmed for 2026
Evonik RESOMER (via Russian representation, distributors and parallel import) ↗ The reference grade. RESOMER is the material named in most existing Russian device and drug dossiers, so it is the default and the incumbent by inertia rather than by active selling.	Global player	—	Euro list pricing plus an intermediary markup and prepayment; landed cost commonly reported anecdotally at 1.2-1.5x the direct-import equivalent, but no verified Russian price point was found.	+ Named in the customer's registration file - switching away costs the customer money and regulatory risk+ Decades of biocompatibility, degradation and clinical validation data, DMF support+ Still listed in Russian polymer supplier directories with a Moscow entry, i.e. reachable− Payment, logistics and lead-time friction; prepayment and no local technical service− FX exposure prices it out of ruble budgets when the ruble weakens− Political risk that supply is interrupted at short notice, which is precisely the argument a domestic supplier makes
Corbion PURASORB (via distributors and parallel import) ↗ The second reference grade, strong in fibre-grade PGA/PLGA for suture and in monomer supply; Corbion and Total Corbion PLA remain listed in Russian polymer supplier directories.	Global player	—	Euro list plus intermediary markup; no verified Russian price point found.	+ Fibre-grade credibility with suture makers; monomer as well as polymer supply+ Dossier incumbency comparable to Evonik− Same payment/logistics/FX friction as Evonik− No local application-development support for custom specifications
Chinese PLGA/PLA suppliers (Jinan Daigang and comparable Shandong/Zhejiang producers) The low-cost alternative that solves the payment problem as well as the price problem - the most direct commercial threat to a domestic supplier competing on availability.	Global player	—	Price-led: typically well below European grades on a per-kg basis, with CNY settlement and working trade lanes into Russia.	+ Lowest landed cost; ruble/yuan settlement is routine+ No sanctions friction, short lead times+ Broad grade coverage including PLGA, PLA, PCL− Documentation depth and batch-to-batch consistency are the standing complaints− No Russian-language technical dialogue or custom-synthesis collaboration− Does not help a customer claim Russian origin under ПП 719 / СТ-1

Customers they leave behind

Rules & barriers to enter

Foreign companies allowed

Yes

Needs a local company set up

Yes

How hard to enter

Tax paperwork

Licenses needed

None for the sale of bulk resorbable polymer as such: raw resin is neither a registered medical device nor a medicinal product, and needs no licence of its own., Лицензия на производство лекарственных средств (Minpromtorg) and GMP compliance if the material is supplied as a pharmaceutical excipient into a registered drug's supply chain., Лицензия Росздравнадзора на производство и техническое обслуживание медицинских изделий if RPS moves downstream into finished device forms rather than semi-finished material., Регистрационное удостоверение on any finished medical device - required of the customer, and the gate that determines when the customer may change material supplier.

Data protection rules

ФЗ-152 «О персональных данных», with the article 18(5) requirement that personal data of Russian citizens be recorded and stored on databases located in Russia. For a B2B material supplier the exposure is limited to CRM and website contact data; the practical requirements are hosting the site and CRM on Russian infrastructure and filing the standard Roskomnadzor operator notification. Not a barrier, but a checklist item for any Yandex Direct and lead-capture activity.

Culture & language hurdles

How we'd win customers

Sellable remotely

Yes

How hard to win customers

Cost to win one customer

$4.5k est.^[ru-20]

Time from contact to deal

12 mo est.^[ru-20]

Needs a local office

Yes

Channels that work

Founder-led direct technical selling into a nameable list of ~40 industrial accounts - this market is small enough to enumerate and call, which makes outbound the highest-yield channel, Russian-language SEO on a very thin keyword set: the substitution queries have low volume but almost no serious competition beyond Новохим, and a page that answers «does switching force re-registration» with real documentation will rank and convert, Yandex Direct on narrow commercial queries - budgets will be tiny because volumes are tiny; useful as a fast test, not a growth engine, Trade exhibitions and conferences where the buyers physically are: Здравоохранение (Russian Healthcare Week), Pharmtech & Ingredients, Аналитика Экспо, Химия, plus surgical and cosmetology congresses, Scientific credibility building: co-authored publications and joint programmes with НМИЦ, ИНЭОС/ИСПМ РАН, ТПУ and medical universities - this is how a material supplier becomes the default in a research tail that later becomes industrial demand, State R&D funding as a customer-acquisition channel: ФСИ programmes, Minpromtorg НИОКР subsidies and НТИ projects that pay RPS to develop a material with a named industrial partner - the partner becomes the customer, Reagent distributors and lab-supply catalogues (Диаэм, Хеликон and similar) to reach the research tail at low cost, Sample-first selling: free 10-50 g evaluation lots with a complete analytical package, because the analytical package is the actual product being sold

The money math

Revenue per customer /yr

$9k est.^{[ru-06] [ru-20]}

Cost to win one customer

$4.5k est.^[ru-20]

Return ratio (LTV/CAC)

4.8 ratio^[ru-20]

Gross margin

60% est.^[ru-20]

Months to earn back a sale

28 mo^[ru-20]

Year-1 cost to enter

$400k est.^{[ru-06] [ru-20]}

3-year return

35%^{[ru-06] [ru-20]}

Months until profitable

42 mo est.^{[ru-06] [ru-20]}

What could go wrong here

Risk	How bad if it happens	How likely
competitiveThe import-substitution position the brief treats as RPS's core structural advantage is already occupied. НПК «Новохим» (Tomsk) sells the same PLGA/PLA/PGA matrix with published inherent-viscosity ranges, has already obtained Russian certification of its polymers as excipients for prolonged-release dosage forms, and markets explicitly against Evonik, Corbion, Ashland, Mitsui and Merck under the line «Замените биополимеры без повторной регистрации». It is better established and it says the thing RPS wants to say. Below it, НПО «ЭкоТек» owns the research/reagent end with published prices and an ordering path, and Chinese suppliers undercut everyone on kilogram-scale price with working payment lanes. RPS is the smallest player in a market of roughly USD 8M. What we'd do: Do not fight for the generic substitution query. Differentiate on the two things no competitor evidences: converted semi-finished forms (fibre, tubing, film, microspheres, filament) and custom small-lot synthesis to a written specification with a full analytical package including PCL and PLCL grades that Новохим does not list. Win positions by being designed in through funded НИОКР rather than substituted in through a price list, and publish the comparability documentation that makes switching regulatorily cheap.
demandTotal dependence on a single small, sanctioned economy. The addressable domestic market is ~USD 8M and only part of it is reachable, while EU/US/UK/Japanese device and pharma customers are effectively closed to a Russian-domiciled supplier regardless of technical merit. The home market has not yet funded the business: ООО «ИНТЕХНОБИОМЕД» reported 1.6M RUB of 2025 revenue (~USD 18,000) against a 24M RUB loss with 4 employees, and its primary registered activity is R&D (OKVED 72.19), not manufacturing. There is no second market to absorb a domestic demand shock, and Russian device manufacturing investment is itself exposed to budget and macro pressure. What we'd do: Diversify along the two axes that remain open: EAEU/CIS export, where Russian-language documentation and the single registration regime remove friction, and non-sanctioning markets (India, Iran, China, Turkey, Brazil) where a Russian supplier is acceptable - both are easier than they look because the company already contracts through offshore entities (UAE Meydan Free Zone and a US Delaware registered-agent address are the only addresses on its public contact page). In parallel, shift revenue mix towards grant- and contract-funded development income to bridge the qualification period, and raise revenue per kilogram by moving into converted forms so that a small volume base can still support the cost structure. Note that the offshore structure diversifies the CONTRACTING counterparty, not the demand base: production, staff and revenue still sit in one sanctioned economy.
currencyStructural currency mismatch. Revenue is ruble-denominated and, for state-linked buyers, contractually fixed in rubles for a year or more, while the cost base is dollar- and euro-linked: analytical instrumentation, GPC columns and reference standards, high-purity reagents and catalysts, and imported spare parts - all of which carry an additional sanctions premium on top of the exchange rate. A 30-40% ruble depreciation compresses gross margin within a quarter and simultaneously makes the imported competition more expensive, so the effect on competitive position is ambiguous while the effect on cash is unambiguously negative. The same volatility makes any USD-denominated market sizing (including the USD 8M in this file) unstable. What we'd do: Price in rubles with an FX-indexation clause above a defined threshold and a quarterly repricing right; hold 6-12 months of buffer stock of critical imported reagents, columns and standards bought when the rate is favourable; require 30-50% advance payment on custom lots; qualify domestic or Chinese substitutes for imported consumables in advance rather than under pressure. The UAE and US entities are a genuine partial hedge here: hard-currency export revenue can be received and imported inputs paid for outside the Russian banking perimeter, which addresses payment routing and correspondent-banking risk. It does nothing about the underlying mismatch between ruble domestic revenue and dollar-linked costs, and nothing about goods origin, customs treatment or the fact that a customer's quality auditor still has to visit Ulyanovsk.
regulatoryCustomers' registration regimes, not RPS's own permissions, govern the pace of substitution. A manufacturer with a registered device or drug cannot change its polymer supplier freely - the change must be assessed under change control and may require a dossier variation, so switching realistically only happens during a re-registration window. The Protocol of 29.12.2025 extended EAEU transition filing to 31.12.2027 with EAEU-only registration from 01.01.2028, pushing those windows further out than the brief assumed and giving customers a legitimate reason to defer material decisions by a year or more. There is also no ГФ РФ pharmacopoeial monograph for PLGA/PLA as excipients, so every pharma sale requires a bespoke specification negotiation. What we'd do: Target new development programmes rather than in-market products, where the material is designed in and no variation is needed. Map customers' registration expiry and EAEU transition dates and time the approach to them. Invest in the comparability data package (GPC, residual monomer and tin, ISO 10993 on the specific grade) so a customer's regulatory affairs team can classify the substitution as a minor change. Pursue certification of lead grades as excipients, the route Новохим has already taken, to remove that objection from pharma conversations.
operationalCapability and credibility gap at industrial scale. With 4 employees and an R&D rather than manufacturing registration, RPS must demonstrate batch-to-batch reproducibility, a certified ГОСТ ISO 13485 quality system, retained samples, stability data and a full per-batch analytical package before any converter or formulator will qualify it - and a failed audit or an out-of-specification batch ends a 12-24 month qualification with no recovery. The analytical instrumentation this requires is import-restricted, and the converted-forms strategy that is the company's best differentiation needs pilot extrusion and fibre-spinning capacity it does not evidently have. What we'd do: Certify the quality system before, not during, the first industrial qualification. Prioritise analytical capability over synthesis capacity - the analytical package is what is actually being sold. Publish CoA templates and characterisation data openly to pre-empt the credibility objection. Secure a toll-manufacturing or joint-venture partner (a fibre or extrusion house) for scale-up rather than building capacity from cash, and fund the instrumentation through Minpromtorg НИОКР subsidies where possible. Start with one or two lead grades done impeccably rather than the full published matrix.

▶🇺🇸 United States

North America · en

Avoid

AVOID — Ranked fourth on blended score and holding computed cell #2, but economically foreclosed rather than merely hard. Column 2 tariffs on Russian-origin goods erase exactly the price wedge that a small challenger sells on, and no offshore invoicing entity changes the origin that triggers them. We decline US x research-custom-synthesis 72.7 by name: the segment fit is real and the high-WTP seed-stage gap is real, but the duty and the negative return apply to the goods, not the segment.

Verified Column 2 duty on the USITC schedule: 15.4c/kg + 45% on Russian-origin polymer versus 6.5% MFN, and 40% on sterile absorbable suture material.
Worst economics in the set: LTV/CAC 2.0 and a 3-year ROI of -120% on a $700k entry - the only negative ROI of the seven.
Ease-of-entry 18 and profit 41.6 despite the highest demand score at 85.2; FDA change control under 21 CFR 807.81 / 814.39 / 314.70 locks incumbents in and much demand is captive to Ethicon, Medtronic and Abbott.
Declining computed cell #2 (US x research-custom-synthesis 72.7): a $700k entry with -120% three-year ROI is not survivable on ~1.6M RUB revenue.

Market attractiveness

Growth momentum

Customer demand

Buying power

Weak competition

Profit potential

Ease of entry

Regulatory safety

Ease of winning customers

Springboard value

All bars 0–100, higher is always better.

The market here

Yearly market size

$560M est.^{[us-01] [us-02] [us-14]}

Growth per year

9% est.^{[us-01] [us-02] [us-13] [us-14]}

Size in ~3 years

$725M^{[us-01] [us-02] [us-14]}

Life stage / how crowded

Mature · saturation

Who buys

Ideal customer: A US pre-clinical or early-feasibility organisation - a university or hospital research lab, a venture-backed resorbable-device or long-acting-injectable startup, or a small formulation CDMO - buying 10 g to 5 kg of custom-spec PLGA, PLLA or PCL for a programme that has no 510(k), PMA or Drug Master File naming a supplier yet, and therefore no regulatory change-control barrier to using a new source.
Who signs the contract: At research scale, the principal investigator or lab director spending grant or SBIR/STTR money (order values below any procurement threshold). At startups, the VP of R&D or Head of Formulation Development, with the CEO/CFO signing anything above ~USD 50k. At established device OEMs and pharma, a strategic sourcing or category manager for polymers and biomaterials who cannot approve a new source without R&D, supplier quality and regulatory affairs all signing off - which is where a Russian-origin supplier dies.

Potential customers

850 organisations est.

Readiness to pay

How badly they want it

Typical yearly budget

$75k est.

What hurts them today

What buyers search for — demand is Growing

Search phrase	Searches /mo	Ad cost per click	Why they search
bioresorbable polymer supplier (en)	260 searches_per_month est.	$6.5 est.	Comparing products
medical grade PLGA resin GMP (en)	170 searches_per_month est.	$4.5 est.	Comparing products
PLGA microspheres supplier (en)	90 searches_per_month est.	$5 est.	Ready to buy
custom PLGA synthesis service (en)	70 searches_per_month est.	$7 est.	Ready to buy
absorbable suture yarn manufacturer (en)	40 searches_per_month est.	$3.5 est.	Comparing products
RESOMER alternative second source (en)	30 searches_per_month est.	$8 est.	Comparing products

Searches nobody answers well yet

Who we'd compete with — 8 suppliers est.^{[us-08] [us-09] [us-10] [us-11] [us-12] [us-13]} serious vendors, moderate market

Competitor	Local or global	Share of market	Price level	Good at / weak at
Evonik (RESOMER and LACTEL) ↗ The default incumbent and the broadest portfolio of standard, custom and specialised bioresorbable polymers, bundled with formulation development and CDMO capability up to finished sterile parenteral product.	Global player	—	Quotation-only, no public price list. Positioned at the top of the market; grade-specific pricing scales from research quantities through GMP commercial lots, with custom grades and development services priced as projects.	+ US manufacturing on the ground: Evonik Birmingham Laboratories in Birmingham, Alabama, with ISO 8 cleanrooms and a purpose-built advanced-biomaterials plant commissioned there - a domestic-source answer no importer can match+ Owns both RESOMER and LACTEL, the two most commonly specified PLGA brands, so it appears on both sides of many second-source evaluations+ Master-file support and regulatory documentation that buyers can reference directly in filings+ Can take a customer from polymer through formulation development to sterile fill-finish, which locks the polymer choice in early− Sized and priced for commercial programmes: small custom lots and unusual specs are slow and expensive to get− Least flexible on non-catalogue specifications at small volume− Premium pricing invites second-source searching from cost-pressured startups
Corbion (PURASORB) ↗ The principal alternative to RESOMER and the usual second name on a US qualification shortlist; strong in both device resins and GMP drug-delivery grades, with upstream integration into lactide monomer.	Global player	—	Quotation-only. Broadly comparable to Evonik at commercial volumes; competes hard on grade breadth (lactide, glycolide, caprolactone homo- and copolymers) rather than on price.	+ Upstream integration into high-purity lactide monomer, insulating it from the narrow monomer supply base that constrains everyone else+ Very broad grade matrix across L/D ratio, molecular weight and end-group - directly overlapping RPS's differentiator+ Established quality documentation and long qualification history in US filings− Manufacturing is in the Netherlands, so it is itself an import into the US and carries transatlantic lead time− Like Evonik, structurally uninterested in gram-scale custom work− Less vertically integrated downstream than Poly-Med - it sells resin, not components
Poly-Med, Inc. ↗ Markets itself as the only vertically integrated partner offering a single source from bioresorbable polymer through finished device or component - resin, fibre spinning, biomedical textiles and device development in one US site (Anderson, South Carolina).	Local player	—	Quotation-only, project-based. Prices the package (resin plus fibre plus device development) rather than the kilogram, which makes direct resin price comparison difficult.	+ The closest structural analogue to RPS's own model - custom resin plus converted forms (fibre, textile) plus contract development - and it is US-domiciled+ Standard and customised medical-grade resins produced on site to customer-specific requirements, which removes RPS's flexibility advantage+ Being American resolves every sanctions, banking, audit-travel and duty question before it is asked− Smaller capacity and narrower grade catalogue than Evonik or Corbion− Less established in pharma excipient/drug-delivery filings than in device textiles− Development-led model means longer, more expensive engagements than a simple resin purchase
Ashland (viatel ultrapure bioresorbable polymers) ↗ Ultrapure GMP-compliant bioresorbable polymers for parenteral controlled release and medical devices, sold on the promise of release-profile reproducibility; five polymer families.	Local player	—	Quotation-only. Positioned on purity and release-profile control rather than price; portfolio expanded in June 2025.	+ US-headquartered specialty chemicals company with an FDA Drug Master File on the portfolio (DMF 33847) that customers can reference - exactly the artefact that makes an incumbent hard to displace+ Sells into pharma accounts through an existing excipient relationship, so the polymer rides in on an established vendor record+ GMP-compliant manufacturing and a recently broadened grade range− Later entrant to bioresorbables than Evonik or Corbion, with a shorter track record in device applications− Manufacturing footprint is outside the US, so it does not carry the domestic-source argument Evonik Birmingham or Poly-Med can make− Narrower converted-form capability - it sells polymer, not fibre, film or tubing
Foster Corporation (Foster, LLC) ↗ US medical-polymer compounder and distributor (Putnam, Connecticut) covering the full spectrum of durable and bioresorbable implantable grades, with custom formulation, regulatory compliance and supply-chain support.	Local player	—	Quotation-only; compounding and distribution margins on top of base resin, so nominally more expensive per kilogram than buying resin direct, but it sells a formulated, processable material rather than a raw polymer.	+ Sits between the polymeriser and the converter and controls the specification at the point where the OEM actually buys+ Distribution relationships mean it can offer several base polymers under one US vendor record and one quality agreement+ Strong US regulatory and supply-chain service wrapper− Not a polymeriser - it compounds and distributes, so it cannot itself tune molecular weight, L/D ratio or end-group chemistry at source− Dependent on upstream suppliers for base resin availability and pricing− Adds a margin layer that price-pressured startups try to bypass
MilliporeSigma (Merck KGaA, Sigma-Aldrich catalogue) ↗ Same-week fulfilment of research quantities from a vendor record every US university and pharma company already has - convenience, not specification.	Global player	—	The only publicly listed pricing in the category: research-quantity RESOMER grades (e.g. RG 503 H, PLGA 50:50 acid-terminated, Mw 24,000-38,000) are catalogued in 5 g and 25 g pack sizes; catalogue prices sit in the high tens to low hundreds of USD per gram, i.e. one to two orders of magnitude above bulk GMP resin per kilogram.	+ Owns the top of the funnel: the research segment RPS can most easily win is the segment that reflexively buys from this catalogue+ Already an approved vendor everywhere, so buying involves no onboarding, no audit and no sanctions screening+ Distributes the incumbent brands, so a lab's first exposure to PLGA is a RESOMER part number− Research grades are not GMP and carry no master file, so work has to be repeated on a filable grade later− Catalogue only - no custom molecular weight, L/D ratio or end-group chemistry− Extremely high price per gram, which is precisely the opening a low-cost custom synthesiser can attack

Customers they leave behind

Rules & barriers to enter

Foreign companies allowed

Yes

Needs a local company set up

How hard to enter

Tax paperwork

Licenses needed

No FDA establishment registration or device listing is required to sell polymer raw material into the US: a resin is a component, not a finished device, and registration/listing obligations fall on the device manufacturer that uses it, An FDA Drug Master File (Type II for a polymer used as a drug-product component, Type IV for an excipient) is legally voluntary but commercially mandatory - without a referenceable master file and a right-of-reference letter, no US pharma customer can cite the material in a filing, A Device Master File (MAF) serves the equivalent function for device customers, US importer of record with a customs bond, and correct HTSUS classification and country-of-origin marking, TSCA compliance for device-use polymers imported as chemical substances (TSCA import certification at entry), unless the material qualifies for the 40 CFR 723.250 polymer exemption; material destined for drug use is excluded from TSCA as an FD&C Act article, If RPS were to ship sterile converted forms (sterile absorbable suture yarn, sterile adhesion barriers), those become regulated articles under 21 CFR and the FDA import entry review applies - though the 510(k)/PMA obligation still sits with the device owner, No US federal licence exists that a Russian supplier can apply for to cure the sanctions/banking problem; OFAC specific licences are transaction-specific and slow

Data protection rules

Not a material barrier for this business. Nothing in the transaction involves patient data or protected health information, so HIPAA and the state privacy statutes (CCPA/CPRA and successors) do not bite on a B2B polymer sale; ordinary contact-data handling for marketing is the only exposure and is straightforward to comply with. The real information-handling risk runs the other way: technical data, analytical methods and process know-how exchanged with a US customer during qualification are potentially subject to US export-control review when transferred to a Russian entity, and US customers' own trade-compliance teams will restrict what engineering detail they can send. Confidentiality agreements are also harder to enforce in either direction given the absence of a working US-Russia commercial-legal channel.

Culture & language hurdles

How we'd win customers

Sellable remotely

Yes

How hard to win customers

Cost to win one customer

$18k est.

Time from contact to deal

8 mo est.

Needs a local office

Yes

Channels that work

Deep technical SEO content on the specific grade parameters buyers search on (molecular weight windows, L:D ratio, end-group chemistry, degradation windows) - the only channel that works without a US legal presence and the one that reaches the research tier, Direct scientific outbound to named academic principal investigators and startup formulation leads, opened on technical substance (a degradation dataset, a custom-spec offer) rather than on price, A US- or EU-domiciled distributor or agent that takes title, acts as importer of record, holds the customs bond and appears on the customer's vendor record - practically the only viable route to any organisation with a procurement function, Listing through a third-party research-chemical reseller or catalogue, where the reseller is the vendor of record and the qualification burden on the buyer is near zero, Free sample programmes with full analytical packages, sized so that a lab can evaluate without a purchase order, Peer-reviewed publication and co-authorship with US academic groups - in this category a paper citing a supplier's grade is a durable acquisition asset, Targeted conference presence (Controlled Release Society Annual Meeting, AAPS PharmSci 360, Society For Biomaterials, MD&M West) - though visa and payment logistics make direct exhibition difficult for a Russian entity and argue for going through a partner's booth

The money math

Revenue per customer /yr

$28k est.^[us-18]

Cost to win one customer

$18k est.

Return ratio (LTV/CAC)

2 ratio est.^[us-18]

Gross margin

45%^{[us-03] [us-18]}

Months to earn back a sale

15 mo^{[us-03] [us-18]}

Year-1 cost to enter

$700k est.

3-year return

-120% est.

Months until profitable

no data

What could go wrong here

Risk	How bad if it happens	How likely
economicColumn 2 tariffs make RPS structurally uncompetitive on price, which is its only wedge. Verified against the USITC tariff schedule: Russian-origin PLA (HTS 3907.70.00.00) and other polyesters covering PLGA/PGA/PCL/PLCL (HTS 3907.99.50) carry 15.4c/kg + 45% versus a 6.5% MFN rate; sterile absorbable suture materials and adhesion barriers (HTS 3006.10.01.00) carry 40% against a rate that is FREE for every other origin; monofilament yarn (HTS 5404.19.80) carries 50%. A supplier whose pitch is better price and more flexible specification cannot absorb a 45% duty against competitors who pay 0-6.5%, and it consumes roughly 14 points of gross margin in the model above. What we'd do: There is no mitigation while the goods are of Russian origin - Column 2 is statutory under Pub. L. 117-110, not discretionary. The only real responses are (a) shift the price argument to specification and lead time rather than cost, accepting parity or premium pricing and therefore a much smaller addressable set; (b) sell only the highest-value-per-kilogram forms (custom research grades, microspheres) where a 45% duty on a small absolute value is tolerable; or (c) change the country of origin through substantial transformation or offshore production. Confirm classification per line with a licensed customs broker before quoting anything - the 3006.10 line moving from FREE to 40% is easy to miss.
regulatorySwitching-cost lock-in means the large, profitable customers are structurally unreachable and the reachable ones churn before they become profitable. Under 21 CFR 807.81(a)(3), 814.39 and 314.70, changing the named polymer supplier on a filed device or drug product can require a new 510(k), a PMA supplement or a prior-approval/CBE-30 supplement with comparability and release-profile data. So displacement of Evonik, Corbion or Ashland at any commercial account is effectively impossible. The reachable segment is pre-filing early-stage work - but those same customers must name a supplier when they do file, and no US sponsor will name a Russian one, so RPS loses the account precisely at the moment it would become valuable. This is why customer lifetime is modelled at 2.5 years with no commercial tail. What we'd do: Accept the model honestly rather than plan around it: treat US early-stage accounts as revenue-plus-credibility, not as a pipeline to commercial supply. Pursue an FDA Drug Master File with a right-of-reference letter, which is the only artefact that could keep an account through filing, while recognising it does not solve the origin problem. Prioritise use cases with no filing at all (academic research, tool compounds, GPC standards) and aesthetic/cosmetic-adjacent applications with shorter regulatory chains. Follow surviving accounts to their offshore development sites where re-sourcing pressure is weaker.
politicalSanctions, banking and vendor screening block market access independently of the law's actual permissions. There is no reliable USD correspondent route for a Ulyanovsk entity after the blocking of Sberbank, VTB, Alfa-Bank and Gazprombank and SWIFT disconnection; EO 14114 secondary-sanctions exposure has closed most third-country routing through the UAE, Turkey and Central Asia; and automated denied-party screening at vendor onboarding rejects a Russian address before any technical evaluation happens. OFAC GL 6D genuinely authorises medicine and medical-device transactions and has no expiration date, but a bulk polymer resin is neither 'medicine' nor a 'medical device', and its status as a 'component for a medical device' is arguable rather than settled - and a compliance officer resolves ambiguity by declining. The regime can also tighten further with no notice. What we'd do: Obtain a written trade-compliance opinion from US counsel on whether the specific product forms fall within GL 6D, and lead with converted sterile forms (suture yarn, adhesion film) where the 'medical device component' argument is strongest, rather than with bulk resin. Route all commerce through a non-Russian entity of record that is the vendor on the customer's books and the importer of record at CBP. Do not attempt crypto or opaque payment routing - it converts a compliance question into an enforcement one. Realistically, treat the US as unaddressable until production origin changes.
competitiveThe incumbents already occupy every position RPS would claim, on home soil. Evonik manufactures RESOMER and LACTEL in Birmingham, Alabama in ISO 8 cleanrooms and can offer a domestic-source argument; Poly-Med in South Carolina runs the same vertically integrated resin-through-component model RPS does, with custom grades made on site; Ashland holds an FDA Drug Master File (DMF 33847) that customers reference directly; Corbion is integrated upstream into lactide monomer. Meanwhile the research tier RPS could most easily win is already served by MilliporeSigma's same-week catalogue, and the price-sensitive end is contested by Chinese and Indian suppliers with none of RPS's origin problems. What we'd do: Do not compete on the incumbents' ground. Concentrate on genuinely unserved gaps: low-MOQ GMP-grade custom lots between 100 g and 5 kg, non-catalogue PLCL comonomer ratios, long (3-5 year) degradation windows, and medical-grade resorbable 3D-printing filament, all of which the incumbents decline or price as full projects. Compete on responsiveness and specification flexibility, evidenced with published data, not on price - which the tariff has already taken away.
operationalEven a won order is hard to fulfil to US standards. Resorbable polymer requires cold, dry, moisture-controlled handling with a limited shelf life, and Russia-US freight now routes indirectly with longer transit and more temperature excursions. US buyers of implantable-grade material expect an on-site supplier audit that they cannot practically conduct in Ulyanovsk, and they will not accept Russian analytical certificates at face value, forcing duplicate testing at a Western laboratory. RPS's own access to Western analytical instrumentation, GPC consumables and cleanroom equipment is constrained by BIS Export Administration Regulations Part 746 controls running the other way, which degrades its ability to maintain and prove implant-grade quality over time. What we'd do: Qualify a validated cold-chain lane with a specialist pharma logistics provider and hold buffer stock in a US or EU bonded warehouse so repeat orders ship domestically. Commission independent third-party testing at an accredited Western laboratory for every lead grade and publish the data, so the CoA is corroborated rather than asserted. Offer remote and video-witnessed audits with a full documentation package as a partial substitute for site visits, and be candid that it is a partial substitute. Secure long-lead analytical consumables and spares in advance, and build a redundant relationship with a third-country testing house.

▶🇮🇪 Ireland

Western Europe · English, Irish

Avoid

AVOID — Legally foreclosed, and this is not a hedge. Reg. (EU) 833/2014 Article 3i with Annex XXI Part B prohibits importing these CN codes of Russian origin; the prohibition binds the buyer, has no medical carve-out, and the words 'directly or indirectly' defeat transshipment. Origin follows last substantial transformation, so a Dubai or Delaware invoice confers no new origin. RPS can be paid by an Irish customer and cannot lawfully deliver to one - the ranking of fifth on blended score is an artefact of scoring demand and profitability that are unreachable.

Prohibited CN codes cover the company's entire catalogue: 3907, 3916, 3917, 3919-3921, 3926 and 5402 - polymer, tubing, film, moulded forms and spun yarn alike.
Ease-of-entry 12.5, the lowest of all seven countries, which is the score correctly registering a closed door.
Demand 70.2 and profit 66.3 are irrelevant while delivery is unlawful; Ashland already manufactures Viatel in Mullingar, in-country, so there is not even a supply gap to argue over.

Market attractiveness

Growth momentum

Customer demand

Buying power

Weak competition

Profit potential

Ease of entry

Regulatory safety

Ease of winning customers

Springboard value

All bars 0–100, higher is always better.

The market here

Yearly market size

$30M est.^{[ie-06] [ie-13] [ie-14] [ie-15] [ie-16]}

Growth per year

11%^{[ie-06] [ie-13] [ie-15]}

Size in ~3 years

$41M^{[ie-06] [ie-15]}

Life stage / how crowded

Growing · saturation

Who buys

Ideal customer: Not the tier-1 OEM. The realistic ideal customer in Ireland is a mid-size resorbable-implant CDMO or a device developer at pre-clinical/early-development stage, where no polymer supplier has yet been named in a regulatory file. Concretely: an Irish contract developer of resorbable textiles, meshes, fibres or scaffolds (Aran Biomedical is the archetype) or a venture-backed device start-up spun out of the Galway/Dublin cluster, buying 1-25 kg lots of a custom-spec copolymer with a defined L/D ratio, molecular weight and end-group, and needing formulation and degradation-profile development support alongside the material. Secondary ICP: a university biomaterials group buying gram-to-hundred-gram research quantities, where qualification burden is near zero. Tier-1 OEM plants (Boston Scientific, Medtronic, Stryker, Abbott) are explicitly NOT the ICP - their qualified-supplier lists are set by US-headquartered global procurement and their filed devices name incumbent suppliers.
Who signs the contract: For a CDMO or start-up: the VP/Director of R&D or the CTO, often with founder or site-GM sign-off, because the material choice is a technical and regulatory commitment rather than a purchasing decision. For a tier-1 OEM site: the economic buyer is not in Ireland at all - it is global category management / strategic sourcing at US headquarters, with the Irish site holding only requisition authority against an already-qualified supplier list. This split is the single most important commercial fact about the Irish cluster.

Potential customers

30 companies est.^{[ie-06] [ie-07] [ie-12] [ie-13] [ie-16]}

Readiness to pay

How badly they want it

Typical yearly budget

$250k est.^[ie-16]

What hurts them today

What buyers search for — demand is Growing

Search phrase	Searches /mo	Ad cost per click	Why they search
bioresorbable polymers supplier (English)	210 searches_per_month est.^[ie-16]	$6.5 est.^[ie-16]	Comparing products
PLGA polymer manufacturer (English)	170 searches_per_month est.^[ie-16]	$5.2 est.^[ie-16]	Comparing products
medical grade PLLA resin (English)	90 searches_per_month est.^[ie-16]	$7.1 est.^[ie-16]	Comparing products
custom polymer synthesis medical device (English)	70 searches_per_month est.^[ie-16]	$8.4 est.^[ie-16]	Comparing products
resorbable suture fibre supplier (English)	40 searches_per_month est.^[ie-16]	$4.8 est.^[ie-16]	Comparing products
polycaprolactone medical grade PCL (English)	260 searches_per_month est.^[ie-16]	$3.9 est.^[ie-16]	Just researching

Searches nobody answers well yet

Who we'd compete with — 6 vendors est.^{[ie-08] [ie-09] [ie-10] [ie-11] [ie-15] [ie-16]} serious vendors, concentrated market

Competitor	Local or global	Share of market	Price level	Good at / weak at
Ashland (Viatel bioresorbable polymers) ↗ The decisive competitor in Ireland, and the reason Ireland is structurally the worst EU target for RPS. Ashland is US-headquartered but MANUFACTURES its Viatel bioresorbable polymer range in Ireland - at the National Science Park, Mullingar, Co. Westmeath, with R&D relocated there from Dublin and two successive IDA Ireland-supported expansions, the second completed August 2024. Ashland supplies more than 70 GMP grades of lactide/glycolide/caprolactone copolymers and explicitly offers custom-made polymer production. That is a near-exact overlap with RPS's entire catalogue AND with RPS's claimed differentiator of custom molecular weight, L/D ratio and end-group. Classified origin 'international' because the corporate parent and global sales are US-based, but the operationally decisive fact is domestic Irish manufacture: an Irish buyer gets an EU-origin, in-country, audit-a-90-minute-drive-away, IDA-endorsed supplier.	Global player	—	Quotation-based, no public price list. Positioned as premium GMP pharmaceutical-grade material with full regulatory support.	+ Manufactures inside Ireland and inside the EU - zero origin, customs or sanctions friction+ 70+ GMP grades plus custom synthesis+ Deep regulatory documentation and DMF support for drug-delivery customers+ Large-corporate balance sheet and multi-site continuity story+ State-agency (IDA) relationship and local cluster embeddedness+ Recent capacity expansion signals supply security− Large-corporate responsiveness on very small development lots− Premium pricing− Bioresorbables are one line inside a large diversified specialty-chemicals group, so strategic priority can shift
Evonik Health Care (RESOMER) ↗ The reference brand of the category. RESOMER is the name most often written directly into device design history files and drug-delivery development reports, which makes it the default incumbent that any challenger must displace through regulatory change control. Manufactures in Germany (Darmstadt) and the US (Birmingham, Alabama), with a full CDMO offer wrapped around the polymer.	Global player	—	Quotation-based for GMP and bulk grades; research quantities retailed through Merck/Sigma-Aldrich at catalogue prices.	+ Strongest brand recognition and the widest installed base in filed devices and drug products+ EU-origin manufacturing+ Full CDMO service wrap from polymer to finished formulation+ Extensive regulatory dossiers and DMFs+ Ubiquity in the academic literature creates pull-through into commercial programmes− Premium pricing− Catalogue-first orientation can make genuinely bespoke specifications slow− Long lead times on custom grades
Corbion (PURASORB) ↗ The principal EU-origin alternative to Evonik, manufacturing in the Netherlands with backward integration into lactide monomer, which gives it a genuine raw-material cost and traceability advantage. Broad PURASORB range of lactide, glycolide, caprolactone and PEG copolymers spanning both medical-device and drug-delivery grades.	Global player	—	Quotation-based, no public pricing.	+ Backward-integrated to lactide monomer - strong supply-chain control and traceability+ EU (Netherlands) origin, short and uncomplicated logistics to Ireland+ Broad grade range covering both device and pharma applications+ Established DMF and compendial documentation− Less service wrap than Evonik's CDMO offer− Weaker position in converted semi-finished forms than in resin− No manufacturing presence in Ireland
Poly-Med Inc. ↗ The closest structural analogue to what RPS says it is: a specialist that sells not just resin but converted resorbable forms - fibres, monofilament and multifilament yarns, meshes, films and tubing - together with contract development. This is the most direct competitor for RPS's fibre, tubing and film lines, and the one that already occupies the 'custom, converted, development-partner' niche that stage 03 identified as RPS's addressable slice. US-based (Anderson, South Carolina).	Global player	—	Quotation-based; positions on development partnership rather than material unit price.	+ Genuine capability in converted forms (fibre, yarn, mesh, film, tubing), not just resin+ Willing to work with development-stage and lower-volume customers+ Deep resorbable fibre-spinning know-how+ Flexible on custom chemistry− Smaller scale and balance sheet than Evonik/Corbion/Ashland− US origin adds customs and, for some EU buyers, supply-chain-length concerns− Less brand presence in EU academic literature
Merck / Sigma-Aldrich (RESOMER and resorbable polymer catalogue) ↗ Not a manufacturer of the medical grades but the dominant CHANNEL for research-scale and early-development quantities, distributing Evonik's RESOMER line among others. This matters disproportionately for Ireland because s-research-custom-synthesis demand from university biomaterials groups is one of the few segments with a near-zero qualification barrier - and Sigma-Aldrich already owns that channel with next-day delivery and a purchase-order relationship every Irish university already has.	Global player	—	Published catalogue pricing for research pack sizes (grams to tens of grams) - the only genuinely transparent pricing in the category.	+ Owns the research-buyer relationship and the frictionless small-quantity purchase path+ Transparent published pricing+ Immediate availability and short lead times+ Trusted established vendor in every Irish research institution's purchasing system− Very high price per gram at research scale− Limited custom-specification capability - catalogue grades only− Does not scale into GMP commercial supply, so wins the researcher but hands the commercial account to the underlying manufacturer
Foster Corporation (a Nolato company) ↗ Competes at the converted-form layer rather than the polymerisation layer - medical polymer compounding, distribution of bioresorbable resins and custom compounds, and supply of extruded/processable forms. Relevant to Ireland because Irish converters often want a processable compound or a semi-finished form rather than neat resin, and Foster has an established partnership footprint with Irish implantable-textile players.	Global player	—	Quotation-based; compounding and tolling economics rather than resin list pricing.	+ Strong in compounding and converted forms+ Existing relationships in the Irish/Galway converter base+ Flexible on smaller compound lots+ Nolato ownership gives scale and continuity− Depends on third-party base resin - not a primary polymer producer− Narrower custom-chemistry capability than a true polymeriser− Less regulatory documentation depth than the resin manufacturers

Customers they leave behind

Rules & barriers to enter

Foreign companies allowed

Needs a local company set up

Yes

How hard to enter

Tax paperwork

Licenses needed

No Irish licence is required to sell a raw polymer per se - the material is not a medical device and the seller is not a manufacturer under EU MDR; the regulatory burden sits with the customer, EU REACH registration of constituent monomers, or appointment of an Only Representative, where the EU importer role is assumed, Where the polymer is supplied as a pharmaceutical excipient, a Drug Master File / ASMF and GMP conformity are commercially mandatory though not a licence, An Irish/EU corporate entity, VAT registration and EORI number would be required for any EU-based operating model

Data protection rules

GDPR applies in full, enforced by the Irish Data Protection Commission, which is one of the EU's most active supervisory authorities because so many multinationals have their EU establishment in Ireland. For a B2B materials business the practical obligations are modest - lawful basis for B2B marketing contact and a compliant privacy notice. On international transfers, the disclosed corporate structure materially eases what would otherwise be a real obstacle: a US-domiciled contracting entity can rely on the EU-US Data Privacy Framework if certified, or on Standard Contractual Clauses otherwise, and a UAE entity can use SCCs with a transfer impact assessment - both ordinary, workable arrangements. Only onward transfer of EU personal data to the Russian operating site raises the harder question, since there is no adequacy decision for Russia and a transfer impact assessment is difficult to pass given state access powers. This is a manageable, second-order compliance item rather than a barrier, and it is not among the reasons Ireland fails.

Culture & language hurdles

How we'd win customers

Sellable remotely

How hard to win customers

Cost to win one customer

no data

Time from contact to deal

24 mo est.^{[ie-15] [ie-16]}

Needs a local office

Yes

Channels that work

NONE are effective for RPS as currently constituted - the goods are import-prohibited, so no channel converts. The channels below describe what WOULD work in this market for a lawfully-supplying entrant, and are included so the entry cost of the compliant path can be assessed rather than as a recommendation for the Russian entity., Direct technical field sales with a materials scientist, not a salesperson, calling on R&D and process engineering - this is how every incumbent wins in Ireland, Cluster-level presence and relationships: Irish Medtech (Ibec) events, the Galway medtech network, Enterprise Ireland and IDA Ireland introductions, Co-development and joint-development agreements with Irish CDMOs, which convert a material sale into a design-in before a device is filed, University and research-centre partnerships (biomaterials and regenerative-medicine groups) to seed specification of the material in programmes that later commercialise, Technical content and published application data - degradation-profile studies, processing guides, biocompatibility summaries - which is the primary discovery route for materials engineers, Trade conferences: MD&M/MedTech Ireland, CPHI, TIDES, Society for Biomaterials, Sample-and-evaluate programmes with genuinely small minimum quantities, which is the single most effective wedge against incumbent MOQ pain

The money math

Revenue per customer /yr

$250k est.^[ie-16]

Cost to win one customer

no data

Return ratio (LTV/CAC)

no data

Gross margin

65% est.^[ie-16]

Months to earn back a sale

no data

Year-1 cost to enter

$10M est.^[ie-16]

3-year return

no data

Months until profitable

no data

What could go wrong here

Risk	How bad if it happens	How likely
regulatoryRPS's entire physical product range is on the EU import-prohibition list. Annex XXI Part B to Regulation (EU) No 833/2014 - as replaced by Annex VI to Regulation (EU) 2022/1904 - lists CN heading 3907 at four-digit level (covering PLLA, PDLLA, PGA, PLGA, PCL and PLCL resins as polyesters in primary forms), together with 3916 (rods and monofilament >1mm, i.e. 3D-printing filament), 3917 (tubing, i.e. stent tubing), 3919/3920/3921 (films, i.e. anti-adhesion films), 3926 (articles of plastics n.e.s.) and 5402 (synthetic filament yarn, i.e. surgical fibres and threads). Article 3i prohibits their purchase, import or transfer, directly or indirectly, where they originate in or are exported from Russia. Article 3i's only derogations are expired contract wind-downs, diplomatic and personal use, and civil nuclear - there is NO medical, pharmaceutical or humanitarian carve-out on the import side, notwithstanding that such carve-outs do exist in the opposite direction under Article 3k. The prohibition binds the Irish purchaser, not only RPS, and the indirect-transfer wording defeats third-country transshipment. CORPORATE STRUCTURE DOES NOT CURE THIS. RPS publicly presents UAE (Dubai free-zone) and US (Delaware registered-agent) addresses and no Russian address, so the contracting and invoicing counterparty can be non-Russian and can be paid normally. Article 3i is indifferent to that: it attaches to goods that originate in Russia or are exported from Russia, and non-preferential origin under Article 60 of the Union Customs Code follows the last substantial transformation, which invoicing and transshipment do not supply. The prohibition binds the Irish purchaser, and the 'directly or indirectly' wording is drafted precisely to catch an intermediary structure. What we'd do: None available at the level of sales execution or corporate structuring - this is not a risk to be managed but a bar to be respected, and no invoicing arrangement resolves it. The only genuine mitigations are to change where the polymer is actually MADE: license the technology and know-how to an EU manufacturer that produces the material itself and thereby confers genuine EU origin through substantial transformation, or establish EU production directly. Both convert RPS from an exporter into a licensor or an EU producer. Confirm the current consolidated Annex XXI text with Irish counsel before acting on any interpretation, and do not rely on the narrow argument that contract R&D services fall outside Article 3i without that advice.
competitiveAshland manufactures its Viatel bioresorbable polymer range inside Ireland, at the National Science Park in Mullingar, supplying more than 70 GMP grades of lactide/glycolide/caprolactone copolymers plus explicitly custom-made polymer production, and has completed two successive IDA Ireland-supported expansions, the most recent in August 2024. This is an almost exact overlap with RPS's catalogue and, critically, with RPS's claimed differentiator of custom molecular weight, L/D ratio and end-group specification. The custom-spec, mid-volume, converted-form niche that stage 03 identified as RPS's addressable slice is therefore not open in Ireland - it is occupied by an EU-origin, in-country, state-endorsed incumbent, with Poly-Med covering the converted-forms niche from the US. What we'd do: Not mitigable in Ireland. Recognise that Ireland offers no white space and no origin advantage, and reallocate commercial effort to the markets identified in stage 03 where RPS's custom-synthesis flexibility is genuinely scarce and where supplier origin is not disqualifying.
competitiveEven setting sanctions entirely aside, the Irish cluster is close to the worst possible target for a new material supplier. Once a device is filed with a named polymer supplier, changing supplier requires re-running biocompatibility and degradation testing and, for implantables, a change to the EU MDR technical documentation reviewed by the notified body - an 18-36 month cycle with real cost and no clinical upside, which buyers avoid. That makes early-R&D programmes the only realistically winnable targets. But Ireland's cluster is dominated by large multinational OEMs manufacturing long-since-filed products against qualified-supplier lists controlled by US global sourcing, so the population of Irish programmes still open to a new material supplier is small - plausibly fewer than a dozen active resorbable programmes nationally, concentrated in a handful of CDMOs and start-ups. What we'd do: In any market, target programmes before their design history file closes: pre-clinical developers, CDMOs at feasibility stage and university spin-outs, offering very small minimum order quantities and degradation-profile development support as the wedge. Never build a plan on displacing an incumbent on a filed device. In Ireland specifically this mitigation is available only to a compliant entity, and even then the target population is thin.
regulatoryOrigin-declaration and circumvention exposure created by the offshore structure itself. Because RPS presents UAE and Delaware addresses while manufacturing in Ulyanovsk, there is an obvious and dangerous temptation to let an Irish buyer infer UAE or US origin from the invoice. Doing so would be materially worse than not trading: the Irish importer is legally responsible for the origin declared on the customs entry, so a misdeclaration creates liability for the CUSTOMER as well as for RPS; deliberately routing or re-invoicing to obscure Russian origin engages the anti-circumvention prohibition in Regulation 833/2014; and under ISO 13485 and EU MDR supplier controls a manufacturing site that turns out to differ from what was represented is a supplier-fraud finding that would trigger customer notification, quarantine of affected lots and potentially a notified-body issue on the customer's device. The risk is not hypothetical drift - it is the predictable failure mode of a company whose public contact page shows no Russian address while its plant is Russian. What we'd do: Be affirmatively transparent about country of manufacture in every first-contact document, quotation and specification sheet, rather than waiting to be asked - the cost of volunteering it is a lost opportunity that was never winnable, and the cost of not volunteering it is a compliance incident naming both parties. Never accept an order into Ireland or any EU member state on the current manufacturing footprint. If EU access is pursued, do it by relocating or licensing production so that EU origin is genuine and can be documented, not by restructuring the paperwork around unchanged goods.
operationalAn offshore invoicing entity does not satisfy an Irish OEM's supplier qualification. ISO 13485 and EU MDR supplier controls require qualification of the manufacturing site, normally including a physical on-site audit for a critical implantable material, plus a change-control agreement naming the real production location and full traceability to the manufacturing batch record. The auditable site is Ulyanovsk. Separately, Irish medtech is a tight, high-trust cluster in which supplier reputation circulates quickly and most large sites are US-owned and apply US-headquarters compliance policy as their own; Ireland's firm public position on the war in Ukraine and its large Ukrainian refugee population make the association commercially costly beyond the compliance question. A structure that looks designed to obscure origin would compound this substantially, prejudicing any future approach - including a later, lawfully-structured EU entity. What we'd do: Do not run outbound campaigns into the Irish cluster on the current manufacturing footprint, and do not present the UAE or Delaware entity in a way that implies non-Russian manufacture. If an EU-based producing structure is ever established, introduce it on its own merits and genuine EU origin rather than as a rebrand of the existing business, and expect origin-of-manufacture, site-audit and ultimate-beneficial-ownership questions at supplier qualification regardless.

▶🇨🇳 China

East Asia · Chinese (Mandarin), English

Avoid

AVOID — Open to Russian-origin goods but structurally unprofitable. Domestic producers set a price floor that a small Russian converter cannot undercut, and policy actively favours domestic substitution, so the one thing RPS could compete on - price against Western premium suppliers - is already occupied by local incumbents on their home ground.

Profitability score 33.1, the lowest of the seven, against demand 84.2 - high volume at prices that do not pay.
Published domestic PLGA at $8-30/g sets the floor, and NMPA approval sits on top of a domestic-substitution policy climate.
Overall 47.4 with ease-of-entry 23 and reg-safety 17.5; no economics were modelled for CN, which itself reflects that no realistic entry case was found.

Market attractiveness

Growth momentum

Customer demand

Buying power

Weak competition

Profit potential

Ease of entry

Regulatory safety

Ease of winning customers

Springboard value

All bars 0–100, higher is always better.

The market here

Yearly market size

$250M est.^{[cn-01] [cn-02] [cn-03] [cn-11] [cn-21] [cn-06]}

Growth per year

13% est.^{[cn-01] [cn-02] [cn-03] [cn-24]}

Size in ~3 years

$360M^{[cn-01] [cn-02]}

Life stage / how crowded

Growing · saturation

Who buys

Ideal customer: A Chinese device OEM or pharma formulator at the pre-filing R&D or pilot stage of a resorbable product, needing a custom polymer spec (defined molecular weight, L/D ratio, terminal group, or a PLCL/PLGA composition) that the domestic catalogue does not carry off the shelf, whose end product is destined for the Chinese domestic market rather than US/EU export, and whose technical team will run a second-source qualification — explicitly NOT an OEM with a device already registered against a named incumbent supplier.
Who signs the contract: For device OEMs, the general manager or VP of R&D — material spend is small in absolute terms but the qualification commitment is a company-level decision, so it rarely sits with purchasing alone. For pharma microsphere programmes, the CMC/formulation head with the regulatory affairs director holding a veto. For research groups, the principal investigator spending grant money.

Potential customers

400 companies est.^{[cn-06] [cn-21]}

Readiness to pay

How badly they want it

Typical yearly budget

$30k/year est.^{[cn-12] [cn-13] [cn-20] [cn-22]}

What hurts them today

What buyers search for — demand is Growing

Search phrase	Searches /mo	Ad cost per click	Why they search
医用级聚乳酸 PLGA 供应商 (zh)	~320/mo est.	$1.4 est.	Comparing products
可吸收缝合线原料聚乙交酯 PGA 厂家 (zh)	~180/mo est.	$1.1 est.	Ready to buy
PLGA 微球药用辅料登记号 (zh)	~140/mo est.	$2.2 est.	Comparing products
医用聚己内酯 PCL 原料价格 (zh)	~260/mo est.	$0.9 est.	Ready to buy
定制合成聚乳酸分子量端基小批量 (zh)	~70/mo est.	$1.8 est.	Comparing products
医疗器械主文档登记原材料可吸收 (zh)	~90/mo est.	$1.6 est.	Just researching

Searches nobody answers well yet

Who we'd compete with — 15 vendors est.^{[cn-14] [cn-15] [cn-16] [cn-17] [cn-18] [cn-19] [cn-04] [cn-05]} serious vendors, fragmented market

Competitor	Local or global	Share of market	Price level	Good at / weak at
Jinan Daigang Biomaterial (济南岱罡生物工程有限公司) ↗ The deepest bioresorbable catalogue in China and the closest direct analogue to Resotech's own product range — breadth and price, with essentially no regulatory packaging.	Local player	—	Quote-only — the entire ~30-page catalogue carries no price fields, and no price point could be obtained. Positioned at the low end; comparable Chinese PLGA on chemical marketplaces runs ~USD 2,800/kg at 1 kg and USD 7,500-15,000/kg at 50-100 g, versus USD 20,000/kg for Western branded at 50 g+.	+ Extraordinary product breadth — lactide/glycolide/TMC/PDO monomers, PLLA/PDLLA/PDLA each in ester, -OH and -COOH endcaps, PLGA at custom ratios 90:10 to 50:50, PCL Mw 4k-280k, PTMC, PPDO, mPEG di-block and PEG tri-block copolymers, 4/5/6-arm star polymers, thermosensitive sol-gel hydrogel+ Also sells converted forms — electrospun membrane, porous foam scaffold sheet/tube/rod, fibre and PLA film — directly overlapping Resotech's converted-form offer+ Published QC spec (LOD ≤0.5%, ROI ≤0.5%, heavy metals ≤10 ppm, catalyst residue ≤200 ppm, residual monomer ≤1%) produced in a 100,000-class cleanroom+ Domestic entity — no duty, no origin question, CNY invoicing with fapiao+ Operating since 2002− No ISO 13485, ISO 10993, USP Class VI or master file claim anywhere on the site — its only third-party test reports are dated 2014 and a test report is not a master file− Website content stale since roughly 2016; founder-led and research-reagent in scale− Cannot support a customer's Class III NMPA submission, so an OEM using it must generate its own biocompatibility and characterisation package− Trades under two near-identical company names with the same contact person, which complicates counterparty diligence
Shandong Caicai Medical Technology (山东采采医疗科技有限公司) The most consequential competitor found in this research and one the original brief did not anticipate. A Jinan-based subsidiary of 谷雨春生物, founded 2019, that has done precisely what a foreign entrant would need to do — built a documented, NMPA-registered bioresorbable portfolio at injectable grade — and got there first.	Local player	—	Quote-only; no price point obtainable. Domestic cost base, and competing for exactly the high-documentation business a foreign entrant would target.	+ Holds multiple NMPA Medical Device Master Files verified on the CMDE public registry — PLA (M2024085-000), PCL Type I and Type II, and PLGA at 8515 (M2023171-000), 7525 (M2024109-000) and 5050 (M2024110-000), the last two explicitly 供注射用 (for injection), which is the hardest specification tier+ Has an approved finished product — China's first NMPA-approved domestic injectable PCL microsphere filler, 塑妍真·真妤 — proving the material through to clinical registration+ Domestic entity: no duty, no origin question, no chemical-import registration burden, CNY invoicing+ Directly contradicts the assumption that documented supply is a Western preserve− Young company (founded 2019) with a shorter track record than the established catalogue houses− Narrower chemistry breadth than Jinan Daigang — no PTMC, PPDO, star or block architectures found− Master file registration is not the same as review: CMDE's own disclaimer states a registered file has been neither reviewed nor necessarily used in a marketed device− Appears focused on injectable and aesthetic applications rather than the full device breadth
Foryou Medical — FORUSORB® / 华素宝® (惠州华阳医疗器械有限公司) ↗ The most credible domestic candidate for a qualified supply relationship: a monomer-to-polymer integrated device manufacturer that also sells feedstock as a distinct B2B brand, carrying a device-grade quality system behind it.	Local player	—	Quote-only; FORUSORB spec sheets and prices not published. Cost position benefits from monomer-to-polymer-to-device integration.	+ Sells glycolide, L-lactide, DL-lactide, p-dioxanone and TMC monomers plus PGA and PLGA polymer as a named raw-material brand — verified on both Chinese and English sites+ Claims ISO 13485 and CE, with FDA 510(k) finished products — the quality system a Class III customer's audit looks for, which the pure-play domestic resin houses lack+ Monomer-to-polymer integration gives both cost and supply-continuity credibility+ Established export track record− FORUSORB product specifications and prices are not published, and deep pages on the site return 404 — hard for a buyer to evaluate without contact− Narrower chemistry than Daigang or Polymtek — PGA and PLGA only, no PCL, PLCL, PTMC or star architectures− Sells to companies that may compete with its own device business, a structural conflict for some buyers− No confirmed master file registration number
Evonik Health Care — RESOMER / LACTEL ↗ The regulatory-grade default. Sells documentation, supply security and the ability to carry a customer through a device or drug filing as much as it sells polymer.	Global player	—	Premium, and verified at the research tier: RESOMER RG 502 H at USD 109 per 1 g and USD 350 per 5 g (USD 70,000-109,000/kg); RG 503 H at USD 165 per 5 g (USD 33,000/kg); L 206 S PLLA at USD 677 per 25 g (USD 27,080/kg). Bulk contract pricing is not published and could not be obtained.	+ Deepest regulatory support package; states RESOMER meets ASTM F2313 with catalyst residue ≤100/150 ppm+ Widest form range of any supplier — granule, powder, filament, tube and medical textile (yarn, mesh, nonwoven), plus composite (HA, β-TCP) and 3D-printing grades+ Acquired LACTEL in 2020, consolidating the drug-delivery catalogue+ Brand that de-risks a reviewer's question+ Shanghai application lab and regulatory support presence− Price is a standing invitation to domestic substitution under VBP cost pressure — 20-30x domestic at comparable pack sizes− cGMP production is only in Birmingham, Alabama and Darmstadt/Jena — nothing is made in China, so all supply is imported with the associated lead time− Slow and expensive for small bespoke lots− Large-account focus leaves pilot-scale custom work underserved
Corbion — PURASORB ↗ The other half of the regulated-grade duopoly, strong on lactide/glycolide monomer and polymer purity, with a broad IV and degradation range (IV 0.2 to 6.0+ dl/g, degradation 0.5 to over 24 months).	Global player	—	Premium and verified through its US small-quantity channel: all standard PDLG/PDL/PL/PLG/PLDL grades at USD 30/g in 1-9 g and USD 20/g at 50 g+ (USD 20,000-30,000/kg); PLC 7015 PLCL at USD 35/g; specialty PDLG 5505G star-glucose at USD 200/g. Bulk pricing not published.	+ Monomer-to-polymer integration and purity control+ Separate device-grade and drug-delivery-grade product families+ Claims ICH Q7 and ISO 9001:2015 GMP+ Established Shanghai commercial presence− Does NOT claim ISO 13485, unlike Poly-Med and unlike domestic competitor Foryou — a gap a well-prepared challenger can point at− Same price exposure to domestic substitution− No confirmed third-party Chinese distributor, so small-quantity Chinese buyers are served awkwardly via US repackagers− Standard catalogue orientation limits appetite for unusual one-off specifications
Research catalogue channel — Sigma-Aldrich/Merck and Akina PolySciTech ↗ Catalogue availability of branded regulated-grade polymer in research pack sizes — the default first purchase for a Chinese academic or early-R&D buyer who wants material this week with no supplier qualification.	Global player	—	The highest per-kg of any channel and the tier Resotech would actually enter against: USD 30/g at 1-9 g falling to USD 20/g at 50 g+ for PURASORB and Ashland Viatel; Aldrich-channel RESOMER from USD 27,000/kg to USD 109,000/kg depending on grade and pack. Convenience pricing, not material pricing.	+ Immediate availability and frictionless small-quantity purchase inside China+ Carries the Evonik, Corbion and Ashland brand names into research accounts, seeding later scale-up preference+ No qualification burden at this order size+ Effectively the only accessible small-quantity route for PURASORB and Viatel− Effective price per kg is extreme, leaving very wide room for a challenger to undercut while still earning a strong margin− Catalogue grades only — no custom synthesis, no defined-end-group or unusual-ratio work− Not a scale-up path; customers must re-source when volumes grow− Pack sizes capped well below pilot scale

Customers they leave behind

Rules & barriers to enter

Foreign companies allowed

Yes

Needs a local company set up

How hard to enter

Tax paperwork

Licenses needed

No Chinese medical device licence attaches to the polymer itself — bulk resorbable resin is a raw material, not a registered device, so no 医疗器械注册证 or 医疗器械经营许可证 is required to sell it, The importer of record must be a Chinese entity with import/export rights and customs registration (海关报关单位注册登记) — in practice a distributor, agent or the customer itself, NMPA 医疗器械主文档登记 (Medical Device Master File), under 国家药监局公告 2021年第36号 — voluntary, free, and explicitly aimed at raw materials (主文档内容主要涉及医疗器械原材料等). A foreign owner CAN file, but must do so through a Chinese agent (境内代理机构), with the dossier in Chinese and a CA certificate, via erps.cmde.org.cn. Crucially it is NOT reviewed at registration — CMDE assesses the file only when a device registrant references it, and the registry page states plainly that registration does not mean the file has been reviewed or used. Commercial term to note: once granted to a customer, the authorisation to reference is irrevocable, For pharma-grade PLGA: registration on the NMPA 化学原料药、药用辅料和药包材登记平台 to obtain an excipient (F-) number. An overseas supplier may register through a resident representative office or Chinese agent, with a Chinese-language dossier and joint liability for its accuracy. Only APIs receive standalone review — an excipient registration sits permanently at status 'I' until a customer's drug application pulls it through to 'A', so the asset cannot be completed in advance of a customer, MEE new chemical substance registration under 生态环境部令第12号 — a REAL AND UNDER-APPRECIATED GATE, not a formality, and it is the single largest compliance item for this business. Medical devices are NOT on the Order 12 exclusion list (which covers pharmaceuticals including APIs, pesticides, cosmetics and food), and excipients are not exempt either. PCL is on the IECSC inventory and is clean. PLA/PLLA, PGA and PLGA were NOT found in the 2013 public inventory, and if genuinely new they cannot use the cheap record-filing (备案) route above 1 tonne/year, because degradable polymers are expressly excluded from the low-concern polymer category — the entire product function is hydrolytic degradation. That forces 简易登记 (1-10 t/y, 8-12 months) or 常规登记 (≥10 t/y, 14-24 months with a full ecotoxicology package). Below 1 t/y the 备案 route survives and activity may begin on submission, so sampling and qualification quantities stay cheap and only scale-up hits the wall. There is NO research exemption — Order 12 puts 研究 explicitly in scope. FIRST ACTION: an MEE-SCC inventory status enquiry costs ~RMB 3,000 (~USD 430) and about two weeks, and covers the confidential portion of the inventory as well — buy it for PLLA, PGA and PLGA before anything else, because it resolves a question that otherwise costs one to two years

Data protection rules

Low practical burden for this business. PIPL and the Data Security Law apply to any Chinese customer contact data collected through a website or CRM, and cross-border transfer of personal information has a filing/standard-contract regime, but a B2B supplier holding a few hundred business contacts sits far below the thresholds that trigger a security assessment. Two practical clarifications matter more than the privacy law itself. First, ICP filing is keyed to HOSTING LOCATION, not language or domain: a Chinese-language site hosted in Hong Kong, Singapore or the EU needs no ICP filing even on a .cn domain, and only a PRC entity can obtain one. So a foreign supplier has three options — host offshore with no filing but poor mainland latency and throttling risk; establish a WFOE and file; or host under the distributor's ICP, which means the distributor legally owns the filing and effectively controls the site. Every verified Chinese competitor carries an ICP number (Daigang 鲁ICP备11027909号-1, Polymtek 粤ICP备2022096756号, Foryou 粤ICP备15063100号), confirming mainland hosting is the local norm. Second, cross-border transfer thresholds are far above this business: under CAC Order 16 a non-CIIO transferring fewer than 100,000 individuals' non-sensitive personal information per year is exempt from standard contracts, certification and security assessment entirely, and a B2B pipeline sits two to three orders of magnitude below that. Note one common misreading — the 'necessary to conclude or perform a contract' exemption does NOT cover B2B contact data, because it requires the natural person to be a party to the contract, which a purchasing manager is not. Practical package: host offshore, publish a Chinese-language privacy notice, take separate unbundled consent for cross-border transfer at form submission, collect no sensitive personal information, and keep an annual count as evidence.

Culture & language hurdles

How we'd win customers

Sellable remotely

How hard to win customers

Cost to win one customer

$18k est.

Time from contact to deal

18 mo est.

Needs a local office

Channels that work

A Chinese distributor or technical agent acting as importer of record, CNY invoicing party and local face — the single highest-leverage channel and close to a precondition for anything beyond sample sales. Note that neither Evonik nor Corbion appears to use one, selling direct from Shanghai offices instead, which leaves the small-quantity Chinese buyer awkwardly served and is an exploitable gap, Chinese chemical and biomaterials sourcing platforms — ChemicalBook, Molbase/摩贝 and 1688 — where domestic competitors actually list and where procurement staff price-discover; ChemicalBook listings were the only place any Chinese medical-polymer price could be found, MEDTEC China (医疗器械设计与制造技术展) — the trade fair aimed at medical device materials, components and contract manufacturing, and a better fit for a raw-material supplier than CMEF, CMEF (中国国际医疗器械博览会) — much larger but finished-device oriented; useful for account mapping and meetings rather than materials lead generation, CPHI China / 世界制药原料中国展 for the pharma drug-delivery segment, where excipient sourcing conversations happen, Direct technical business development into a named account list — the reachable universe is small enough to work by name rather than by funnel, WeChat official account plus Chinese-language technical content; WeChat is the working channel for ongoing engineer-to-engineer contact, Academic and CAS-institute relationships, joint papers and conference presence as a low-cost credibility route into research and early-R&D buyers — the segment where the competition is a USD 30/g catalogue price rather than a cheap domestic quote, Baidu organic presence via a Chinese-language, China-hosted site — slow, and gated on an ICP filing that requires a Chinese entity

The money math

Revenue per customer /yr

$12k/year est.^{[cn-12] [cn-13] [cn-20]}

Cost to win one customer

$18k est.

Return ratio (LTV/CAC)

1.3^{[cn-12] [cn-13] [cn-06]}

Gross margin

50% est.^{[cn-12] [cn-13] [cn-20]}

Months to earn back a sale

36 mo^{[cn-12] [cn-13] [cn-06]}

Year-1 cost to enter

$150k est.

3-year return

-19%^{[cn-12] [cn-13] [cn-06]}

Months until profitable

40 mo est.^[cn-06]

What could go wrong here

Risk	How bad if it happens	How likely
competitiveDomestic producers compete hard on chemistry breadth and price, and the overlap with Resotech's own range is close to total. Jinan Daigang alone offers lactide/glycolide/TMC/PDO monomers, PLLA/PDLLA/PDLA in three endcap variants, PLGA at custom ratios, PCL across Mw 4k-280k, PTMC, PPDO, block copolymers and star architectures — plus converted forms including electrospun membrane, porous scaffold and fibre. That is the Resotech product concept, already present domestically, with no duty, no origin question and prices roughly 40-60% of Western branded at like-for-like pack sizes and ~USD 2,810/kg at the 1 kg tier. Volume-based procurement keeps compressing device prices and pushes that pressure back onto material cost. The nuance that the broad-catalogue houses (Daigang, Polymtek) publish no ISO 13485, ISO 10993 or USP Class VI claim is real but must NOT be generalised into comfort. The CMDE master file registry shows roughly ten OTHER Chinese suppliers already holding NMPA master files for bioresorbable polymers, several at injectable grade — 山东采采 holds PLGA 7525 and 5050 registered 供注射用 plus PLA and PCL, and has an approved domestic injectable microsphere filler on the market — while Evonik's only master file is PEEK and Corbion has none. The documented tier in China is therefore already domestic, not Western, and the quality-and-documentation gap that would justify a foreign premium is closing rapidly and not in a Russian entrant's favour. Underneath this, VBP keeps compressing the money available for material: coronary stents fell roughly 93% in the 2020 national procurement (about RMB 13,000 to under RMB 1,000) and multi-province absorbable suture tenders have taken average cuts near 29% with maxima above 55%, so a stent or suture OEM simply cannot absorb premium imported resin. What we'd do: Do not compete on catalogue chemistry or price against the domestic base, and do not assume documentation alone is a differentiator — the registry evidence shows it no longer is, because domestic suppliers hold injectable-grade master files while Evonik and Corbion hold none for bioresorbables. The defensible ground is narrower: documented BESPOKE synthesis at pilot scale in chemistries the master-file holders do not cover (PLCL, defined end-groups, high-IV fibre and tubing grades, star and block architectures), plus the research tier where the real competitor is a USD 20-30/g catalogue price rather than a domestic quote. Holding ISO 13485, a full ISO 10993 package and an NMPA master file is the entry ticket rather than the advantage. Concentrate on non-VBP, non-reimbursed segments — aesthetics and pharma long-acting injectables — where margin survives, and qualify out of any opportunity where the buyer's first question is price per kilogram.
regulatorySwitching cost locks the installed base, though the MECHANISM IS NOT THE ONE USUALLY ASSUMED and this was corrected during research. A raw-material supplier change does NOT automatically trigger a licence-item change: supplier is absent from the enumerated 变更注册 triggers in 市场监管总局令第47号 (which are 产品名称、型号规格、结构及组成、适用范围、产品技术要求、进口医疗器械的生产地址), and CMDE's 《无源医疗器械产品原材料变化评价指南》 places supplier and grade change in the lowest-risk bucket ④, where the registrant performs a risk assessment and decides whether re-registration is needed. The real barrier is therefore a VALIDATION PROGRAMME rather than a filing — for a bioresorbable implant, full physicochemical characterisation (Mw/Mn, residual monomer, residual solvent, metals), GB/T 16886 biocompatibility re-testing, sterilisation revalidation (both EO and gamma attack PLA molecular weight), degradation-profile re-verification and mechanical testing. That is a 12-24 month, seven-figure-RMB commitment, and it escalates into a formal 变更注册 only if the change reaches 产品技术要求 or 结构及组成. The practical consequence is unchanged and arguably strengthened: displacing a qualified incumbent resin is very hard, commercially attractive in-production accounts are effectively unreachable, and early design-in is worth far more than price. On the pharma side the lock is at least as strong, because for a PLGA microsphere the polymer IS the release-controlling element, so a supplier change is a formulation change rather than an inert-filler swap. A SEPARATE AND LARGER REGULATORY BARRIER surfaced in research: MEE new chemical substance registration. Medical devices are not exempt under 生态环境部令第12号, PLA/PGA/PLGA were absent from the 2013 public IECSC inventory, and degradable polymers are expressly barred from the cheap record-filing route above 1 tonne/year — so commercial-scale supply could require 简易登记 or 常规登记 taking 8-24 months plus a full ecotoxicology package, before a single kilogram ships at scale. A SECOND, SLOWER-BURNING REGULATORY RISK sits in procurement policy. Imported raw material is currently insulated from domestic-substitution rules — 财库便函〔2021〕551号 mandates 100% domestic procurement across 137 medical device categories but reaches only imported FINISHED devices, and a Chinese-made device built from imported resin still qualifies as 本国产品 under the attribute-change test in 国办发〔2025〕34号. That insulation is conditional: MOF has a five-year window to set per-category component-cost thresholds, and if domestic content is eventually assessed at component level for resorbable categories, imported polymer would shift from irrelevant to disqualifying for any tendered product. Compounding the difficulty, 财库便函〔2021〕551号 is an unpublished internal circular, so the rule that governs this cannot be read by a foreign supplier at all. What we'd do: Buy an MEE-SCC inventory status enquiry for PLLA, PGA and PLGA immediately — ~RMB 3,000 and two weeks resolves whether commercial-scale supply needs a 1-2 year chemical registration, and it is the cheapest decision-relevant information available anywhere in this market. Sequence volumes to stay under the 1 tonne/year record-filing threshold during qualification, which keeps the chemical barrier cheap until a customer justifies crossing it. Target exclusively pre-filing programmes and make that an explicit qualification criterion. Get the polymer named in the customer's dossier at first filing, which converts the validation burden from a barrier into a moat working in the supplier's favour — and price accordingly, because the customer is buying out of a seven-figure revalidation, not just buying resin. File an NMPA master file early: it is voluntary, free, unreviewed until referenced, and open to foreign owners through a Chinese agent, so it is unusually cheap positioning — but note the authorisation to a customer is irrevocable once granted. On the procurement-policy risk: retain a Chinese regulatory adviser with sight of internal circulars and provincial 不予采购进口产品清单, because these texts are not public and the constraint is otherwise only discoverable through a customer's lost tender. Favour customers whose products sell into private hospitals and aesthetic clinics over those dependent on government tenders, since the domestic-content rules apply to public procurement.
politicalRussian manufacturing origin, correctly scoped. The payment half of this risk is substantially mitigated by the company's own structure: it publicly lists UAE (Dubai free-zone) and US (Delaware) addresses, so a Chinese buyer can contract with and pay a non-Russian entity in USD, EUR or AED, avoiding the Chinese-bank screening that has obstructed Russia-China settlement since 2024. What remains is origin risk, and an offshore invoice does not remove it. The goods are made in Ulyanovsk, so customs origin documents say Russia; a Chinese OEM exporting its finished device to the US or EU must still assess whether Russian-origin input creates exposure, pushing the addressable pool toward domestically-focused programmes; and the customer's QA function audits the manufacturing site, not the invoicing entity, so Class III qualification requires site-level evidence and often an audit in Russia. A subtler risk: a buyer who discovers the Russian origin late, having contracted with a Dubai entity, may treat the discovery itself as a disclosure failure — more damaging than the origin would have been if stated up front. What we'd do: State manufacturing origin plainly and early in the technical package rather than letting it surface during the audit — the origin is not disqualifying for domestically-focused Chinese programmes, but a late discovery is. Use the UAE or Delaware entity as contracting and settlement counterparty and present the payment route as a solved question with a named bank and currency. Invest in making the Ulyanovsk site audit-ready (site-level ISO 13485, remote audit capability, documented change notification), because that, not the invoice, is what a Class III customer's QA actually tests. Screen accounts toward products destined for the Chinese domestic market. Verify the entity and shipping arrangements internally before making any of these claims to a customer.
operationalIntellectual-property leakage through the development model, and it is sharper here than in most markets because a domestic producer with near-identical chemistry breadth already exists. The company's differentiation is bespoke synthesis know-how — molecular weight control, L/D ratio, terminal group chemistry, degradation tuning. A contract-R&D engagement necessarily exposes specification detail and, at scale-up, process understanding, inside an ecosystem where Jinan Daigang already offers every endcap variant and copolymer architecture in the Resotech range. The realistic failure mode is not patent theft but a customer using the developed specification to brief a cheaper local supplier at the point of commercialisation — precisely when the revenue was supposed to arrive. What we'd do: Stage disclosure: share property specifications and performance data freely, hold synthesis route and process parameters back. Charge properly for development work so the engagement is profitable in its own right rather than a loss-leader against uncertain future supply. Prefer selling converted semi-finished forms over resin, since the conversion step embeds know-how that is harder to hand to a substitute supplier. Above all, prioritise being named in the customer's regulatory filing — a far more durable lock than any contractual clause, because it makes substitution a regulatory event.
demandPipeline mortality, cycle length, and a reachable slice much smaller than the headline market. The reachable customer set is pre-filing R&D and pilot programmes; most never reach commercial production, and those that do take years. On the corrected economics the average account now repays its acquisition cost (LTV/CAC ~1.3, payback ~36 months against a 4-year assumed life) but with thin surplus, and a three-year China effort still returns about -19%. Two demand-side findings sharpen this: verified data shows the aesthetic-injectable boom consumes barely 150 kg of polymer a year across the two leading products, so the fastest-growing segment cannot carry a materials business on tonnage; and a bottom-up mass reconstruction of Chinese demand lands well below the USD 250M top-down market size, meaning the merchant resin opportunity may be materially smaller than the headline figure suggests. What we'd do: Sequence entry so cost is incurred only as evidence accumulates: start with research and custom-synthesis micro-orders, which need no local presence, no audit and almost no qualification spend, and where the competing price is USD 20-30/g — let those references pay for the first trade fair rather than the reverse. Set an explicit go/no-go checkpoint at 18-24 months keyed to a concrete milestone, being named in at least one customer's NMPA filing, rather than to revenue, which lags. Fund China from proven markets rather than as a standalone bet, and treat the research-scale channel as an acceptable end-state if industrial conversion does not appear.

▶🇹🇷 Turkey

Middle East & Turkey · Turkish, English

Consider

CONSIDER — The clean line against Ireland: import of Russian-origin polymer into Turkey is lawful, it is simply unattractive. The EU-Turkey Customs Union pulls Turkish converters inside the EU regulatory perimeter, so the ISO 13485 audit, the MDR Annex II site entry and the customs origin declaration all resolve to Ulyanovsk no matter which entity invoices. We explicitly decline computed cell #4, TR x aesthetic-injectables 67.7, because that score does not price in the exclusive-distribution lock or the 6% return; the only wedges worth probing are research, veterinary work outside MDR, and BOMs not yet frozen.

Highest ACV in the set at $55k, but the worst payback of any non-AVOID market at 29 months, LTV/CAC 4.3 and a 3-year ROI of 6% on a $128k entry.
Only ~18 industrial accounts nationwide out of ~100 realistic buyers, and Evonik locked IMCD as exclusive distributor from 01.07.2025.
Overall score 46.3 with ease-of-entry 30 and reg-safety 17.5 - the regulatory exposure is EU-grade because the Customs Union makes it so.
Declining TR x aesthetic-injectables 67.7 despite its top-8 rank: the named wedges are research, veterinary (outside MDR) and not-yet-frozen BOMs, none of which justify $128k ahead of Kazakhstan at $45k.

Market attractiveness

Growth momentum

Customer demand

Buying power

Weak competition

Profit potential

Ease of entry

Regulatory safety

Ease of winning customers

Springboard value

All bars 0–100, higher is always better.

The market here

Yearly market size

$8.5M est.^{[tr-01] [tr-04] [tr-05] [tr-06] [tr-14] [tr-18]}

Growth per year

10 pct est.^{[tr-01] [tr-18]}

Size in ~3 years

$11.3M^{[tr-01] [tr-18]}

Life stage / how crowded

Growing · saturation

Who buys

Ideal customer: Two distinct profiles. PRIMARY (revenue): a Turkish family-owned or mid-cap converter of 50-400 staff that already spins, extrudes or moulds resorbable polymer in-house - a suture house (Dogsan, Katsan, Boz Medikal profile), an orthopaedic implant maker adding a resorbable interference-screw or anchor line, or an aesthetics manufacturer making PDO threads and PLLA biostimulators. It buys 50-500 kg/yr of one or two grades, currently from Evonik/Corbion at Western prices under FX pressure, holds ISO 13485, and is either CE-marked or actively pursuing CE. SECONDARY (entry wedge): a university, TUSEB/TUBITAK-funded or teknopark R&D group needing 5-100 g of a bespoke composition (specific L/D ratio, molecular weight or end-group) that no catalogue supplier will make at that scale - exactly RPS's custom-synthesis strength, and a buyer whose purchase carries no regulatory file and therefore no supplier-qualification barrier. A THIRD wedge worth naming separately is veterinary-grade material: Katsan's own catalogue states it produces for both human and veterinary use (hem insan hem de veterinerlik), and veterinary devices sit outside MDR, removing the single largest documentation obstacle.
Who signs the contract: At converters: the owner/general manager or purchasing director, who in Turkish mid-cap device firms is frequently a family principal and signs personally on any change of an implant-grade input. At research institutions: the principal investigator holding a TUBITAK/TUSEB project budget, with the university purchasing office (satinalma) executing under public-procurement rules.

Potential customers

100 companies_and_institutions est.^{[tr-01] [tr-04] [tr-05] [tr-06] [tr-16] [tr-18]}

Readiness to pay

How badly they want it

Typical yearly budget

$90k est.^{[tr-14] [tr-18]}

What hurts them today

What buyers search for — demand is Growing

Search phrase	Searches /mo	Ad cost per click	Why they search
emilebilir polimer tedarikci (Turkish)	20 searches_per_month est.^[tr-18]	$1.6 est.^[tr-18]	Comparing products
PLGA mikrokure (Turkish)	40 searches_per_month est.^[tr-18]	$0.9 est.^[tr-18]	Just researching
biyobozunur polimer uretici (Turkish)	70 searches_per_month est.^[tr-18]	$1.1 est.^[tr-18]	Comparing products
emilebilir sutur hammaddesi (Turkish)	10 searches_per_month est.^[tr-18]	$2.1 est.^[tr-18]	Ready to buy
poli laktik asit tibbi sinif PLLA (Turkish)	30 searches_per_month est.^[tr-18]	$1.4 est.^[tr-18]	Just researching
polikaprolakton PCL satin al (Turkish)	25 searches_per_month est.^[tr-18]	$1 est.^[tr-18]	Ready to buy

Searches nobody answers well yet

Who we'd compete with — 6 vendors est. serious vendors, concentrated market

Competitor	Local or global	Share of market	Price level	Good at / weak at
Evonik Health Care (RESOMER), distributed in Turkey by IMCD ↗ The default implant-grade resorbable polymer for a device that must pass a notified body. RESOMER is the broadest standard, custom and specialised biodegradable polymer portfolio in the market, backed by regulatory support files and GMP manufacture.	Global player	—	Premium. Catalogue and framework pricing at kilogram scale is not published; small research packs are sold through Merck/Sigma-Aldrich at research-grade prices. Positioned to be paid for regulatory certainty rather than to win on price.	+ As of 1 July 2025 IMCD is Evonik's EXCLUSIVE distributor for RESOMER implantable-grade polymers across the EEA, UK, Switzerland and TURKEY specifically - a named, dated, in-country channel that RPS has no equivalent of (src-tr-07)+ IMCD brings a dedicated medical-polymer sales specialist team and 80+ application laboratories in 60 countries, so a Turkish converter gets local technical support in addition to resin+ Deepest grade range and the strongest regulatory dossier position; incumbency inside existing MDR technical files is self-reinforcing+ Distribution through IMCD lowers the effective MOQ, removing one of the few openings a small custom supplier had− Highest price point, which bites hardest exactly where Turkish converters are squeezed by frozen SGK reimbursement and TRY depreciation− Genuinely bespoke compositions at 1-20 kg scale remain slow and expensive to obtain− The 2025 move to a distributor model adds a margin layer and can lengthen the technical dialogue for a non-standard requirement
Corbion (PURASORB) ↗ The co-development partner: lactide, glycolide, caprolactone and PEG (co-)polymers, explicitly marketed around working side-by-side with customers to co-develop products and scale polymer technology to GMP standard - the closest incumbent analogue to RPS's contract-R&D-plus-supply model.	Global player	—	Premium, quotation-based; no public price list. Broadly comparable to Evonik.	+ Explicitly supports the same processing routes RPS sells into - extrusion, injection moulding, 3D printing and fibre spinning+ Named position in cosmetic injections, which is the fastest-moving Turkish segment+ GMP scale-up path gives a customer confidence that a development project can become serial supply+ Long incumbency in existing device files− No Turkey-specific distributor or in-country technical presence was found, so service is remote relative to IMCD's− Detailed regulatory documentation (DMF, ISO 13485 status, biocompatibility packages) is not published, so buyers must engage before they can compare− Same hard-currency price exposure for TRY-earning converters
Poly-Med, Inc. ↗ Resorbable polymer plus resorbable fibre, yarn, mesh and monofilament - it sells the converted form, not just the resin, which puts it in direct competition with exactly the semi-finished forms RPS wants to grow.	Global player	—	Premium, project-based; strongest on value-added fibre rather than raw resin.	+ Sells finished fibre and yarn, which is a more valuable and stickier product than resin and is precisely where RPS claims differentiation+ Deep suture and textile-implant know-how, matching the strongest Turkish converter segment+ US regulatory track record that supports FDA-facing customer files− US origin means full exposure to US export controls and no incentive to serve sanctions-adjacent supply chains− No identified Turkish distributor or in-country presence− Higher cost base than Asian competitors on commodity fibre grades
Chinese medical-grade polyester suppliers (Jinan Daigang Biomaterial, Dalian Sinobio Chemistry, Shaanxi Saien Biotech and peers) ↗ Cheap, fast, low-MOQ resorbable polyester with thin regulatory documentation - the same value proposition RPS intends to occupy, already occupied.	Global player	—	Aggressively low and publicly quoted, which is unusual in this market: medical-grade PLGA listed at USD 8-12/g (Dalian Sinobio, MOQ 1 g), USD 11-22/g (Senzhuo, Shaanxi Saien) and USD 12-30/g for microsphere grades, with kilogram-scale framework pricing well below Western catalogue levels (src-tr-14).	+ This is RPS's most dangerous competitor set, because it attacks on the identical axis - price and small-lot flexibility - while carrying none of RPS's payment or geopolitical friction+ Published prices and 1 g minimum orders make trial purchasing frictionless, which is decisive for research buyers+ Chinese suppliers already ship medical consumables into Turkey at scale and the import channel is established and bankable+ No sanctions exposure; a Turkish bank will settle a China payment without hesitation− Documentation depth is generally thinner than Evonik/Corbion, so notified-body acceptance for a Class III implantable is not assured− Batch-to-batch consistency and residual monomer control are a recurring buyer concern− Limited genuine custom synthesis - most offer catalogue L:G ratios rather than a specified terminal group or narrow MW target, which is the one place RPS can still differentiate
Merck / Sigma-Aldrich (RESOMER research catalogue, Merck Ilac Ecza ve Kimya, Istanbul) ↗ The default research-scale channel. For a Turkish university group ordering 5 g of PLGA, Sigma-Aldrich is the path of least resistance: local entity, TRY invoicing, university framework accounts, next-week delivery.	Global player	—	Very high per gram, catalogue-listed, gram to tens-of-grams packs. Irrelevant for industrial volumes, decisive for research volumes.	+ Owns the research/custom-synthesis segment that is RPS's most realistic entry wedge, and owns it through purchasing infrastructure (framework contracts, local invoicing) rather than through product superiority+ Local Turkish presence removes customs, currency and procurement friction entirely, and lets a university buy on an existing framework account in TRY+ Brand trust with academic buyers and immediate availability− Only catalogue compositions - it will not synthesise a bespoke L/D ratio, molecular weight or end-group, which is the exact gap RPS fills− Extremely expensive per gram, so a group needing 100 g+ has a real incentive to look elsewhere− No scale-up path from research gram to production kilogram
Ashland (Viatel bioresorbable polymers) ↗ Bioresorbable polymers positioned around drug-delivery and device applications with pharma-grade documentation and a pharmaceutical-excipient heritage.	Global player	—	Premium, quotation-based.	+ Pharmaceutical documentation depth (DMF practice) that RPS cannot currently match+ EU manufacturing base, which is the cleanest possible provenance for an EU-facing technical file− Weakest relevance of the set in Turkey specifically, because the Turkish PLGA drug-delivery manufacturing base that would buy it does not appear to exist− No identified Turkish channel

Customers they leave behind

Rules & barriers to enter

Foreign companies allowed

Yes

Needs a local company set up

How hard to enter

Tax paperwork

Licenses needed

None for the polymer itself as a raw material - no TITCK licence, UTS registration or authorised representative is required to import a non-device chemical/polymer input (inferred, low confidence, see local_entity_note), Standard Turkish import formalities: customs declaration, HS classification (bioresorbable polyesters fall under primary-form plastics headings, chapter 39), certificate of origin, and where applicable a chemical import notification, Chemical regulatory compliance under KKDIK (Turkey's REACH analogue), which requires registration by a Turkish importer or an only representative for substances above tonnage thresholds - low practical relevance at the kilogram volumes in play here, but it must be checked before scaling, The CUSTOMER requires CE marking and UTS registration for the finished device; RPS's obligation is to supply the documentation that supports it, For any drug-delivery application, the customer's pharmaceutical filing requires excipient-grade documentation RPS does not currently hold

Data protection rules

KVKK (Kisisel Verilerin Korunmasi Kanunu, Law No 6698), closely aligned with GDPR, including a cross-border transfer regime that was liberalised in 2024 to add standard contractual clauses alongside the previous explicit-consent and undertaking routes. Low materiality for RPS: a B2B materials business processes contact data for a small number of technical and purchasing counterparts. The more sensitive information flows are commercial - customer formulations, grade specifications and degradation-profile data exchanged during contract development - which are protected by NDA rather than by data protection law, and which Turkish converters will guard closely given their export exposure.

Culture & language hurdles

How we'd win customers

Sellable remotely

How hard to win customers

Cost to win one customer

$28k est.^[tr-18]

Time from contact to deal

14 mo est.^{[tr-03] [tr-13] [tr-18]}

Needs a local office

Channels that work

A local agent or distributor - decisive, and confirmed as the market norm. Every credible competitor either has one (Evonik via IMCD, exclusively for Turkey since 1 July 2025) or a local entity (Merck). trade.gov records local representation as essential to operating in this market (src-tr-07, src-tr-09). For RPS an agent solves the problem it cannot solve remotely: local technical credibility and physical presence with family-run converters who buy on relationship. It does NOT need to solve a payment problem - RPS's UAE and US entities (src-tr-21) already give the buyer an ordinary hard-currency counterparty - which is a meaningful simplification of the agent brief and of what RPS must offer to attract one, Named-account direct outbound to a target list of roughly 18 industrial converters. With a buying base this small, this is not a marketing channel, it is a business-development list - Dogsan, Katsan, Boz Medikal, TST, Hipokrat, Tipsan and their peers can be approached individually by name, Expomed Eurasia (Istanbul, annual) and MEDICA Dusseldorf, where Turkish converters and their purchasing teams both exhibit and buy - the highest-yield way to convert a cold list into a face-to-face relationship in a market where face-to-face is required, University, TUSEB/TUBITAK institute and teknopark research groups approached directly through academic conferences, published papers and departmental contact - slow, low-value, but the only segment winnable without a supplier-qualification battle, and the source of the technical references that later unlock industrial accounts, Turkish-language technical content: datasheets, degradation-profile selection guides and supplier-qualification documentation packs. Not a lead generator at this search volume, but a credibility requirement once a conversation starts, Sample and trial-lot programmes with free or near-free qualification quantities - the standard mechanism in specialty materials, and the only realistic way past 'has it ever been used in a CE-marked device?', Veterinary device makers and veterinary suture lines as a deliberate lower-barrier entry route, given the absence of MDR obligations

The money math

Revenue per customer /yr

$55k^{[tr-14] [tr-18]}

Cost to win one customer

$28k est.^[tr-18]

Return ratio (LTV/CAC)

4.3 ratio^[tr-18]

Gross margin

55 pct est.^{[tr-09] [tr-14] [tr-18] [tr-21]}

Months to earn back a sale

29 mo^{[tr-18] [tr-21]}

Year-1 cost to enter

$128k est.^{[tr-18] [tr-21]}

3-year return

6 pct^{[tr-18] [tr-21]}

Months until profitable

32 mo^{[tr-18] [tr-21]}

What could go wrong here

Risk	How bad if it happens	How likely
regulatorySupplier qualification failure on MDR-grade technical files - the binding constraint. Turkish device makers sit inside the EU regulatory perimeter: the European Commission confirms that manufacturers established in Turkey place devices on the EU market with no EU authorised representative (src-tr-03), and the leading converters are built around that access (Dogsan MDR-certified across 50+ countries, Katsan CE and ISO 13485 shipping to North America and Europe, TST in 40+ countries). Their notified bodies audit their supply chains. Substituting an implant-grade resin from a supplier with no EU or US regulatory track record, no device master file and no history of use in a CE-marked implant triggers a technical-file amendment and, on a Class III implantable, notified-body review. Many converters will decline to start that process at all; others will start it and never finish. Unlike payment friction, this has no workaround inside 12 months. What we'd do: Do not attack qualified implantable lines first. Sequence deliberately: (1) research and custom-synthesis accounts, which carry no regulatory file; (2) veterinary lines, which sit outside MDR; (3) new product lines where the BOM is not yet frozen, so RPS is specified in rather than swapped in. In parallel, close the documentation gap as a global investment, not a Turkish one - ISO 13485 certification by a body EU customers accept, a full ISO 10993 package on lead grades, residual-monomer and heavy-metal specifications, formal change-control and change-notification agreements, and audit rights. Offer to fund the customer's qualification testing. Target second-source qualification rather than sole-source displacement, which is a far lower bar for a quality manager to approve.
economicPayment and settlement friction - DOWNGRADED from the initial reading of this market once RPS's own structure was verified. RPS publicly lists a UAE address (Meydan Free Zone, Dubai) and a US registered-agent address in Wilmington, Delaware, and no Russian address (src-tr-21), so a Turkish buyer can contract with and pay a UAE or US entity in USD or EUR through ordinary correspondent banking. The severe Turkish bank de-risking documented against RUSSIAN counterparties - closed corporate accounts, blanket blockages, refusal of lira and rouble transfers, two-to-three-week delays, automated screening rejecting non-sanctioned goods (src-tr-10, src-tr-11, src-tr-12) - does not apply to that route. What remains is enhanced diligence rather than refusal: a Turkish bank or a customer's compliance team may look through the invoicing entity to the Russian manufacturing origin visible on the origin declaration and shipping documents, slowing onboarding and prompting questions. Residual exposure remains if the corporate structure changes, if a specific transaction must route through Russia, or if a customer's own bank applies a stricter policy than the law requires. What we'd do: Invoice from the UAE free-zone or Delaware entity in USD or EUR and settle the Turkey leg through ordinary correspondent banking rather than any Russia-facing route. Be able to explain the corporate structure and the goods origin accurately and unprompted in the first commercial conversation - a structure that looks like concealment when discovered later is far more damaging than one disclosed early, and misrepresenting origin would itself be disqualifying. Confirm before quoting which entity invoices and from where goods physically ship, since both drive customs origin treatment and diligence. Keep the historical fallbacks documented but unused unless needed: Turkish state banks settling national-currency payments for medicine and medical goods, or a third-country intermediary. Keep exposure per shipment modest until the first two payments have cleared cleanly.
operationalManufacturing ORIGIN, not corporate domicile, is what the customer's quality system tests - and a Dubai or Delaware invoice does not move it. Whichever entity contracts, the polymer is made in Ulyanovsk, Russia, so the ISO 13485 supplier qualification, the supplier audit (increasingly an on-SITE audit for an implant-grade raw material), the manufacturing-site details in the customer's MDR Annex II technical documentation, and the Turkish customs origin declaration all land on a Russian facility. A Turkish converter whose revenue depends on EU and US sales may then decline the input on its own compliance policy, at a Western customer's insistence, or to avoid a question from its notified body - and Turkey's role as a transit hub for goods bound for Russia has drawn sustained Western scrutiny, so firms with Russian supply relationships attract heightened diligence. The refusal is rarely stated as the reason, so RPS may spend a full CAC on an account that was never winnable. A second, subtler exposure: if the UAE/US structure is presented in a way the buyer later reads as having obscured the origin, the discovery destroys the relationship more thoroughly than an upfront disclosure ever would. What we'd do: Disclose manufacturing origin proactively and early, and treat the audit-readiness of the Ulyanovsk site as the real deliverable - practical access for a customer or notified-body auditor, or an accepted remote/third-party audit protocol, is worth more here than any contracting structure. Qualify accounts on export exposure in the first technical meeting (ask directly about EU/US revenue share) and deprioritise heavily EU-facing converters in favour of domestically focused, MENA/Central-Asia-facing, aesthetics, veterinary and research buyers. Lead with technical substance - patents, publications, custom-synthesis capability - rather than with domicile. Verify Turkish customs origin treatment and duty consequences for Russian-origin chapter-39 primary-form polymer before quoting landed prices, since EU-origin competitors enter duty-free under the Customs Union.
demandCurrency and reimbursement squeeze compressing customers' ability to pay. The lira is on a managed-depreciation path of roughly 1-2% per month with consensus forecasts clustering around USD/TRY 49-52 by end-2026 and inflation in the high-20s to mid-30s (src-tr-15), while trade.gov records SGK reimbursement prices unchanged for seven years (src-tr-09) and TUSEB names FX volatility and imported-input dependence as a standing sector threat (src-tr-01). Converters selling into the 71%-public market therefore cannot pass input costs through. The same fact that makes a cheaper resin attractive also means the buyer will demand extended terms, resist prepayment, and push price down continuously - precisely the terms a supplier with payment-channel risk cannot grant. What we'd do: Invoice exclusively in USD or EUR and never carry TRY receivables. Price the FX and payment-routing cost into the quoted rate rather than absorbing it. Prioritise the customer segments insulated from SUT: exporters earning hard currency, private aesthetics and medical tourism (cash-pay, hard-currency, least price-constrained), and grant-funded research. Offer consignment stock in Turkey as a value lever instead of a discount, since it addresses the converter's real problem - carrying hard-currency inventory - without cutting price.
competitiveDisplacement by Chinese suppliers attacking on the identical axis. Dalian Sinobio, Shaanxi Saien, Jinan Daigang and peers publish medical-grade PLGA prices of USD 8-30/g with minimum orders as low as 1 g (src-tr-14), offering the same cheap-and-flexible proposition RPS intends to occupy, with no sanctions exposure, an established Turkish import channel and - decisively - a manufacturing origin that raises no question in a supplier audit or an EU-facing technical file. Note that the Chinese tier's old edge on bankability has largely evaporated now that RPS can invoice from Dubai or Delaware (src-tr-21); what survives is price and origin-neutrality, and origin-neutrality is the one RPS cannot answer. Meanwhile the premium end has just consolidated its Turkish position: IMCD became Evonik's exclusive RESOMER distributor for Turkey on 1 July 2025 (src-tr-07), adding local technical support and lower effective MOQs at the top of the market. RPS risks being squeezed from both ends with no defensible middle. What we'd do: Do not compete on catalogue grades or on price per kilogram, where the Chinese floor is unreachable and the Turkish buyer has no switching incentive. Compete only where genuine custom synthesis is the product - specified L/D ratio, narrow molecular-weight target, defined terminal groups at 1-20 kg scale - which neither the Chinese tier (catalogue ratios) nor Sigma-Aldrich (no synthesis) will do. Reinforce with the converted semi-finished forms (fibre, tubing, film, microspheres, filament) that raise switching cost and margin, and with contract R&D, which sells capability rather than commodity and is the one offer no competitor in this market matches at RPS's scale.

§06

Market Segment Analysis

The market split by customer type — who the buyers are, how much each group spends worldwide, and how fast each group is growing.

Customer segment	Worldwide spend /yr	Growth /yr	Notes
Absorbable sutures, meshes and soft-tissue barriers Fibre-grade PGA/PGLA/PLGA resin, drawn fibre and yarn, absorbable mesh and reinforcement, anti-adhesion barrier film, staple and clip stock sold to wound-closure and soft-tissue device OEMs and converters. Buying criteria are strength-retention profile, knot security, batch-to-batch inherent-viscosity consistency and a documented degradation window.	$620M est.^[seg-01]	7% est.^[seg-01]	Largest and most mature segment; entrenched incumbents and captive in-house spinning mean volume without margin. For RPS the accessible slice is converted forms (fibre, yarn, cast film) rather than commodity resin.
Drug-delivery and parenteral formulation PLGA and PLA used as the release-controlling matrix in long-acting injectable depots: microspheres, in-situ forming gels and implants, and nanoparticles, sold to pharma companies, generic developers and drug-delivery CDMOs. The most documentation-heavy segment: GMP/ICH Q7 manufacture, a referenceable drug master file, and tight control of molecular weight, monomer ratio and end-group chemistry.	$560M est.^[seg-01]	15% est.^[seg-01]	Highest revenue per kilogram and the stickiest customers, but the longest and most expensive qualification cycle; the referenceable DMF requirement is the single hardest barrier for a Russian-origin supplier.
Orthopaedic, spinal, dental and craniomaxillofacial fixation High-molecular-weight PLLA and PLDLA moulding and machining stock, rod and billet, for resorbable interference screws, pins, suture anchors, tacks, plates and membranes in sports medicine, trauma, spine, dental and CMF surgery, including polymer-matrix composite implants.	$340M est.^[seg-01]	9% est.^[seg-01]	Steady rather than fast; metal fixation remains a live competing option and the memory of early resorbable-implant osteolysis still slows adoption. Long strength-retention requirements (12-36+ months) make requalification costly, so incumbency is unusually durable.
Cardiovascular scaffolds, stent coatings and vascular grafts Ultra-high-purity high-molecular-weight PLLA and PLLA/PCL for bioresorbable vascular scaffolds and extruded tubing ready for laser cutting, low-molecular-weight PLGA for drug-eluting coatings on permanent metal stent platforms, plus vascular grafts and cardiac patches. The most stringent specification of any segment on residual monomer, residual metals and resorption predictability.	$85M est.^[seg-01]	5% est.^[seg-01]	Smallest and least mature; deliberately scored conservatively per stage 02. Extruded stent tubing is a real RPS product fit, but the buyer pool is narrow and PMA-class change control makes second-sourcing exceptionally hard.
Aesthetic and dermatology injectables PLLA and PCL microparticles in carrier gel for collagen-stimulating biostimulator fillers, plus resorbable implants in dermatology and reconstruction, sold as polymer to a tight particle-size, crystallinity and residual-solvent specification or as finished microspheres. Scoped to PLLA/PCL collagen stimulators only.	$210M est.^[seg-01]	16% est.^[seg-01]	Fastest-growing and least regulation-bound of the six, with a qualification path measured in months rather than years; the best growth-to-barrier ratio in the set for a supplier without a Western regulatory dossier.
Research, tissue engineering and custom small-lot synthesis Gram- to kilogram-scale lots, frequently bespoke compositions no catalogue supplier stocks, sold to universities, institutes, hospital labs, startups and corporate R&D for tissue-engineering scaffolds, 3D printing and electrospinning, and early device or formulation feasibility, plus fee-based contract synthesis and development services. Pre-commercial buyers only.	$135M est.^[seg-01]	12% est.^[seg-01]	Low absolute revenue but the highest margin and near-zero supplier-qualification burden, and it is the acquisition funnel for the other five: a scaffold or formulation prototyped on a supplier's polymer tends to stay on it into clinical work. Structurally the best-fit segment for RPS across almost every country studied.

Worldwide spend by segment

USD per year

§07

Country × Segment Opportunity Matrix

Each cell scores one combination of country and customer segment, 0–100 — darker means a better place to focus. Hover a cell for the reasons.

Absorbable sutures, meshes and soft-tissue barriers

Drug-delivery and parenteral formulation

Orthopaedic, spinal, dental and craniomaxillofacial fixation

Cardiovascular scaffolds, stent coatings and vascular grafts

Aesthetic and dermatology injectables

Research, tissue engineering and custom small-lot synthesis

🇮🇳 India

🇰🇿 Kazakhstan

🇷🇺 Russia

🇺🇸 United States

🇮🇪 Ireland

🇨🇳 China

🇹🇷 Turkey

lower opportunityhigher

The best combinations

1🇷🇺 Russia × Aesthetic and dermatology injectables
Russian and CIS aesthetics manufacturers currently import finished Korean thread and biostimulator product and have no domestic material partner, and PCL and PLCL are absent from Novokhim's published range, so the segment with the market's highest growth rate has close to no domestic competitor.
79.9/100
2🇺🇸 United States × Research, tissue engineering and custom small-lot synthesis
The only US cell where a 45% duty is survivable, because gram-to-kilogram research lots sell at catalogue-plus pricing far above a Ulyanovsk cost base, and stage 05 lists four distinct unserved needs here at once: kilogram bridge lots, medical-grade printing filament, non-catalogue PLCL ratios and labs priced out of catalogue rates.
72.7/100
3🇷🇺 Russia × Absorbable sutures, meshes and soft-tissue barriers
The strongest single cell in the grid: stage 05 found three Russian suppliers of resorbable resin and none of converted forms, so resorbable fibre, yarn and cast anti-adhesion film for domestic suture and mesh makers is an open position that matches RPS's existing product page, sold inside the customs border at domestic margins.
72.7/100
4🇹🇷 Turkey × Aesthetic and dermatology injectables
Turkey's aesthetics manufacturing and medical-tourism industry sells largely into MENA rather than the EU, which is the case where the hub thesis actually holds: non-CE export routes will accept Russian-origin input, and Corbion targets aesthetics but nobody serves small custom lots.
67.7/100
5🇷🇺 Russia × Drug-delivery and parenteral formulation
A small but growing domestic depot-formulation base with no Russian pharmacopoeial monograph for these excipients, which stage 05 flags as an opening for documented supply with a defensible analytical dossier rather than a barrier, since no domestic competitor holds one either.
64.6/100

§08

Customer Analysis — Who Buys

Current customers: Not published on the site; no named customers, references or case studies. Inferred from the applications and product forms listed: medical device manufacturers (sutures, meshes, stents/endovascular devices, orthopaedic implants), pharmaceutical and drug-delivery formulators, aesthetic/dermal filler producers, and research and product-development groups needing custom-synthesised resorbable polymer. The Russian-language company page states that several plants producing endovascular devices have already been launched in Russia, implying endovascular device manufacturing is an established outlet for the material.

Market	Ideal customer	Decision maker	Customers
🇨🇳 China	A Chinese device OEM or pharma formulator at the pre-filing R&D or pilot stage of a resorbable product, needing a custom polymer spec (defined molecular weight, L/D ratio, terminal group, or a PLCL/PLGA composition) that the domestic catalogue does not carry off the shelf, whose end product is destined for the Chinese domestic market rather than US/EU export, and whose technical team will run a second-source qualification — explicitly NOT an OEM with a device already registered against a named incumbent supplier.	For device OEMs, the general manager or VP of R&D — material spend is small in absolute terms but the qualification commitment is a company-level decision, so it rarely sits with purchasing alone. For pharma microsphere programmes, the CMC/formulation head with the regulatory affairs director holding a veto. For research groups, the principal investigator spending grant money.	400 companies est.^{[cn-06] [cn-21]}
🇮🇳 India	An Indian formulation-development or device-R&D team at a mid-size pharma/CDMO or suture-mesh manufacturer, starting a NEW resorbable programme aimed at the domestic or non-US/EU export market, buying 2-50 kg/yr of custom-spec PLGA/PLLA/PCL and needing molecular-weight, L/D-ratio and end-group tailoring plus responsive technical support at a price meaningfully below Evonik/Corbion list.	Head of Procurement / VP Supply Chain for commercial volumes; for development lots the Head of Formulation Development (pharma) or R&D Director / Head of Materials (device OEM) signs off directly out of a project budget.	75 companies est.^{[in-01] [in-11] [in-12] [in-15] [in-17] [in-18]}
🇮🇪 Ireland	Not the tier-1 OEM. The realistic ideal customer in Ireland is a mid-size resorbable-implant CDMO or a device developer at pre-clinical/early-development stage, where no polymer supplier has yet been named in a regulatory file. Concretely: an Irish contract developer of resorbable textiles, meshes, fibres or scaffolds (Aran Biomedical is the archetype) or a venture-backed device start-up spun out of the Galway/Dublin cluster, buying 1-25 kg lots of a custom-spec copolymer with a defined L/D ratio, molecular weight and end-group, and needing formulation and degradation-profile development support alongside the material. Secondary ICP: a university biomaterials group buying gram-to-hundred-gram research quantities, where qualification burden is near zero. Tier-1 OEM plants (Boston Scientific, Medtronic, Stryker, Abbott) are explicitly NOT the ICP - their qualified-supplier lists are set by US-headquartered global procurement and their filed devices name incumbent suppliers.	For a CDMO or start-up: the VP/Director of R&D or the CTO, often with founder or site-GM sign-off, because the material choice is a technical and regulatory commitment rather than a purchasing decision. For a tier-1 OEM site: the economic buyer is not in Ireland at all - it is global category management / strategic sourcing at US headquarters, with the Irish site holding only requisition authority against an already-qualified supplier list. This split is the single most important commercial fact about the Irish cluster.	30 companies est.^{[ie-06] [ie-07] [ie-12] [ie-13] [ie-16]}
🇰🇿 Kazakhstan	A Kazakh manufacturer that already holds a registration certificate for a resorbable medical device and currently imports the polymer or the braided yarn it converts — in practice today this describes exactly one company, RuMa Farm: an ISO 13485-certified suture converter in the Almaty area running clean rooms, braiding/coating and needle attachment, selling into hospital tenders and the state guaranteed-benefit package, and therefore under permanent cost pressure and local-content pressure. Secondary ICP: a university or state research institute doing tissue-engineering, 3D bioprinting or drug-carrier work that needs 50 g to 5 kg of specified-molecular-weight PLLA/PLGA/PCL with a certificate of analysis, in Russian, on a short lead time and without an EU import procedure. Tertiary and currently hypothetical ICP: an entrepreneur setting up domestic conversion of aesthetic PDO/PLLA lifting threads or resorbable dental membranes as an import-substitution play under the local-content regime.	At the converter: the owner or general director. Kazakh medical-device manufacturers of this size are owner-managed, and a change of a critical registered raw material is an owner-level decision because it carries re-registration and revalidation cost. The production/technical director and the QA/regulatory manager (responsible for the registration dossier) hold the effective veto. At a university: the principal investigator holds the technical decision, but the purchase is executed by the procurement office against a state grant or programme-targeted funding line, which imposes competitive-procurement formalities on anything above a low threshold.	6 organisations est.^{[kz-03] [kz-04] [kz-11] [kz-15] [kz-16] [kz-17]}
🇷🇺 Russia	A Russian manufacturer or formulator that has an existing or planned product whose active component is a resorbable aliphatic polyester, is currently buying (or has lost access to) Evonik RESOMER / Corbion PURASORB grades through an intermediary, and needs 5-500 kg/yr of a specified molecular weight, L/D ratio and end-group with a full batch documentation package in Russian. Two sub-profiles: (1) pharma development groups formulating PLGA microsphere or implant depot forms, where the polymer is a registered excipient and documentation depth matters more than price; (2) suture, mesh, thread and film converters who need fibre-grade PGA/PGLA or PLLA in kilogram lots at a price that survives comparison with Chinese resin. A third, lower-value but faster-closing profile is the university/NMITs laboratory buying 5-100 g for a grant-funded programme.	Technical director or production director at converters; head of pharmaceutical development (руководитель отдела фармразработки) or R&D director at pharma; for state institutes, the head of the contract service (контрактная служба) executing under 44-ФЗ/223-ФЗ. Final sign-off on a material change at a manufacturer with a registered product usually sits with the general director because it touches the registration dossier.	210 organisations est.^{[ru-09] [ru-11] [ru-12] [ru-18] [ru-20] [ru-21]}
🇹🇷 Turkey	Two distinct profiles. PRIMARY (revenue): a Turkish family-owned or mid-cap converter of 50-400 staff that already spins, extrudes or moulds resorbable polymer in-house - a suture house (Dogsan, Katsan, Boz Medikal profile), an orthopaedic implant maker adding a resorbable interference-screw or anchor line, or an aesthetics manufacturer making PDO threads and PLLA biostimulators. It buys 50-500 kg/yr of one or two grades, currently from Evonik/Corbion at Western prices under FX pressure, holds ISO 13485, and is either CE-marked or actively pursuing CE. SECONDARY (entry wedge): a university, TUSEB/TUBITAK-funded or teknopark R&D group needing 5-100 g of a bespoke composition (specific L/D ratio, molecular weight or end-group) that no catalogue supplier will make at that scale - exactly RPS's custom-synthesis strength, and a buyer whose purchase carries no regulatory file and therefore no supplier-qualification barrier. A THIRD wedge worth naming separately is veterinary-grade material: Katsan's own catalogue states it produces for both human and veterinary use (hem insan hem de veterinerlik), and veterinary devices sit outside MDR, removing the single largest documentation obstacle.	At converters: the owner/general manager or purchasing director, who in Turkish mid-cap device firms is frequently a family principal and signs personally on any change of an implant-grade input. At research institutions: the principal investigator holding a TUBITAK/TUSEB project budget, with the university purchasing office (satinalma) executing under public-procurement rules.	100 companies_and_institutions est.^{[tr-01] [tr-04] [tr-05] [tr-06] [tr-16] [tr-18]}
🇺🇸 United States	A US pre-clinical or early-feasibility organisation - a university or hospital research lab, a venture-backed resorbable-device or long-acting-injectable startup, or a small formulation CDMO - buying 10 g to 5 kg of custom-spec PLGA, PLLA or PCL for a programme that has no 510(k), PMA or Drug Master File naming a supplier yet, and therefore no regulatory change-control barrier to using a new source.	At research scale, the principal investigator or lab director spending grant or SBIR/STTR money (order values below any procurement threshold). At startups, the VP of R&D or Head of Formulation Development, with the CEO/CFO signing anything above ~USD 50k. At established device OEMs and pharma, a strategic sourcing or category manager for polymers and biomaterials who cannot approve a new source without R&D, supplier quality and regulatory affairs all signing off - which is where a Russian-origin supplier dies.	850 organisations est.

§09

What Buyers Search For

Search numbers here are analyst estimates (no keyword tool was connected) — use them to compare markets against each other, not as exact figures.

Filter by phrase or market

Market	Search phrase	Searches /mo	Cost /click	Why they search	Trend
🇨🇳 China	医用级聚乳酸 PLGA 供应商 (zh)	~320/mo est.	$1.4 est.	Comparing products	Growing
🇨🇳 China	可吸收缝合线原料聚乙交酯 PGA 厂家 (zh)	~180/mo est.	$1.1 est.	Ready to buy	Growing
🇨🇳 China	PLGA 微球药用辅料登记号 (zh)	~140/mo est.	$2.2 est.	Comparing products	Growing
🇨🇳 China	医用聚己内酯 PCL 原料价格 (zh)	~260/mo est.	$0.9 est.	Ready to buy	Growing
🇨🇳 China	定制合成聚乳酸分子量端基小批量 (zh)	~70/mo est.	$1.8 est.	Comparing products	Growing
🇨🇳 China	医疗器械主文档登记原材料可吸收 (zh)	~90/mo est.	$1.6 est.	Just researching	Growing
🇮🇳 India	PLGA supplier India (en)	~90/mo est.^[in-23]	$2.5 est.^[in-23]	Comparing products	Growing
🇮🇳 India	bioresorbable polymer manufacturer (en)	~210/mo est.^[in-23]	$3.2 est.^[in-23]	Comparing products	Growing
🇮🇳 India	PLGA 50:50 price (en)	~140/mo est.^[in-23]	$2.1 est.^[in-23]	Ready to buy	Growing
🇮🇳 India	polyglycolic acid suture raw material (en)	~70/mo est.^[in-23]	$1.4 est.^[in-23]	Comparing products	Growing
🇮🇳 India	medical grade polycaprolactone PCL India (en)	~60/mo est.^[in-23]	$1.8 est.^[in-23]	Comparing products	Growing
🇮🇳 India	biodegradable polymer for controlled release drug delivery (en)	~330/mo est.^[in-23]	$2.8 est.^[in-23]	Just researching	Growing
🇮🇪 Ireland	bioresorbable polymers supplier (English)	210 searches_per_month est.^[ie-16]	$6.5 est.^[ie-16]	Comparing products	Growing
🇮🇪 Ireland	PLGA polymer manufacturer (English)	170 searches_per_month est.^[ie-16]	$5.2 est.^[ie-16]	Comparing products	Growing
🇮🇪 Ireland	medical grade PLLA resin (English)	90 searches_per_month est.^[ie-16]	$7.1 est.^[ie-16]	Comparing products	Growing
🇮🇪 Ireland	custom polymer synthesis medical device (English)	70 searches_per_month est.^[ie-16]	$8.4 est.^[ie-16]	Comparing products	Growing
🇮🇪 Ireland	resorbable suture fibre supplier (English)	40 searches_per_month est.^[ie-16]	$4.8 est.^[ie-16]	Comparing products	Growing
🇮🇪 Ireland	polycaprolactone medical grade PCL (English)	260 searches_per_month est.^[ie-16]	$3.9 est.^[ie-16]	Just researching	Growing
🇰🇿 Kazakhstan	полигликолид купить (Russian)	20 searches_per_month est.^[kz-19]	$0.5 est.^[kz-19]	Ready to buy	Flat
🇰🇿 Kazakhstan	рассасывающийся шовный материал производство (Russian)	40 searches_per_month est.^[kz-19]	$0.6 est.^[kz-19]	Comparing products	Flat
🇰🇿 Kazakhstan	биорезорбируемые полимеры медицинского назначения (Russian)	25 searches_per_month est.^[kz-19]	$0.4 est.^[kz-19]	Just researching	Flat
🇰🇿 Kazakhstan	PLGA полимер купить Казахстан (Russian)	10 searches_per_month est.^[kz-19]	$0.8 est.^[kz-19]	Ready to buy	Flat
🇰🇿 Kazakhstan	полилактид PLLA медицинский сырье поставщик (Russian)	15 searches_per_month est.^[kz-19]	$0.5 est.^[kz-19]	Comparing products	Flat
🇰🇿 Kazakhstan	медициналық сіңетін жіп полимер (Kazakh)	5 searches_per_month est.^[kz-19]	$0.2 est.^[kz-19]	Just researching	Flat
🇷🇺 Russia	полилактид медицинского назначения купить (ru)	~40/mo est.	$0.9 est.	Ready to buy	Growing
🇷🇺 Russia	PLGA микросферы поставщик (ru)	~30/mo est.	$1.2 est.	Comparing products	Growing
🇷🇺 Russia	биорезорбируемые полимеры производитель Россия (ru)	~70/mo est.	$0.8 est.	Comparing products	Growing
🇷🇺 Russia	сополимер лактида и гликолида купить (ru)	~50/mo est.	$1 est.	Ready to buy	Growing
🇷🇺 Russia	поликапролактон медицинский купить PCL (ru)	~60/mo est.	$0.7 est.	Ready to buy	Growing
🇷🇺 Russia	аналог Resomer Purasorb российский (ru)	~20/mo est.	$1.5 est.	Comparing products	Growing
🇹🇷 Turkey	emilebilir polimer tedarikci (Turkish)	20 searches_per_month est.^[tr-18]	$1.6 est.^[tr-18]	Comparing products	Growing
🇹🇷 Turkey	PLGA mikrokure (Turkish)	40 searches_per_month est.^[tr-18]	$0.9 est.^[tr-18]	Just researching	Growing
🇹🇷 Turkey	biyobozunur polimer uretici (Turkish)	70 searches_per_month est.^[tr-18]	$1.1 est.^[tr-18]	Comparing products	Growing
🇹🇷 Turkey	emilebilir sutur hammaddesi (Turkish)	10 searches_per_month est.^[tr-18]	$2.1 est.^[tr-18]	Ready to buy	Growing
🇹🇷 Turkey	poli laktik asit tibbi sinif PLLA (Turkish)	30 searches_per_month est.^[tr-18]	$1.4 est.^[tr-18]	Just researching	Growing
🇹🇷 Turkey	polikaprolakton PCL satin al (Turkish)	25 searches_per_month est.^[tr-18]	$1 est.^[tr-18]	Ready to buy	Growing
🇺🇸 United States	bioresorbable polymer supplier (en)	260 searches_per_month est.	$6.5 est.	Comparing products	Growing
🇺🇸 United States	medical grade PLGA resin GMP (en)	170 searches_per_month est.	$4.5 est.	Comparing products	Growing
🇺🇸 United States	PLGA microspheres supplier (en)	90 searches_per_month est.	$5 est.	Ready to buy	Growing
🇺🇸 United States	custom PLGA synthesis service (en)	70 searches_per_month est.	$7 est.	Ready to buy	Growing
🇺🇸 United States	absorbable suture yarn manufacturer (en)	40 searches_per_month est.	$3.5 est.	Comparing products	Growing
🇺🇸 United States	RESOMER alternative second source (en)	30 searches_per_month est.	$8 est.	Comparing products	Growing

Questions real buyers ask

你们有没有医疗器械主文档登记号？能不能授权我们在注册申报中引用？(Do you hold a Medical Device Master File registration number and will you authorise us to cross-reference it?)
药用辅料登记号能提供吗？能支持关联审评吗？(Can you provide an excipient registration number and support the bundled review?)
能提供 ISO 13485 证书、ISO 10993 生物相容性报告和 USP Class VI 数据吗？(Can you supply ISO 13485, ISO 10993 and USP Class VI documentation?)
分子量、特性粘度、L/D 比例和端基能定制到什么精度？最小起订量是多少？(How precisely can you customise Mw, IV, L/D ratio and end-group, and what is the MOQ?)
批次间一致性怎么保证？COA 里有没有残留单体、残留锡和内毒素数据？(How is batch-to-batch consistency assured, and does the COA report residual monomer, residual tin and endotoxin?)
公斤级的价格是多少？和 100 克装比能便宜多少？(What is the kilogram-scale price, and how much cheaper is it than the 100 g pack?)
合同主体是哪家公司？在哪里开票、用什么币种结算？生产地在哪里？(Which legal entity do we contract with, where is the invoice issued and in what currency, and where is the material actually manufactured?)
原产地是俄罗斯吗？如果我们的器械要出口到欧美，会不会有合规问题？(Is the country of origin Russia, and if our device is exported to the US or EU does that create a compliance problem?)
生产现场能接受我们的质量审核吗？能不能安排现场或远程审厂？(Will you accept our supplier audit of the manufacturing site, on-site or remote?)
Do you have a US FDA Type IV excipient DMF we can reference in our ANDA, and if not, what can we file with?
Can you supply ISO 10993 biocompatibility and USP Class VI data on the exact grade and batch?
What is the batch-to-batch variability in inherent viscosity and residual monomer, and will you commit to it in the specification?
Is the polymer tin-free / what is the residual catalyst level?
What is your minimum order quantity for a 500 g development lot, and what is the lead time to India?
Can you match the degradation profile of RESOMER RG 503H / PURASORB PDLG 5002A?
How do we pay you, and will our bank clear the transaction?
What happens to our regulatory filing if your supply is interrupted — do you have a second manufacturing site?
Can you also supply the converted form (spun fibre, extruded tubing, cast film) rather than only resin?
What inherent viscosity and molecular weight do I need for a 12-month resorption profile?
Do you have a DMF/ASMF, and will you provide a letter of authorisation?
What is your residual monomer, residual solvent, and heavy-metal specification, and is it Ph.Eur./USP compendial?
Can you supply ISO 10993 biocompatibility data and a full change-control agreement?
Will you accept an on-site ISO 13485 supplier audit, and what is your quality-system certification?
What is the minimum order quantity and lead time for a custom L/D ratio?
Where is the material manufactured, and what is the country of origin on the customs declaration?
How do you guarantee batch-to-batch consistency of degradation rate over a multi-year device life?
Do you hold ISO 13485, and can you show a GMP or ICH Q7 basis for pharmaceutical-grade material?
Can you supply a full ISO 10993 biocompatibility package and a material master file that our regulatory affairs team can put straight into an NCELS or EAEU dossier?
Can you sell us braided coated yarn ready for needle attachment, or only resin? What we buy today is yarn, not polymer.
What is the minimum order quantity, and can you ship 5 kg rather than 50 kg?
How consistent is inherent viscosity batch to batch, and will you certify it on every lot?
If we name you in our registration dossier, will you commit to supply continuity for the life of the registration, and what happens if sanctions tighten?
How do we actually pay you — will our bank clear a transfer to a Russian legal entity, and can we settle in tenge or roubles?
What is the lead time to Almaty, and do we need a customs declaration or only the EAEU statistical form and the indirect-tax declaration?
What are the storage conditions and shelf life, and does the material need refrigerated storage we do not currently have?
Will you help fund or run the requalification and revalidation work if we switch to you?
Which of your entities will invoice us — the UAE company or the Russian one — and how does that change our import VAT, our customs paperwork and our bank's view of the payment?
Does substituting your polymer for RESOMER/PURASORB force me to re-register my device or vary my drug dossier?
What is in the batch documentation package - CoA, GPC molecular-weight distribution, residual lactide/glycolide, residual tin, heavy metals, endotoxins, sterility?
Is the material certified in Russia as an excipient (вспомогательное вещество), and do you hold ГОСТ ISO 13485?
What is the minimum order quantity, the lead time for a custom inherent viscosity, and can you repeat the same lot in two years?
Do you have ISO 10993 biocompatibility data on the grade, or must I generate it?
Can you supply the converted form (fibre, tubing, film, microspheres) or only the resin?
Price per kg in rubles, payment terms, and whether the price is FX-indexed.
Are you in the Minpromtorg register of Russian industrial products, so my finished device can claim Russian origin under ПП 719?
Do you hold ISO 13485, and can you supply a full CoA, DMF-equivalent material file and ISO 10993 biocompatibility data package?
Has your polymer ever been used in a CE-marked implantable device, and will our notified body accept it in our technical file?
What exactly changes in our MDR technical documentation if we switch resin supplier, and how long will the notified body take?
Which legal entity do we contract with and pay, where is the polymer actually manufactured, and will our quality system need to audit that site?
What are the lead time, MOQ and shelf life, and can you hold consignment stock in Turkey?
Can you match the inherent viscosity, residual monomer and heavy-metal specification we already have written into our device file?
What is the price per kilogram versus Evonik and Corbion at our annual volume, and in which currency do you invoice?
Can you supply semi-finished fibre or tubing rather than resin, so we skip the extrusion step?
Do you hold a US FDA Drug Master File (Type II or IV) or Device Master File, and will you issue a letter of right of reference?
Is the material manufactured under ISO 13485 and cGMP, and in what cleanroom classification?
What are your residual monomer, residual solvent and tin (stannous octoate) catalyst specifications, and can you show the CoA?
Do you have ISO 10993 biocompatibility and USP Class VI data on this grade, and who ran it?
What is the minimum order quantity, the lead time for a custom molecular weight and L:D ratio, and the shelf life and storage condition?
Will you accept an on-site supplier audit and sign a quality agreement with change-notification obligations?
How do you control batch-to-batch inherent viscosity, and what is your historical variation across lots?
Can you scale this exact grade from grams to tens of kilograms without a change in process or specification?

§10

Competitive Landscape

Competitor	Local or global	Competes with us in	Good at	Weak at
Ashland (Viatel bioresorbable polymers) ↗ The third Western catalogue option, leaning on Ashland's existing pharmaceutical-excipient relationships in India to cross-sell bioresorbables into formulators that already buy its cellulosics.	Global player	🇮🇳 🇮🇪 🇰🇿 🇹🇷	+ Existing Indian excipient customer relationships and supply-chain trust to build on+ Full regulatory documentation package expected of a Western excipient supplier+ Bundled technical service	− Smaller bioresorbable share of mind than RESOMER or PURASORB− Narrower grade portfolio− Same price and MOQ objections as the other Western suppliers
Corbion (PURASORB) ↗ The principal EU-origin alternative to Evonik, manufacturing in the Netherlands with backward integration into lactide monomer, which gives it a genuine raw-material cost and traceability advantage. Broad PURASORB range of lactide, glycolide, caprolactone and PEG copolymers spanning both medical-device and drug-delivery grades.	Global player	🇮🇪 🇰🇿 🇹🇷 🇺🇸	+ Backward-integrated to lactide monomer - strong supply-chain control and traceability+ EU (Netherlands) origin, short and uncomplicated logistics to Ireland+ Broad grade range covering both device and pharma applications+ Established DMF and compendial documentation	− Less service wrap than Evonik's CDMO offer− Weaker position in converted semi-finished forms than in resin− No manufacturing presence in Ireland
Evonik Health Care (RESOMER) ↗ The default safe choice: 30+ years of commercial use, the deepest regulatory dossier in the category, US FDA excipient DMF coverage, multi-site supply security, and formulation-development services alongside the resin.	Global player	🇮🇳 🇮🇪	+ Referenceable regulatory files that de-risk an ANDA or MDR submission+ Broadest grade portfolio including PEG-PLGA and specialty end-groups+ Supply-security narrative (multiple plants) that matters enormously once a product is filed+ In-house formulation development and toll manufacturing that pulls customers in early	− Price is the single most common complaint from Indian buyers− MOQ and lead time are unattractive for small development lots− Limited appetite for genuinely bespoke small-volume grades− Slow, committee-driven response to a small Indian startup
Poly-Med Inc. ↗ The closest structural analogue to what RPS says it is: a specialist that sells not just resin but converted resorbable forms - fibres, monofilament and multifilament yarns, meshes, films and tubing - together with contract development. This is the most direct competitor for RPS's fibre, tubing and film lines, and the one that already occupies the 'custom, converted, development-partner' niche that stage 03 identified as RPS's addressable slice. US-based (Anderson, South Carolina).	Global player	🇮🇪 🇰🇿	+ Genuine capability in converted forms (fibre, yarn, mesh, film, tubing), not just resin+ Willing to work with development-stage and lower-volume customers+ Deep resorbable fibre-spinning know-how+ Flexible on custom chemistry	− Smaller scale and balance sheet than Evonik/Corbion/Ashland− US origin adds customs and, for some EU buyers, supply-chain-length concerns− Less brand presence in EU academic literature
Poly-Med, Inc. ↗ Resorbable polymer plus resorbable fibre, yarn, mesh and monofilament - it sells the converted form, not just the resin, which puts it in direct competition with exactly the semi-finished forms RPS wants to grow.	Global player	🇹🇷 🇺🇸	+ Sells finished fibre and yarn, which is a more valuable and stickier product than resin and is precisely where RPS claims differentiation+ Deep suture and textile-implant know-how, matching the strongest Turkish converter segment+ US regulatory track record that supports FDA-facing customer files	− US origin means full exposure to US export controls and no incentive to serve sanctions-adjacent supply chains− No identified Turkish distributor or in-country presence− Higher cost base than Asian competitors on commodity fibre grades
Jinan Daigang Biomaterial (济南岱罡生物工程有限公司) ↗ The deepest bioresorbable catalogue in China and the closest direct analogue to Resotech's own product range — breadth and price, with essentially no regulatory packaging.	Local player	🇨🇳	+ Extraordinary product breadth — lactide/glycolide/TMC/PDO monomers, PLLA/PDLLA/PDLA each in ester, -OH and -COOH endcaps, PLGA at custom ratios 90:10 to 50:50, PCL Mw 4k-280k, PTMC, PPDO, mPEG di-block and PEG tri-block copolymers, 4/5/6-arm star polymers, thermosensitive sol-gel hydrogel+ Also sells converted forms — electrospun membrane, porous foam scaffold sheet/tube/rod, fibre and PLA film — directly overlapping Resotech's converted-form offer+ Published QC spec (LOD ≤0.5%, ROI ≤0.5%, heavy metals ≤10 ppm, catalyst residue ≤200 ppm, residual monomer ≤1%) produced in a 100,000-class cleanroom+ Domestic entity — no duty, no origin question, CNY invoicing with fapiao+ Operating since 2002	− No ISO 13485, ISO 10993, USP Class VI or master file claim anywhere on the site — its only third-party test reports are dated 2014 and a test report is not a master file− Website content stale since roughly 2016; founder-led and research-reagent in scale− Cannot support a customer's Class III NMPA submission, so an OEM using it must generate its own biocompatibility and characterisation package− Trades under two near-identical company names with the same contact person, which complicates counterparty diligence
Shandong Caicai Medical Technology (山东采采医疗科技有限公司) The most consequential competitor found in this research and one the original brief did not anticipate. A Jinan-based subsidiary of 谷雨春生物, founded 2019, that has done precisely what a foreign entrant would need to do — built a documented, NMPA-registered bioresorbable portfolio at injectable grade — and got there first.	Local player	🇨🇳	+ Holds multiple NMPA Medical Device Master Files verified on the CMDE public registry — PLA (M2024085-000), PCL Type I and Type II, and PLGA at 8515 (M2023171-000), 7525 (M2024109-000) and 5050 (M2024110-000), the last two explicitly 供注射用 (for injection), which is the hardest specification tier+ Has an approved finished product — China's first NMPA-approved domestic injectable PCL microsphere filler, 塑妍真·真妤 — proving the material through to clinical registration+ Domestic entity: no duty, no origin question, no chemical-import registration burden, CNY invoicing+ Directly contradicts the assumption that documented supply is a Western preserve	− Young company (founded 2019) with a shorter track record than the established catalogue houses− Narrower chemistry breadth than Jinan Daigang — no PTMC, PPDO, star or block architectures found− Master file registration is not the same as review: CMDE's own disclaimer states a registered file has been neither reviewed nor necessarily used in a marketed device− Appears focused on injectable and aesthetic applications rather than the full device breadth
Foryou Medical — FORUSORB® / 华素宝® (惠州华阳医疗器械有限公司) ↗ The most credible domestic candidate for a qualified supply relationship: a monomer-to-polymer integrated device manufacturer that also sells feedstock as a distinct B2B brand, carrying a device-grade quality system behind it.	Local player	🇨🇳	+ Sells glycolide, L-lactide, DL-lactide, p-dioxanone and TMC monomers plus PGA and PLGA polymer as a named raw-material brand — verified on both Chinese and English sites+ Claims ISO 13485 and CE, with FDA 510(k) finished products — the quality system a Class III customer's audit looks for, which the pure-play domestic resin houses lack+ Monomer-to-polymer integration gives both cost and supply-continuity credibility+ Established export track record	− FORUSORB product specifications and prices are not published, and deep pages on the site return 404 — hard for a buyer to evaluate without contact− Narrower chemistry than Daigang or Polymtek — PGA and PLGA only, no PCL, PLCL, PTMC or star architectures− Sells to companies that may compete with its own device business, a structural conflict for some buyers− No confirmed master file registration number
Evonik Health Care — RESOMER / LACTEL ↗ The regulatory-grade default. Sells documentation, supply security and the ability to carry a customer through a device or drug filing as much as it sells polymer.	Global player	🇨🇳	+ Deepest regulatory support package; states RESOMER meets ASTM F2313 with catalyst residue ≤100/150 ppm+ Widest form range of any supplier — granule, powder, filament, tube and medical textile (yarn, mesh, nonwoven), plus composite (HA, β-TCP) and 3D-printing grades+ Acquired LACTEL in 2020, consolidating the drug-delivery catalogue+ Brand that de-risks a reviewer's question+ Shanghai application lab and regulatory support presence	− Price is a standing invitation to domestic substitution under VBP cost pressure — 20-30x domestic at comparable pack sizes− cGMP production is only in Birmingham, Alabama and Darmstadt/Jena — nothing is made in China, so all supply is imported with the associated lead time− Slow and expensive for small bespoke lots− Large-account focus leaves pilot-scale custom work underserved
Corbion — PURASORB ↗ The other half of the regulated-grade duopoly, strong on lactide/glycolide monomer and polymer purity, with a broad IV and degradation range (IV 0.2 to 6.0+ dl/g, degradation 0.5 to over 24 months).	Global player	🇨🇳	+ Monomer-to-polymer integration and purity control+ Separate device-grade and drug-delivery-grade product families+ Claims ICH Q7 and ISO 9001:2015 GMP+ Established Shanghai commercial presence	− Does NOT claim ISO 13485, unlike Poly-Med and unlike domestic competitor Foryou — a gap a well-prepared challenger can point at− Same price exposure to domestic substitution− No confirmed third-party Chinese distributor, so small-quantity Chinese buyers are served awkwardly via US repackagers− Standard catalogue orientation limits appetite for unusual one-off specifications
Research catalogue channel — Sigma-Aldrich/Merck and Akina PolySciTech ↗ Catalogue availability of branded regulated-grade polymer in research pack sizes — the default first purchase for a Chinese academic or early-R&D buyer who wants material this week with no supplier qualification.	Global player	🇨🇳	+ Immediate availability and frictionless small-quantity purchase inside China+ Carries the Evonik, Corbion and Ashland brand names into research accounts, seeding later scale-up preference+ No qualification burden at this order size+ Effectively the only accessible small-quantity route for PURASORB and Viatel	− Effective price per kg is extreme, leaving very wide room for a challenger to undercut while still earning a strong margin− Catalogue grades only — no custom synthesis, no defined-end-group or unusual-ratio work− Not a scale-up path; customers must re-source when volumes grow− Pack sizes capped well below pilot scale
Corbion Biomaterials (PURASORB) ↗ The lactide-chemistry specialist — backward integrated into its own lactide/glycolide monomer, which underwrites a purity and consistency story, with a very wide PURASORB grade matrix across PLLA, PDLLA, PLGA, PCL, PDO and copolymers.	Global player	🇮🇳	+ Monomer backward integration gives a genuine consistency and traceability argument+ Very broad grade matrix, including fibre-grade and high-IV PLLA that suture and scaffold makers need+ Established regulatory support documentation	− Same price objection as Evonik in an Indian cost structure− Less India-local technical field presence than Evonik− Custom synthesis for small accounts is not the commercial model
Nomisma Healthcare Pvt. Ltd. ↗ The domestic Indian PLGA/PLA producer. Vadodara, Gujarat, founded 2017/2018, ~11-25 employees. Supplies lyophilised, tin-free, sterilised PLGA and PLA (21 PLGA variants listed) plus L-lactide and DL-lactide monomer, with grades varied by molecular weight, molar ratio and end group (hydroxy, ester, carboxylic acid, PEG). Claims IPEC GMP and 21 CFR compliance, ISO 9001 and WHO-GMP certification, clean-room manufacture, and use in FDA-approved commercial formulations.	Local player	🇮🇳	+ Domestic supplier — no import duty, no forex, no sanctions question, no 30-45 day sea leg, and it counts as local content under Make-in-India preferences+ Offers exactly the custom MW / molar-ratio / end-group tailoring that is RPS's differentiator, at Indian prices+ Physically close to the Vadodara-Ahmedabad-Mumbai pharma cluster, so a formulation scientist can visit+ Sells small development lots without European MOQ friction	− Very small company (est. 11-25 staff) — supply-security and business-continuity risk is a real objection once a product is filed− Thin regulatory dossier relative to Evonik/Corbion; no comparable long commercial track record− Marketplace-led sales presence signals a small operation to a large buyer− Limited or no converted semi-finished forms (spun fibre, extruded tubing, cast film) — resin only
Chinese suture-grade PGA / PGLA and PLA producers (Jinan Daigang, BMG-class and similar) Volume, price and short lead times to India. Sells resin and, importantly, finished PGA yarn, which lets an Indian suture maker skip polymer purchase and qualification entirely.	Global player	🇮🇳	+ Unbeatable landed price at tonnage+ Short and reliable shipping into Indian west-coast ports+ Willing to sell yarn as well as resin, removing a processing step for the customer+ Payment is routine — no bank will refuse a China-India invoice	− Documentation and biocompatibility dossiers are often thin or inconsistent− Batch-to-batch variability is the standing complaint− Not credible for a regulated-market pharma filing− Little to no custom-synthesis or technical-development capability
Merck / Sigma-Aldrich (RESOMER and catalogue biodegradable polymers) ↗ Instant availability of named research grades with a published price, an Indian entity to invoice, and next-week delivery — the default for anyone starting a project.	Global player	🇮🇳	+ Owns the moment of first purchase, which is exactly where a new supplier could otherwise win+ Frictionless procurement inside Indian institutional purchasing rules+ Brand trust in the lab	− Prohibitively expensive above ~100 g, so it never converts into the commercial account− No custom synthesis− Distributes others' polymer rather than tailoring it
Merck / Sigma-Aldrich (RESOMER and resorbable polymer catalogue) ↗ Not a manufacturer of the medical grades but the dominant CHANNEL for research-scale and early-development quantities, distributing Evonik's RESOMER line among others. This matters disproportionately for Ireland because s-research-custom-synthesis demand from university biomaterials groups is one of the few segments with a near-zero qualification barrier - and Sigma-Aldrich already owns that channel with next-day delivery and a purchase-order relationship every Irish university already has.	Global player	🇮🇪	+ Owns the research-buyer relationship and the frictionless small-quantity purchase path+ Transparent published pricing+ Immediate availability and short lead times+ Trusted established vendor in every Irish research institution's purchasing system	− Very high price per gram at research scale− Limited custom-specification capability - catalogue grades only− Does not scale into GMP commercial supply, so wins the researcher but hands the commercial account to the underlying manufacturer
Foster Corporation (a Nolato company) ↗ Competes at the converted-form layer rather than the polymerisation layer - medical polymer compounding, distribution of bioresorbable resins and custom compounds, and supply of extruded/processable forms. Relevant to Ireland because Irish converters often want a processable compound or a semi-finished form rather than neat resin, and Foster has an established partnership footprint with Irish implantable-textile players.	Global player	🇮🇪	+ Strong in compounding and converted forms+ Existing relationships in the Irish/Galway converter base+ Flexible on smaller compound lots+ Nolato ownership gives scale and continuity	− Depends on third-party base resin - not a primary polymer producer− Narrower custom-chemistry capability than a true polymeriser− Less regulatory documentation depth than the resin manufacturers
Chinese medical-grade PLGA/PGA resin and yarn producers (cluster: Jinan Daigang Biomaterial, Huizhou Foryou Medical, Shenzhen Polymtek and similar) ↗ [Home base: China. No entity, distributor or technical presence in Kazakhstan.] Cost-equivalent material with adequate paperwork. Sells on landed price per kilogram and on willingness to supply the exact converted form (braided, coated, ready for needle attachment) rather than raw resin.	Global player	🇰🇿	+ Lowest landed cost of any credible source, which is decisive for a converter selling into state tenders+ Sells the converted form the customer actually wants — braided coated yarn, not just resin+ Flexible minimum order quantities and willingness to run trial lots+ Long-established supply relationships with exactly this class of converter+ No sanctions or payment-compliance friction for a Kazakh buyer	− Long lead times and sea or long-haul rail transit into landlocked Kazakhstan, with customs clearance at the external EAEU border− Documentation frequently thin or English-only, and not written for a Russian-language regulatory dossier− Batch-to-batch inherent-viscosity variability is a recurring complaint and directly affects braiding and strength retention− No technical support in Russian and no realistic prospect of a plant visit− Cannot do genuine custom synthesis to a specified molecular weight and end-group chemistry for small volumes
Evonik Health Care (RESOMER, LACTEL) ↗ [Home base: Germany. No entity, distributor or technical presence in Kazakhstan.] The reference standard. Sells regulatory certainty — the drug and device master files, the audit history and the name that regulators and partners already recognise.	Global player	🇰🇿	+ Deepest regulatory documentation and master-file support in the industry+ Widest grade range across L/D ratio, molecular weight and end-group chemistry+ Reputation that de-risks a customer's own registration and partnering+ Proven supply reliability and capacity	− Price far above what a tender-constrained Kazakh converter can absorb− Minimum order quantities and commercial process built for large OEMs, not for a plant buying a few hundred kilograms− No local entity, no Russian-language technical service, no realistic account attention in Kazakhstan− EU export procedure, external-border customs clearance and long lead times into a landlocked market− Reluctance to take on small Central Asian accounts with Russian-linked supply chains
Merck KGaA / Sigma-Aldrich ↗ [Home base: Germany / United States. No entity, distributor or technical presence in Kazakhstan.] Convenience and availability for laboratory quantities. Sells the catalogue, the existing procurement relationship and next-week delivery rather than a supply partnership.	Global player	🇰🇿	+ Already embedded in Kazakh university procurement through existing reagent suppliers+ No minimum order quantity — a lab can buy 5 g+ Fast, predictable, low-friction ordering with no compliance questions+ Trusted brand in academic purchasing	− Research-grade only, explicitly excluded from clinical or production use, so it can never follow a customer into manufacturing− Extremely high cost per gram once quantities exceed laboratory scale− No custom synthesis, no molecular-weight or end-group tailoring, no technical partnership− No path from a research account to a commercial supply agreement
НПК «Новохим» (Tomsk) - biopolymers division ↗ The domestic import-substitution supplier, stated explicitly: the site markets its polymers as alternatives to Evonik, Corbion, Ashland, Mitsui and Merck under the slogan «Замените биополимеры без повторной регистрации» (replace biopolymers without re-registration), and states the products are certified in Russia as вспомогательные вещества for prolonged-release dosage forms.	Local player	🇷🇺	+ Product matrix overlaps RPS almost exactly: PLGA at 50:50, 75:25, 90:10 and custom X:100-X, PLA in L and DL isomers, PGA, with published inherent-viscosity ranges (PLGA 50:50 0.15-0.9 dL/g; PLGA 75:25 0.15-1.5 dL/g; PLA 0.25-2.2 dL/g) and custom viscosity «под ваши требования»+ Has already solved the regulatory framing that gates pharma sales - Russian certification as an excipient for prolonged-release forms+ Owns the exact positioning the brief treats as RPS's core structural advantage, and says it in the customer's own words+ Real production site in Tomsk with a chemical-industry base around it	− No published capacity, scale or customer references; could not verify revenue or headcount (no Tomsk «Новохим» entity surfaced in company-registry search)− Resin only - no evidence of converted semi-finished forms (fibre, extruded tubing, film, microspheres, filament), which is where RPS's differentiation would sit− No PCL or PLCL evidenced in the published range, unlike RPS− No public prices, so buyers cannot self-qualify without a sales conversation
НПО «ЭкоТек» ↗ Catalogue reagent and biomedical-materials house: research-scale biodegradable polymers sold alongside screening kits for drug-form development (PEG-PLGA offered as part of a nanoparticle screening kit).	Local player	🇷🇺	+ Published prices and an ordering path - the only competitor found that lets a buyer self-serve+ Adjacent reagent catalogue creates recurring contact with exactly the research tail RPS wants as lead flow+ Serves gram-scale demand fast, without qualification	− Research/reagent scale; not evidenced as a kilogram-scale supply-chain partner for a registered product− Unclear whether it synthesises or repackages, which matters for batch traceability and dossier support− No device-grade quality system or converted forms evidenced
АО «ВНИИСВ» (Tver) Synthetic-fibre research-production institute listed in Russian polymer supplier directories as a polylactide producer; reported to have run medical high-purity PLA capacity since around 2015.	Local player	🇷🇺	+ Fibre-spinning competence, which is exactly the conversion step suture makers need+ Industrial-scale infrastructure and state-institute standing	− PLA only - no PGA, PLGA, PCL or PLCL breadth evidenced− No web-visible commercial offer, price list or specification sheet; institute-paced responsiveness− The directory listing carries no medical-grade claim, so the medical PLA capability could not be confirmed for 2026
Evonik RESOMER (via Russian representation, distributors and parallel import) ↗ The reference grade. RESOMER is the material named in most existing Russian device and drug dossiers, so it is the default and the incumbent by inertia rather than by active selling.	Global player	🇷🇺	+ Named in the customer's registration file - switching away costs the customer money and regulatory risk+ Decades of biocompatibility, degradation and clinical validation data, DMF support+ Still listed in Russian polymer supplier directories with a Moscow entry, i.e. reachable	− Payment, logistics and lead-time friction; prepayment and no local technical service− FX exposure prices it out of ruble budgets when the ruble weakens− Political risk that supply is interrupted at short notice, which is precisely the argument a domestic supplier makes
Corbion PURASORB (via distributors and parallel import) ↗ The second reference grade, strong in fibre-grade PGA/PLGA for suture and in monomer supply; Corbion and Total Corbion PLA remain listed in Russian polymer supplier directories.	Global player	🇷🇺	+ Fibre-grade credibility with suture makers; monomer as well as polymer supply+ Dossier incumbency comparable to Evonik	− Same payment/logistics/FX friction as Evonik− No local application-development support for custom specifications
Chinese PLGA/PLA suppliers (Jinan Daigang and comparable Shandong/Zhejiang producers) The low-cost alternative that solves the payment problem as well as the price problem - the most direct commercial threat to a domestic supplier competing on availability.	Global player	🇷🇺	+ Lowest landed cost; ruble/yuan settlement is routine+ No sanctions friction, short lead times+ Broad grade coverage including PLGA, PLA, PCL	− Documentation depth and batch-to-batch consistency are the standing complaints− No Russian-language technical dialogue or custom-synthesis collaboration− Does not help a customer claim Russian origin under ПП 719 / СТ-1
Evonik Health Care (RESOMER), distributed in Turkey by IMCD ↗ The default implant-grade resorbable polymer for a device that must pass a notified body. RESOMER is the broadest standard, custom and specialised biodegradable polymer portfolio in the market, backed by regulatory support files and GMP manufacture.	Global player	🇹🇷	+ As of 1 July 2025 IMCD is Evonik's EXCLUSIVE distributor for RESOMER implantable-grade polymers across the EEA, UK, Switzerland and TURKEY specifically - a named, dated, in-country channel that RPS has no equivalent of (src-tr-07)+ IMCD brings a dedicated medical-polymer sales specialist team and 80+ application laboratories in 60 countries, so a Turkish converter gets local technical support in addition to resin+ Deepest grade range and the strongest regulatory dossier position; incumbency inside existing MDR technical files is self-reinforcing+ Distribution through IMCD lowers the effective MOQ, removing one of the few openings a small custom supplier had	− Highest price point, which bites hardest exactly where Turkish converters are squeezed by frozen SGK reimbursement and TRY depreciation− Genuinely bespoke compositions at 1-20 kg scale remain slow and expensive to obtain− The 2025 move to a distributor model adds a margin layer and can lengthen the technical dialogue for a non-standard requirement
Chinese medical-grade polyester suppliers (Jinan Daigang Biomaterial, Dalian Sinobio Chemistry, Shaanxi Saien Biotech and peers) ↗ Cheap, fast, low-MOQ resorbable polyester with thin regulatory documentation - the same value proposition RPS intends to occupy, already occupied.	Global player	🇹🇷	+ This is RPS's most dangerous competitor set, because it attacks on the identical axis - price and small-lot flexibility - while carrying none of RPS's payment or geopolitical friction+ Published prices and 1 g minimum orders make trial purchasing frictionless, which is decisive for research buyers+ Chinese suppliers already ship medical consumables into Turkey at scale and the import channel is established and bankable+ No sanctions exposure; a Turkish bank will settle a China payment without hesitation	− Documentation depth is generally thinner than Evonik/Corbion, so notified-body acceptance for a Class III implantable is not assured− Batch-to-batch consistency and residual monomer control are a recurring buyer concern− Limited genuine custom synthesis - most offer catalogue L:G ratios rather than a specified terminal group or narrow MW target, which is the one place RPS can still differentiate
Merck / Sigma-Aldrich (RESOMER research catalogue, Merck Ilac Ecza ve Kimya, Istanbul) ↗ The default research-scale channel. For a Turkish university group ordering 5 g of PLGA, Sigma-Aldrich is the path of least resistance: local entity, TRY invoicing, university framework accounts, next-week delivery.	Global player	🇹🇷	+ Owns the research/custom-synthesis segment that is RPS's most realistic entry wedge, and owns it through purchasing infrastructure (framework contracts, local invoicing) rather than through product superiority+ Local Turkish presence removes customs, currency and procurement friction entirely, and lets a university buy on an existing framework account in TRY+ Brand trust with academic buyers and immediate availability	− Only catalogue compositions - it will not synthesise a bespoke L/D ratio, molecular weight or end-group, which is the exact gap RPS fills− Extremely expensive per gram, so a group needing 100 g+ has a real incentive to look elsewhere− No scale-up path from research gram to production kilogram
Evonik (RESOMER and LACTEL) ↗ The default incumbent and the broadest portfolio of standard, custom and specialised bioresorbable polymers, bundled with formulation development and CDMO capability up to finished sterile parenteral product.	Global player	🇺🇸	+ US manufacturing on the ground: Evonik Birmingham Laboratories in Birmingham, Alabama, with ISO 8 cleanrooms and a purpose-built advanced-biomaterials plant commissioned there - a domestic-source answer no importer can match+ Owns both RESOMER and LACTEL, the two most commonly specified PLGA brands, so it appears on both sides of many second-source evaluations+ Master-file support and regulatory documentation that buyers can reference directly in filings+ Can take a customer from polymer through formulation development to sterile fill-finish, which locks the polymer choice in early	− Sized and priced for commercial programmes: small custom lots and unusual specs are slow and expensive to get− Least flexible on non-catalogue specifications at small volume− Premium pricing invites second-source searching from cost-pressured startups
Ashland (viatel ultrapure bioresorbable polymers) ↗ Ultrapure GMP-compliant bioresorbable polymers for parenteral controlled release and medical devices, sold on the promise of release-profile reproducibility; five polymer families.	Local player	🇺🇸	+ US-headquartered specialty chemicals company with an FDA Drug Master File on the portfolio (DMF 33847) that customers can reference - exactly the artefact that makes an incumbent hard to displace+ Sells into pharma accounts through an existing excipient relationship, so the polymer rides in on an established vendor record+ GMP-compliant manufacturing and a recently broadened grade range	− Later entrant to bioresorbables than Evonik or Corbion, with a shorter track record in device applications− Manufacturing footprint is outside the US, so it does not carry the domestic-source argument Evonik Birmingham or Poly-Med can make− Narrower converted-form capability - it sells polymer, not fibre, film or tubing
Foster Corporation (Foster, LLC) ↗ US medical-polymer compounder and distributor (Putnam, Connecticut) covering the full spectrum of durable and bioresorbable implantable grades, with custom formulation, regulatory compliance and supply-chain support.	Local player	🇺🇸	+ Sits between the polymeriser and the converter and controls the specification at the point where the OEM actually buys+ Distribution relationships mean it can offer several base polymers under one US vendor record and one quality agreement+ Strong US regulatory and supply-chain service wrapper	− Not a polymeriser - it compounds and distributes, so it cannot itself tune molecular weight, L/D ratio or end-group chemistry at source− Dependent on upstream suppliers for base resin availability and pricing− Adds a margin layer that price-pressured startups try to bypass
MilliporeSigma (Merck KGaA, Sigma-Aldrich catalogue) ↗ Same-week fulfilment of research quantities from a vendor record every US university and pharma company already has - convenience, not specification.	Global player	🇺🇸	+ Owns the top of the funnel: the research segment RPS can most easily win is the segment that reflexively buys from this catalogue+ Already an approved vendor everywhere, so buying involves no onboarding, no audit and no sanctions screening+ Distributes the incumbent brands, so a lab's first exposure to PLGA is a RESOMER part number	− Research grades are not GMP and carry no master file, so work has to be repeated on a filable grade later− Catalogue only - no custom molecular weight, L/D ratio or end-group chemistry− Extremely high price per gram, which is precisely the opening a low-cost custom synthesiser can attack

How crowded each market is

🇨🇳 China

Serious vendors

15 vendors est.^{[cn-14] [cn-15] [cn-16] [cn-17] [cn-18] [cn-19] [cn-04] [cn-05]}

Market shape

fragmented

No published market-share data exists for medical-grade resorbable polymer supply in China at this scope, so every est_market_share_pct is deliberately null rather than guessed. THE COMPETITIVE PICTURE WAS REVISED TWICE DURING THIS RESEARCH AND THE SECOND REVISION IS THE IMPORTANT ONE. The first read, from vendor websites, was that the Chinese base competes on chemistry breadth and price but not on documentation: Jinan Daigang and Shenzhen Polymtek, the two deepest catalogues, publish no ISO 13485, ISO 10993, USP Class VI or master file claim, and Daigang's only third-party test reports date from 2014. That is still true of those two companies. But reading the CMDE master file registry — 1,555 entries, independently re-verified here — overturns the generalisation. Roughly ten Chinese suppliers ALREADY HOLD NMPA master files for bioresorbable polymers, several at injectable grade: 山东采采 alone holds PLA, PCL Type I/II and PLGA at 8515, 7525 and 5050 with the last two registered 供注射用, and has an approved domestic injectable PCL microsphere filler on the market. Meanwhile Evonik holds exactly ONE master file and it is PEEK, not RESOMER; Corbion appears nowhere in the registry at all. So the documented-supply tier in China is not Western — it is domestic, and it is already built. The 'empty middle' thesis therefore holds only in a much narrower form than it first appeared: the gap is not documented supply in general, which Chinese firms now occupy, but documented BESPOKE synthesis at pilot scale across unusual chemistries (PLCL, defined end-groups, high-IV fibre and tubing grades, star and block architectures) where the master-file holders are narrow and the broad-catalogue houses are undocumented. That gap is real but considerably smaller than the brief anticipated, and the domestic quality-and-documentation gap that would have justified a premium is closing fast and not in a foreign entrant's favour. CAVEAT ON THE REGISTRY: CMDE's own disclaimer states registration means neither review nor use in a marketed device, so a master file is evidence of intent and process capability, not of approved quality. IMPORTANT CAVEAT ON PRICING: all verified prices are research and sample tier. Bulk contract pricing could not be obtained for ANY supplier, Western or Chinese; plausible-looking bulk figures encountered during research traced to an autogenerated content farm and were rejected rather than used. Pack size, not country of origin, dominates the price comparison — comparing a Western 5 g vial to a Chinese 100 g bag manufactures a false gap.

🇮🇳 India

Serious vendors

6 companies est.^{[in-02] [in-03] [in-05] [in-06] [in-07]}

Market shape

moderate

Structure: the Indian market splits into two almost separate economies. The DOLLAR economy is pharma-grade PLGA/PLA for depot formulations, where Evonik and Corbion are close to unassailable for anything destined for a US or EU filing, because their US FDA Type IV excipient DMFs are referenceable and a Ulyanovsk SME's cannot be. The TONNAGE economy is suture-grade PGA/PGLA, where Chinese producers set the price floor and no Western supplier competes on price at all. Nomisma Healthcare sits between them and is the most important single finding for RPS in India: it is a domestic manufacturer offering the identical pitch — custom molecular weight, molar ratio and end-group tailoring, tin-free, small lots, Indian prices — with none of RPS's payment, freight or sanctions friction, and it is the reason a Russian supplier cannot win India on 'cheaper than Evonik' alone. The est_market_share_pct figures for Evonik, Corbion and the Chinese bloc are ANALYST ESTIMATES of the India resorbable-polymer spend, not sourced measurements; no India-specific share study was found, and shares are left null where there is no defensible basis. Declared shares sum to 67%, with the balance spread across Nomisma, Ashland, Merck/Sigma and a long tail of traders and re-packers.

🇮🇪 Ireland

Serious vendors

6 vendors est.^{[ie-08] [ie-09] [ie-10] [ie-11] [ie-15] [ie-16]}

Market shape

concentrated

No Ireland-level market-share data exists for this category at any published source, so every est_market_share_pct is null rather than invented; the sum is therefore 0 and trivially within the 100 cap. Qualitative ordering with reasonable confidence: Evonik and Corbion lead the merchant resin market into Ireland, Ashland holds a structurally privileged position because it manufactures domestically in Mullingar, Sigma-Aldrich dominates research-quantity flow, and Poly-Med and Foster split the converted-form and compounding niche. The critical competitive conclusion for RPS is not that the market is crowded in the ordinary sense - six meaningful suppliers is a concentrated oligopoly, not a crowded market - but that the specific gap RPS aims at (custom specification, small-to-mid lots, converted forms, contract development) is precisely the gap Ashland fills FROM INSIDE IRELAND and Poly-Med fills from the US. Ireland offers no open niche and no origin advantage.

🇰🇿 Kazakhstan

Serious vendors

4 competitors est.^{[kz-12] [kz-18]}

Market shape

moderate

The competitive picture in Kazakhstan is not a crowded field, it is a vacuum with a price floor. None of Evonik, Corbion, Poly-Med or Ashland has any presence in the country; they reach it, if at all, by direct export or an EU distributor, and none of them will fight for an account of this size. The realistic incumbent for the one account that matters is Chinese braided PGA/PGLA yarn, competing purely on landed cost, and the true competitive threat to the whole market is structural rather than commercial: the Kazakh healthcare system can simply keep importing finished suture and finished cosmetic threads, in which case no polymer is bought domestically by anyone. RPS's differentiation is therefore not price against China and not documentation against Evonik, but the combination no incumbent has — Russian-language technical service, no customs border, days rather than weeks of transit, custom specification at small volume, and a willingness to co-fund the requalification that switching a registered device's raw material requires. The most important unknown in this section is empirical and cheap to resolve: identify RuMa Farm's current resin or yarn supplier. SHARE FIGURES: est_market_share_pct is carried as a plain number to satisfy the schema, so the evidence behind each figure is preserved in competition.share_estimate_derivation. In summary, none of these shares is observed — no Kazakh import statistics for medical-grade bioresorbable polymer were found, and the market is small enough that a single account determines it. The Chinese cluster figure of 45% is an inference from the economics of a tender-constrained converter, not a measurement; Evonik (12%) and Corbion (10%) reflect reference-grade and dossier-name purchases only; Sigma-Aldrich (15%) is large only against the tiny research denominator; Poly-Med and Ashland are null because no route into Kazakhstan was found at all. Shares sum to 82%, with the balance unattributed. Confirming RuMa Farm's actual incumbent supplier would replace this entire estimate with a fact and is the cheapest high-value research step available.

🇷🇺 Russia

Serious vendors

6 competitors est.^{[ru-03] [ru-07] [ru-08] [ru-10] [ru-20]}

Market shape

fragmented

Two findings matter more than the competitor list itself. FIRST - the brief's premise that Western supply has been cut off is NOT evidenced. Searches for Evonik/Corbion supply restrictions, price increases and lead times to Russian buyers returned nothing specific; what did surface points the other way (2022 trade-press reporting in which Evonik's CEO said the company would follow sanctions, which have not covered many chemical products, and that business with Russia could continue; academic work on medical sanctions confirms medicines and medical devices are broadly exempted on humanitarian grounds). Evonik, Corbion and Total Corbion PLA are all still listed in a Russian polymer supplier directory, Evonik with a Moscow entry. The honest reading is friction - intermediaries, prepayment, longer lead times, lost technical support, FX exposure - not absence. SECOND - the strongest confirmation that Western resin is still obtainable comes from a competitor: Новохим's pitch «Замените биополимеры без повторной регистрации» only makes commercial sense if buyers currently hold, and could continue holding, Evonik/Corbion material. Parallel import is therefore a live constraint on pricing and on the substitution argument, not a footnote. Taken together, RPS's claimed structural advantage is real but neither exclusive (Новохим holds the same ground, better established) nor absolute (the incumbent material still arrives). No market-share data exists for any player; all shares are null.

🇹🇷 Turkey

Serious vendors

6 vendors est.

Market shape

concentrated

No share data exists for this market at country level and none was invented - every est_market_share_pct is null. Qualitative ordering, from what was verified: Evonik/RESOMER is the likely leader in implantable-grade resin and has just strengthened its position with a named, dated Turkish channel (IMCD exclusive distributor from 1 July 2025, src-tr-07); Corbion is the closest peer and targets aesthetics explicitly; Merck/Sigma-Aldrich effectively owns the research segment through local entity and university purchasing infrastructure rather than product; the Chinese tier is the fastest-growing and is the direct threat to RPS's price-and-flexibility positioning; Poly-Med and Ashland are present but narrower in Turkey. The competitive structure is concentrated at the top and fragmented at the bottom, with essentially nothing in the middle - which is where RPS is trying to sell.

🇺🇸 United States

Serious vendors

8 suppliers est.^{[us-08] [us-09] [us-10] [us-11] [us-12] [us-13]}

Market shape

moderate

All est_market_share_pct are deliberately null. No source publishes US-level revenue splits for medical-grade bioresorbable polymer; Mordor characterises the resorbable polymers market's concentration only as 'medium', and the private and captive players (Poly-Med, in-house OEM production) do not disclose. Assigning invented percentages would be worse than an honest gap. Directionally, Evonik and Corbion together are believed to hold the clear majority of the US merchant market, with Evonik advantaged domestically by its Birmingham, Alabama manufacturing; Poly-Med, Ashland and Foster split most of the remainder; and research-scale catalogue sales are a small revenue slice but a disproportionately large share of first-contact events. The competitive structure is 'moderate' rather than 'concentrated' precisely because a fragmented research and custom-synthesis tail exists - which is the only tier a new entrant can enter. Critically for RPS, competition is NOT the binding constraint in the US: even at a materially better price and specification flexibility, a Russian-domiciled supplier fails at vendor onboarding before a technical comparison happens.

§11

Industry Analysis

A barbell merchant market sitting under a much larger finished-device industry, with significant captive integration. Upstream, lactide and glycolide monomer supply is concentrated, though several Chinese producers (Daigang, Polymtek, Foryou) are monomer-to-polymer integrated. In the middle, a small number of international regulated-grade houses — none of which manufacture in China — coexist with a broad domestic producer base clustered in Shandong/Jinan, Shenzhen, Chengdu and Changchun that splits into two groups — broad catalogue houses competing on chemistry range and price without regulatory documentation, and a growing set of NMPA master-file holders (Jinan, Changchun, Chengdu, Shenzhen, Guangzhou, Nanjing) competing on documented, registered grades including injectable PLGA. Downstream, the largest Chinese converters in sutures, meshes and anti-adhesion products polymerise their own material, and the leading aesthetic-injectable makers are vertically integrated from polymer to finished vial, so a meaningful share of national consumption never reaches the merchant market. Sales are relationship- and specification-led, by quotation; no supplier at any tier publishes bulk pricing.

Market	Deal size	Sales cycle	Margin	How buying works
🇨🇳 China	$4k est.^{[cn-12] [cn-13] [cn-20]}	18 mo est.	55% est.^{[cn-12] [cn-13] [cn-20]}	Two-speed. Research and development-lot purchases are informal and fast — a WeChat conversation, a quotation, a small order, often through a local reagent distributor or a marketplace listing, with the PI or R&D engineer deciding. Qualification-grade purchases are formal and slow: technical specification review, sample characterisation against the buyer's own methods, a documentation audit (ISO 13485, ISO 10993, USP Class VI, COA content), an on-site or remote audit of the manufacturing site, then a framework agreement with continuity-of-supply and change-notification clauses. Chinese buyers negotiate hard and routinely benchmark a foreign quote against a domestic one — but the verified evidence that the cheapest domestic options carry no biocompatibility dossier means the benchmark is not like-for-like, and a well-prepared supplier can reframe it. Settlement currency and the ability to invoice through an entity the buyer's finance team is comfortable with are practical gating items, not afterthoughts.
🇮🇳 India	$12k est.^{[in-05] [in-06] [in-08]}	15 mo est.^{[in-13] [in-14] [in-23]}	60% est.^{[in-05] [in-06] [in-08] [in-23]}	Two-track. Development-stage purchases are made by the R&D or formulation head against a project budget with light process — this is the winnable door. Commercial purchases run through a formal supplier-qualification process: vendor registration, ISO 13485 / GMP certificate review, a written quality agreement, often an on-site or remote supplier audit, incoming-goods testing against an agreed specification, and a change-control clause forbidding any process or site change without notification. Indian procurement is explicitly and aggressively price-negotiated — a first quotation is expected to be an opening position, and multi-round negotiation plus a demand for 60-90 day credit terms is standard. Public-sector and institutional buyers add tender rules, GeM portal listing and Make-in-India domestic-content preference. Samples are expected free; the volume of unpaid sampling before a first order is a real cost line.
🇮🇪 Ireland	$250k est.^[ie-16]	24 mo est.^{[ie-15] [ie-16]}	65% est.^[ie-16]	Formal, documented and audit-driven. An Irish medtech site operating under ISO 13485 must qualify every supplier of a material that becomes part of the device: supplier questionnaire, quality-system certificate review, on-site audit for critical suppliers, agreed incoming specification, a written quality/change-control agreement obliging the supplier to notify before any process or specification change, and initial batch qualification. For an implantable resorbable material the customer must additionally hold biocompatibility (ISO 10993) and degradation data traceable to that supplier's material, and under EU MDR the supplier and material appear in the technical documentation reviewed by the notified body. US-owned sites - which is most of the Irish cluster - layer a global trade-compliance and supplier-risk screen on top, run from US headquarters and applying US as well as EU policy. Country of manufacture is captured explicitly at the questionnaire stage and is verified by audit: ISO 13485 and EU MDR supplier controls require qualification of the MANUFACTURING SITE, and for a critical implantable material that normally means a physical on-site audit of the plant that actually makes the polymer. This is the decisive procedural point for RPS. An offshore contracting entity - a UAE free-zone or Delaware company issuing the invoice - satisfies none of it: the auditable site is Ulyanovsk, the customs entry declares Russian origin, and the change-control agreement must name the real manufacturing location. The practical consequence is that a Russian-manufactured material is screened out at supplier qualification regardless of the corporate structure wrapped around the sale, and independently of whether the underlying trade is lawful.
🇰🇿 Kazakhstan	$25k est.^{[kz-03] [kz-12] [kz-18]}	12 mo est.^{[kz-01] [kz-18]}	60 percent est.^{[kz-12] [kz-18]}	Kazakh public healthcare procurement runs through SK-Pharmacia (ТОО «СК-Фармация»), the single distributor for medicines and medical devices within the state guaranteed volume of free medical care and the compulsory social health insurance system. RPS will never bid there and should not plan to: SK-Pharmacia buys finished drugs and devices, not raw polymer. Its relevance is entirely derivative but genuinely important — SK-Pharmacia's long-term offtake contracts are the mechanism that gives a domestic manufacturer the multi-year volume certainty needed to commit to a raw-material supplier and to absorb the cost of a registration variation. As of August 2026 there were 83 such long-term supply contracts covering 2,022 product designations with 31 domestic producers [src-kz-05]. Alongside this sits the local-content regime — Kazakhstani content (казахстанское содержание) evidenced by a СТ-KZ certificate of origin — which gives domestic manufacturers preference in state procurement. Two consequences follow for RPS. First, the local-content regime is a tailwind at one remove: it favours the domestic converter, and RPS sells to that converter. Second, RPS's imported polymer does not itself count toward Kazakhstani content, so RPS should never position on local content and should instead help the customer argue that the conversion performed in Kazakhstan is where the value is added. Hospital-level and private-clinic purchasing outside the state system runs on ordinary tenders and long-standing distributor relationships, where personal contact and incumbency matter more than specification.
🇷🇺 Russia	$12k est.^{[ru-07] [ru-08] [ru-20]}	12 mo est.^[ru-20]	60% est.^[ru-20]	Three regimes run in parallel. (1) State and municipal buyers, state institutes and NMITs procure under 44-ФЗ; state corporations and many state-owned manufacturers under 223-ФЗ - both mean electronic tenders, formal technical specifications, published contract history, and an acute price focus once a spec is written. A supplier who helps write a customer's ТЗ has an enormous advantage. (2) Commercial converters and pharma buy directly by contract, with prepayment or partial advance, ruble denomination, and long qualification before the first order. (3) The national-regime rules for procurement were consolidated into ПП РФ №1875 of 23.12.2024, effective from 01.01.2025, replacing the earlier patchwork of ПП 617 (industrial goods), ПП 878 and ПП 102 (medical devices, the «третий лишний» rule). The mechanism that matters for RPS is indirect and must not be overstated: these preferences attach to the finished device or drug, not to the raw polymer. RPS does not win a preference by being Russian; its customer does - and the customer needs provably Russian-origin inputs and localised production stages to qualify under ПП 719 and obtain a СТ-1 certificate and an entry in the Minpromtorg register of Russian industrial products. Selling a domestic resin that helps a converter clear those origin criteria is a real, but derived, commercial argument.
🇹🇷 Turkey	$8k est.^{[tr-14] [tr-18]}	14 mo est.^{[tr-03] [tr-13] [tr-18]}	45 pct est.^{[tr-09] [tr-14] [tr-18]}	Two channels with opposite characteristics. PUBLIC (71% of the market, src-tr-01): the Social Security Institution (SGK) sets reimbursement through the SUT list, and public hospitals tender through EKAP (ekap.kik.gov.tr) under the Public Procurement Law, where trade.gov records price as the leading award criterion (src-tr-09). Critically, trade.gov also records that SGK reimbursement prices had not changed in seven years - so as the lira depreciated, converters selling into the public system absorbed the entire input-cost increase. This is the central economic fact of the Turkish market and it cuts both ways for RPS: it makes a cheaper non-Western resin genuinely attractive, and it simultaneously destroys any ability to charge a premium or impose hard-currency prepayment. Public hospital consumption is tracked in MKYS, which recorded 30.5% domestically manufactured versus 69.5% imported by value in 2024 (src-tr-01). RPS does not sell into these tenders directly - it sells to the converter who does - but the tender economics set its customers' willingness to pay. PRIVATE/EXPORT/AESTHETICS: private hospitals, aesthetic clinics, medical tourism and export orders are negotiated commercially, price in hard currency and are far less constrained. RPS's realistic customers are the ones with export or cash-pay revenue, not the ones dependent on SUT.
🇺🇸 United States	$45k est.	14 mo est.	62% est.	Technically led and compliance-gated. A programme scientist selects the grade on specification and sample performance; the purchase then passes through supplier quality (ISO 13485 supplier qualification, quality agreement, change-notification commitments, and normally an on-site audit for an implantable-grade material), regulatory affairs (does the supplier hold a referenceable master file), and legal/trade compliance (OFAC SDN and denied-party screening on the vendor record, plus export-control review). Since FDA's Quality Management System Regulation aligned 21 CFR 820 with ISO 13485, supplier controls are a legal obligation on the buyer, not a preference. Large OEMs and pharma run formal vendor onboarding portals where a Russian address is an escalation trigger; many onboarding systems reject it outright. Below roughly USD 5,000, university and hospital labs buy on a purchase card through a catalogue distributor with no supplier qualification at all - the only genuinely low-friction procurement path in the market.

How vendors charge in this industry

Catalogue resin sale by quotation, priced per kg with steep pack-size tiering
Research-catalogue sale by the gram at a very large premium to bulk
Custom synthesis to a customer specification (molecular weight, comonomer ratio, end-group), priced per lot
Converted semi-finished forms sold at a value-add premium over resin (fibre, tubing, film, mesh, microspheres, filament)
Fee-based contract development and microsphere CDMO work that converts into recurring material supply
Captive and vertically integrated production inside device and injectable manufacturers
Distributor, agent and repackager resale, including US repackagers serving as the small-quantity channel for European brands
Catalogue resin sale by quotation with grade-specific pricing and MOQ
Custom/contract synthesis of a bespoke grade billed as development fee plus per-kg supply
Appointed exclusive or semi-exclusive distributor taking 15-30% on resale, carrying stock and doing first-line technical support
Bundled material-plus-development-service (supplier runs formulation feasibility to lock the customer to its grade)
Sale of converted semi-finished forms (fibre, tubing, film, microspheres) at a large step-up over resin value
E-commerce catalogue for research quantities at premium per-gram pricing
Long-term rate contract / annual price agreement once a product is filed, which is where the margin and the lock-in both live
Catalogue GMP resin sold by quotation against multi-year framework/blanket purchase agreements
Custom synthesis and contract development billed as fee-for-service plus subsequent material supply
Converted semi-finished forms (fibre, yarn, tubing, film, microspheres) sold at a substantial value-add margin over resin
Integrated CDMO models bundling polymer, formulation development and finished-component manufacture
Distribution of research-scale quantities through catalogue e-commerce (Sigma-Aldrich model)
Captive/vertically-integrated in-house polymerisation by large OEMs
Direct material supply by quotation, with no public price list and long technical qualification before first commercial order
Long-term supply agreement locked to a registered device dossier — the polymer is named in the registration, which converts a one-off sale into multi-year recurring supply and simultaneously makes displacement of an incumbent very hard
Fee-based contract R&D and custom synthesis, where the supplier co-develops the specification and it is written into the customer's dossier
Distributor resale for laboratory quantities, piggy-backing on existing university reagent-procurement relationships
Toll or semi-finished conversion — selling braided yarn, film or filament rather than resin, which is what a small converter actually wants to buy
Import-and-repack distribution of finished devices, which is the dominant model in the wider Kazakh medical-device trade and the model RPS must displace at the margin
Quotation-based B2B resin supply against a written technical specification (продажа по запросу цены), ruble contracts, prepayment or 30-50% advance
Catalogue reagent sales in gram lots to research buyers, with published prices and e-commerce ordering
Fee-based contract synthesis and НИОКР/ОКР development contracts, frequently financed by state programmes (ФСИ, Минпромторг субсидии на НИОКР) rather than by the customer
Toll conversion and joint development with a converter, where the material supplier co-develops the customer's product to design the material in
Framework annual supply agreements once a supplier is qualified into a registered product
Domestic conversion for the public tender market - the state accounts for 71% of the Turkish medical device market (src-tr-01), so volume is won on EKAP tenders where price is the leading criterion (src-tr-09)
Export-led conversion: the leading suture and implant houses earn a large share abroad (Dogsan 50+ countries, TST 40+, Katsan across North America, Europe and the Middle East), which is precisely why their material documentation must be EU/US-acceptable
Import-and-distribute: the dominant model by firm count, with 2,166 registered importers and 6,079 dealers serving a 69.5%-imported hospital consumption base
Local representation of foreign principals via authorised representative and distributor structures
Cash-pay aesthetics and medical tourism, which operates outside SGK reimbursement, prices in hard currency and is the least price-constrained buyer group in the country
Contract manufacturing and private label for foreign brands
Catalogue resin sales by grade code under a quality agreement, priced per kilogram with volume tiers
Custom synthesis and toll polymerisation to a customer-specified molecular weight, comonomer ratio and end-group, priced as a development project plus supply
Multi-year supply agreements with right of reference to the supplier's FDA Drug Master File or Device Master File - the mechanism that creates the lock-in
Vertically integrated resin-to-component contract manufacturing (polymer, fibre, textile, finished component under one roof)
Fee-based formulation and development services used as a funnel into long-term material supply
Research-scale catalogue distribution through lab supply e-commerce, at very high price per gram and near-zero qualification burden

§12

Rules & Barriers to Entry

Market	Local entity	Licenses	Localization	Data protection
🇨🇳 China	No	No Chinese medical device licence attaches to the polymer itself — bulk resorbable resin is a raw material, not a registered device, so no 医疗器械注册证 or 医疗器械经营许可证 is required to sell it, The importer of record must be a Chinese entity with import/export rights and customs registration (海关报关单位注册登记) — in practice a distributor, agent or the customer itself, NMPA 医疗器械主文档登记 (Medical Device Master File), under 国家药监局公告 2021年第36号 — voluntary, free, and explicitly aimed at raw materials (主文档内容主要涉及医疗器械原材料等). A foreign owner CAN file, but must do so through a Chinese agent (境内代理机构), with the dossier in Chinese and a CA certificate, via erps.cmde.org.cn. Crucially it is NOT reviewed at registration — CMDE assesses the file only when a device registrant references it, and the registry page states plainly that registration does not mean the file has been reviewed or used. Commercial term to note: once granted to a customer, the authorisation to reference is irrevocable, For pharma-grade PLGA: registration on the NMPA 化学原料药、药用辅料和药包材登记平台 to obtain an excipient (F-) number. An overseas supplier may register through a resident representative office or Chinese agent, with a Chinese-language dossier and joint liability for its accuracy. Only APIs receive standalone review — an excipient registration sits permanently at status 'I' until a customer's drug application pulls it through to 'A', so the asset cannot be completed in advance of a customer, MEE new chemical substance registration under 生态环境部令第12号 — a REAL AND UNDER-APPRECIATED GATE, not a formality, and it is the single largest compliance item for this business. Medical devices are NOT on the Order 12 exclusion list (which covers pharmaceuticals including APIs, pesticides, cosmetics and food), and excipients are not exempt either. PCL is on the IECSC inventory and is clean. PLA/PLLA, PGA and PLGA were NOT found in the 2013 public inventory, and if genuinely new they cannot use the cheap record-filing (备案) route above 1 tonne/year, because degradable polymers are expressly excluded from the low-concern polymer category — the entire product function is hydrolytic degradation. That forces 简易登记 (1-10 t/y, 8-12 months) or 常规登记 (≥10 t/y, 14-24 months with a full ecotoxicology package). Below 1 t/y the 备案 route survives and activity may begin on submission, so sampling and qualification quantities stay cheap and only scale-up hits the wall. There is NO research exemption — Order 12 puts 研究 explicitly in scope. FIRST ACTION: an MEE-SCC inventory status enquiry costs ~RMB 3,000 (~USD 430) and about two weeks, and covers the confidential portion of the inventory as well — buy it for PLLA, PGA and PLGA before anything else, because it resolves a question that otherwise costs one to two years	Chinese-language technical documentation is effectively mandatory — datasheets, COAs, safety data sheets and the quality dossier must be readable by an R&D engineer and a regulatory affairs officer who may not work in English; Chinese-language commercial front: a Mandarin website with an ICP filing, a WeChat official account and a Chinese-speaking technical contact reachable in China hours; COA content matched to the domestic spec floor buyers already expect — residual monomer, catalyst residue, heavy metals, LOD and ROI reported as a matter of course; CNY quotation capability alongside USD/EUR, with an invoicing route that can produce a fapiao — normally solved through the distributor or agent; Local technical support able to attend the customer's site during processing trials, and a manufacturing site prepared to host or remotely support a customer audit; Documentation formatted to what an NMPA submission expects, which is not identical to a CE or FDA package	Low practical burden for this business. PIPL and the Data Security Law apply to any Chinese customer contact data collected through a website or CRM, and cross-border transfer of personal information has a filing/standard-contract regime, but a B2B supplier holding a few hundred business contacts sits far below the thresholds that trigger a security assessment. Two practical clarifications matter more than the privacy law itself. First, ICP filing is keyed to HOSTING LOCATION, not language or domain: a Chinese-language site hosted in Hong Kong, Singapore or the EU needs no ICP filing even on a .cn domain, and only a PRC entity can obtain one. So a foreign supplier has three options — host offshore with no filing but poor mainland latency and throttling risk; establish a WFOE and file; or host under the distributor's ICP, which means the distributor legally owns the filing and effectively controls the site. Every verified Chinese competitor carries an ICP number (Daigang 鲁ICP备11027909号-1, Polymtek 粤ICP备2022096756号, Foryou 粤ICP备15063100号), confirming mainland hosting is the local norm. Second, cross-border transfer thresholds are far above this business: under CAC Order 16 a non-CIIO transferring fewer than 100,000 individuals' non-sensitive personal information per year is exempt from standard contracts, certification and security assessment entirely, and a B2B pipeline sits two to three orders of magnitude below that. Note one common misreading — the 'necessary to conclude or perform a contract' exemption does NOT cover B2B contact data, because it requires the natural person to be a party to the contract, which a purchasing manager is not. Practical package: host offshore, publish a Chinese-language privacy notice, take separate unbundled consent for cross-border transfer at form submission, collect no sensitive personal information, and keep an annual count as evidence.
🇮🇳 India	No	Importer-Exporter Code (IEC) — held by the Indian buyer or the appointed distributor, not by RPS, GST registration for the Indian importing entity, No CDSCO import licence is required for the polymer itself: Form MD-14/MD-15 applies to finished medical devices, and a raw material or semi-finished component imported for local manufacture falls under the Indian manufacturer's own CDSCO manufacturing licence (Form MD-5 for Class A/B, MD-9 for Class C/D) rather than a separate material registration, The Indian customer's device or drug licence is what carries the material: absorbable sutures, meshes, resorbable fixation and bioresorbable scaffolds are Class C/D under the Medical Device Rules 2017, requiring an MD-9 manufacturing licence and central-licensing-authority scrutiny of the material specification, For a pharmaceutical use, the polymer is an excipient characterised inside the customer's CDSCO application under the New Drugs and Clinical Trials Rules 2019 — India has no standalone excipient DMF register equivalent to the US Type IV DMF, If RPS were to sell a finished converted form as a device rather than a material, an Indian Authorised Agent holding Form MD-42 registration plus MD-14/MD-15 import licensing would become mandatory — a strong argument for selling material, not devices, BIS registration is not applicable to these polymers; no product-specific Indian standard licence exists for resorbable resin	No statutory localisation of manufacturing, testing or data for imported medical-grade polymer; Commercial-practical localisation: an Indian entity must be the importer of record (IEC + GST), so an appointed distributor or the customer itself takes that role; Make-in-India public-procurement preference and the medical-device PLI scheme reward domestic content in the finished device, which indirectly advantages Nomisma and disadvantages any importer — a reason to consider local repacking, local warehousing or a local converting partner later; English-language documentation is required in practice; Russian-language CoAs, test reports and quality manuals must be professionally translated and ideally issued bilingually; Indian buyers expect local stock or at least a bonded/consignment arrangement for commercial grades to avoid holding 30-45 days of sea transit in their own working capital	Digital Personal Data Protection Act 2023 (DPDP Act) governs personal data of Indian data principals, with consent, purpose-limitation and breach-notification duties and government power to restrict transfers to notified countries. For a B2B materials business the exposure is limited to CRM contact data and sampling records, but a Russian-domiciled data controller should assume that Russia could in principle be a notified restricted destination and keep Indian contact data in a documented, minimal, consent-backed form. Separately, customers will require confidentiality agreements covering their formulation and grade specifications, which is the more commercially material data question.
🇮🇪 Ireland	Yes	No Irish licence is required to sell a raw polymer per se - the material is not a medical device and the seller is not a manufacturer under EU MDR; the regulatory burden sits with the customer, EU REACH registration of constituent monomers, or appointment of an Only Representative, where the EU importer role is assumed, Where the polymer is supplied as a pharmaceutical excipient, a Drug Master File / ASMF and GMP conformity are commercially mandatory though not a licence, An Irish/EU corporate entity, VAT registration and EORI number would be required for any EU-based operating model	No data-localisation or local-content requirement applies in Ireland; English-language technical and regulatory documentation is expected as standard - no translation obligation arises since English is an official language; For the only lawful route (an EU-based producing entity), the material would need to be genuinely manufactured in the EU: EU non-preferential origin under the Union Customs Code turns on last substantial transformation, so re-packaging, re-labelling or simple blending of Russian-origin polymer in a third country or in the EU would NOT confer new origin and would not escape Article 3i	GDPR applies in full, enforced by the Irish Data Protection Commission, which is one of the EU's most active supervisory authorities because so many multinationals have their EU establishment in Ireland. For a B2B materials business the practical obligations are modest - lawful basis for B2B marketing contact and a compliant privacy notice. On international transfers, the disclosed corporate structure materially eases what would otherwise be a real obstacle: a US-domiciled contracting entity can rely on the EU-US Data Privacy Framework if certified, or on Standard Contractual Clauses otherwise, and a UAE entity can use SCCs with a transfer impact assessment - both ordinary, workable arrangements. Only onward transfer of EU personal data to the Russian operating site raises the harder question, since there is no adequacy decision for Russia and a transfer impact assessment is difficult to pass given state access powers. This is a manageable, second-order compliance item rather than a barrier, and it is not among the reasons Ireland fails.
🇰🇿 Kazakhstan	No	None for the polymer itself. Medical-grade bioresorbable polymer sold as a raw material to a manufacturer is neither a medical device nor a medicinal product, so it requires no registration certificate (регистрационное удостоверение) in Kazakhstan and no EAEU device registration. The registration burden sits entirely with the customer that makes a device from it. This is the single most under-appreciated fact about this market entry: RPS's regulatory deliverable in Kazakhstan is documentary, not licensing., Registration IS required if RPS sells a finished or sterile form that is itself presented as a medical device — for example sterile packaged suture thread, a sterile anti-adhesion film or a stent tube supplied as a device. Selling non-sterile bulk yarn, resin, film stock or filament as an intermediate to a licensed manufacturer avoids this entirely, and that is the correct commercial structure for entry., Standard EAEU intra-union trade documentation: contract, invoice, CMR/transport documents, safety data sheet in Russian, and the statistical form of goods movement. No customs declaration and no import duty on movement from Russia to Kazakhstan., Sanitary-epidemiological documentation for a chemical substance may be requested at the customer's or the regulator's initiative depending on how the material is classified; a Russian-language SDS and composition declaration should be prepared in advance., No Kazakh business licence, accreditation or local representative is legally required to export and sell B2B into Kazakhstan from Russia.	No requirement for a local legal entity, local representative or local manufacturing in order to sell B2B into Kazakhstan.; Kazakhstani content (казахстанское содержание) evidenced by a СТ-KZ certificate of origin gives domestic manufacturers preference in state procurement. RPS's imported polymer does not count toward the customer's Kazakhstani content, but the conversion the customer performs domestically does — RPS should be positioned as the input that enables domestic value-add, never as a local-content contributor.; Product labelling and accompanying documentation for goods circulating in Kazakhstan are expected in Kazakh and Russian; the drift of state policy is toward more Kazakh-language documentation over time. For a bulk intermediate this means a bilingual label and Russian-language SDS and certificate of analysis, which is a low cost.; Technical and regulatory documentation intended for a customer's registration dossier must be in Russian; supplying it only in English shifts translation and notarisation cost onto the customer and is a recurring complaint against Western suppliers.	Kazakhstan's Law on personal data and its protection (2013, as amended) is modelled on the same lineage as Russian law and includes a data-localisation requirement: personal data of Kazakh citizens must be stored in databases located on Kazakh territory. Practical exposure for RPS is minimal, because this is a business-to-business materials sale with no consumer data and no processing of patient information. The only touchpoints are contact details of customer employees in a CRM and any website analytics or lead forms serving Kazakh visitors. Prudent handling is to keep Kazakh customer contact records inside the ordinary contractual relationship, avoid building a marketing database of Kazakh individuals, and add a Russian-language privacy notice to any lead form. This is a hygiene item, not a barrier to entry.
🇷🇺 Russia	Yes	None for the sale of bulk resorbable polymer as such: raw resin is neither a registered medical device nor a medicinal product, and needs no licence of its own., Лицензия на производство лекарственных средств (Minpromtorg) and GMP compliance if the material is supplied as a pharmaceutical excipient into a registered drug's supply chain., Лицензия Росздравнадзора на производство и техническое обслуживание медицинских изделий if RPS moves downstream into finished device forms rather than semi-finished material., Регистрационное удостоверение on any finished medical device - required of the customer, and the gate that determines when the customer may change material supplier.	Personal-data localisation under ФЗ-152 ст.18(5) - Russian hosting for website and CRM; Russian-language documentation throughout: ТУ, batch passports/CoA, safety data sheets, technical dossiers; customers' regulatory teams will not accept English-only packages; ПП 719 localisation criteria - the synthesis and conversion stages must physically occur in Russia for the output to count as Russian-origin, which is what makes a domestic supplier valuable to a customer chasing origin status; СТ-1 certificate of origin from the Chamber of Commerce and entry in the Minpromtorg register of Russian industrial products; Ruble contracting and Russian accounting/VAT treatment; state buyers will not contract in foreign currency	ФЗ-152 «О персональных данных», with the article 18(5) requirement that personal data of Russian citizens be recorded and stored on databases located in Russia. For a B2B material supplier the exposure is limited to CRM and website contact data; the practical requirements are hosting the site and CRM on Russian infrastructure and filing the standard Roskomnadzor operator notification. Not a barrier, but a checklist item for any Yandex Direct and lead-capture activity.
🇹🇷 Turkey	No	None for the polymer itself as a raw material - no TITCK licence, UTS registration or authorised representative is required to import a non-device chemical/polymer input (inferred, low confidence, see local_entity_note), Standard Turkish import formalities: customs declaration, HS classification (bioresorbable polyesters fall under primary-form plastics headings, chapter 39), certificate of origin, and where applicable a chemical import notification, Chemical regulatory compliance under KKDIK (Turkey's REACH analogue), which requires registration by a Turkish importer or an only representative for substances above tonnage thresholds - low practical relevance at the kilogram volumes in play here, but it must be checked before scaling, The CUSTOMER requires CE marking and UTS registration for the finished device; RPS's obligation is to supply the documentation that supports it, For any drug-delivery application, the customer's pharmaceutical filing requires excipient-grade documentation RPS does not currently hold	No local-content requirement applies to a raw material input. However, Turkish public procurement applies a domestic-goods price advantage of up to 15% in tenders, and TUSEB is running an explicit localisation (yerlilesme) programme with project funding aimed at reducing the sector's dependence on imported products, RAW MATERIALS and services (src-tr-01). This is a genuine double-edged fact for RPS: the policy creates demand for domestic conversion of resorbable polymer, which RPS can supply, but its long-run objective is domestic upstream capability, which would eventually displace any import; Turkish-language labelling and instructions for use are required for finished devices; for a raw material, Turkish-language technical datasheets and safety data sheets are a commercial expectation rather than a legal one; No requirement for local manufacture, local warehousing or local testing of a polymer input, though consignment stock held in Turkey is a strong commercial differentiator given FX and lead-time exposure	KVKK (Kisisel Verilerin Korunmasi Kanunu, Law No 6698), closely aligned with GDPR, including a cross-border transfer regime that was liberalised in 2024 to add standard contractual clauses alongside the previous explicit-consent and undertaking routes. Low materiality for RPS: a B2B materials business processes contact data for a small number of technical and purchasing counterparts. The more sensitive information flows are commercial - customer formulations, grade specifications and degradation-profile data exchanged during contract development - which are protected by NDA rather than by data protection law, and which Turkish converters will guard closely given their export exposure.
🇺🇸 United States	No	No FDA establishment registration or device listing is required to sell polymer raw material into the US: a resin is a component, not a finished device, and registration/listing obligations fall on the device manufacturer that uses it, An FDA Drug Master File (Type II for a polymer used as a drug-product component, Type IV for an excipient) is legally voluntary but commercially mandatory - without a referenceable master file and a right-of-reference letter, no US pharma customer can cite the material in a filing, A Device Master File (MAF) serves the equivalent function for device customers, US importer of record with a customs bond, and correct HTSUS classification and country-of-origin marking, TSCA compliance for device-use polymers imported as chemical substances (TSCA import certification at entry), unless the material qualifies for the 40 CFR 723.250 polymer exemption; material destined for drug use is excluded from TSCA as an FD&C Act article, If RPS were to ship sterile converted forms (sterile absorbable suture yarn, sterile adhesion barriers), those become regulated articles under 21 CFR and the FDA import entry review applies - though the 510(k)/PMA obligation still sits with the device owner, No US federal licence exists that a Russian supplier can apply for to cure the sanctions/banking problem; OFAC specific licences are transaction-specific and slow	A US-domiciled or at minimum non-Russian entity of record for invoicing, W-9/W-8 handling and vendor onboarding - practically mandatory even though not legally required; US-held consignment or buffer stock: buyers expect days-not-months lead time on repeat orders, and a resorbable resin needs cold, dry, moisture-controlled storage in transit and at rest; A US-time-zone technical contact who can answer specification and troubleshooting questions same-day; Documentation in US English on US templates: CoA, specification sheet, safety data sheet in OSHA HazCom/GHS format, quality agreement, change-notification protocol; A US-accessible audit path - buyers of implantable-grade materials expect to physically audit the manufacturing site, and US auditors will not travel to Ulyanovsk; Master file held with FDA, in English, maintained under an annual report cycle	Not a material barrier for this business. Nothing in the transaction involves patient data or protected health information, so HIPAA and the state privacy statutes (CCPA/CPRA and successors) do not bite on a B2B polymer sale; ordinary contact-data handling for marketing is the only exposure and is straightforward to comply with. The real information-handling risk runs the other way: technical data, analytical methods and process know-how exchanged with a US customer during qualification are potentially subject to US export-control review when transferred to a Russian entity, and US customers' own trade-compliance teams will restrict what engineering detail they can send. Confidentiality agreements are also harder to enforce in either direction given the absence of a working US-Russia commercial-legal channel.

§13

How to Win Customers

Market	Search	Paid ads	Outreach	Partners	Remote	Office	Cost /customer
🇨🇳 China	✓	✗	✓	✓	✗	✗	$18k est.
🇮🇳 India	✓	✓	✓	✓	✓	✗	$15k est.^{[in-20] [in-21] [in-23]}
🇮🇪 Ireland	✗	✗	✗	✓	✗	✓	no data
🇰🇿 Kazakhstan	✗	✗	✓	✓	✓	✗	$12k est.^[kz-18]
🇷🇺 Russia	✓	✓	✓	✓	✓	✓	$4.5k est.^[ru-20]
🇹🇷 Turkey	✗	✗	✓	✓	✗	✗	$28k est.^[tr-18]
🇺🇸 United States	✓	✓	✓	✓	✓	✓	$18k est.

Channels that work best

A Chinese distributor or technical agent acting as importer of record, CNY invoicing party and local face — the single highest-leverage channel and close to a precondition for anything beyond sample sales. Note that neither Evonik nor Corbion appears to use one, selling direct from Shanghai offices instead, which leaves the small-quantity Chinese buyer awkwardly served and is an exploitable gap
Chinese chemical and biomaterials sourcing platforms — ChemicalBook, Molbase/摩贝 and 1688 — where domestic competitors actually list and where procurement staff price-discover; ChemicalBook listings were the only place any Chinese medical-polymer price could be found
MEDTEC China (医疗器械设计与制造技术展) — the trade fair aimed at medical device materials, components and contract manufacturing, and a better fit for a raw-material supplier than CMEF
CMEF (中国国际医疗器械博览会) — much larger but finished-device oriented; useful for account mapping and meetings rather than materials lead generation
CPHI China / 世界制药原料中国展 for the pharma drug-delivery segment, where excipient sourcing conversations happen
Direct technical business development into a named account list — the reachable universe is small enough to work by name rather than by funnel
WeChat official account plus Chinese-language technical content; WeChat is the working channel for ongoing engineer-to-engineer contact
Academic and CAS-institute relationships, joint papers and conference presence as a low-cost credibility route into research and early-R&D buyers — the segment where the competition is a USD 30/g catalogue price rather than a cheap domestic quote
Baidu organic presence via a Chinese-language, China-hosted site — slow, and gated on an ICP filing that requires a Chinese entity
An appointed Indian technical distributor or agent carrying stock and acting as importer of record — the single highest-leverage move, since it solves the IEC/GST, customs, credit-terms, physical-presence and (with the right partner) payment-routing problems at once; the consolidated specialty-excipient distributors (IMCD India post-Signet, Barentz post-Anshul, Azelis) are the obvious targets but are also the most likely to decline a Russian principal on their own compliance policy, so a mid-size independent Indian distributor is the realistic partner
Direct technical business development to formulation-development heads and device R&D directors at NEW programmes — the only door that avoids change-control lock-in, and the one that rewards RPS's actual differentiator (custom MW, L/D ratio, end group, stated degradation window)
CPHI India and PMEC India (the pharma ingredient and machinery show) for the drug-delivery segment; Medical Fair India and the India MedTech Expo for the device segment — in a cluster-based market these are where a new supplier gets a hearing
A structured academic sampling programme with SCTIMST, IIT polymer and biomaterials groups, NIPERs, CSIR labs and CIPET: small revenue, near-zero qualification burden, publications that cite the material, and the students who become tomorrow's formulation heads
Contract R&D sold as the entry product rather than the polymer — a paid degradation-profile or release-matching study creates a commercial relationship, generates data on RPS's own grade, and sidesteps the price comparison entirely
IndiaMART and TradeIndia B2B marketplace listings — unglamorous but demonstrably where Indian buyers of exactly this material transact (Nomisma's primary shopfront)
English-language technical content SEO: grade-selection guides, degradation-profile comparisons, RESOMER/PURASORB equivalence tables, CoA parameter explainers — cheap, durable, and matched to how Indian technical buyers research
LinkedIn outbound to named formulation scientists and QA/RA heads in the Gujarat, Hyderabad, Mumbai and Bengaluru clusters
A UAE-based commercial and logistics presence used as the customer-facing invoicing, stocking and settlement entity — the standard structure for this trade lane and a material de-risking of the bank-refusal problem
NONE are effective for RPS as currently constituted - the goods are import-prohibited, so no channel converts. The channels below describe what WOULD work in this market for a lawfully-supplying entrant, and are included so the entry cost of the compliant path can be assessed rather than as a recommendation for the Russian entity.
Direct technical field sales with a materials scientist, not a salesperson, calling on R&D and process engineering - this is how every incumbent wins in Ireland
Cluster-level presence and relationships: Irish Medtech (Ibec) events, the Galway medtech network, Enterprise Ireland and IDA Ireland introductions
Co-development and joint-development agreements with Irish CDMOs, which convert a material sale into a design-in before a device is filed
University and research-centre partnerships (biomaterials and regenerative-medicine groups) to seed specification of the material in programmes that later commercialise
Technical content and published application data - degradation-profile studies, processing guides, biocompatibility summaries - which is the primary discovery route for materials engineers
Trade conferences: MD&M/MedTech Ireland, CPHI, TIDES, Society for Biomaterials
Sample-and-evaluate programmes with genuinely small minimum quantities, which is the single most effective wedge against incumbent MOQ pain
Direct named-account outbound to a target list of fewer than ten organisations — with a buying base this small, there is no funnel to build, only a list to work. RuMa Farm is target number one and the entire commercial case for the country largely rests on it.
In-person technical visits to Almaty and Astana. A plant visit with a materials scientist who can discuss braiding behaviour and inherent-viscosity control is worth more than any amount of digital activity, and it is precisely what no incumbent supplier offers.
Trade exhibitions — KIHE (Kazakhstan International Healthcare Exhibition) in Almaty and Astana Zdorovie — which function less as lead generation than as the accepted venue for a first face-to-face meeting in this business culture.
Academic and research partnerships: joint work, free or subsidised sample material, and co-authorship with Nazarbayev University, KazNU, Satbayev and the medical universities. These accounts are small in revenue but generate published references, train the next generation of specifiers, and can pull RPS into state-funded programme grants.
Russian-language technical content — datasheets, degradation and strength-retention data, comparison guidance and regulatory-documentation explainers. This works as sales-enablement and credibility material rather than as a traffic channel, because search volume is negligible.
Industry associations and professional bodies in Kazakh pharma and medical devices, which provide the warm introductions that cold outreach cannot.
A local agent or laboratory-supply distributor for research quantities, which solves university procurement formalities and small-shipment logistics without requiring RPS to establish anything in-country.
Jurisdictional flexibility used as a sales instrument: opening the commercial conversation by asking whether the customer's bank and accountant would prefer a UAE or a Russian-entity invoice [src-kz-24] converts the single most awkward topic in the relationship into evidence that RPS has thought about the customer's problem. No Chinese, German or Dutch competitor can offer that choice.
Founder-led direct technical selling into a nameable list of ~40 industrial accounts - this market is small enough to enumerate and call, which makes outbound the highest-yield channel
Russian-language SEO on a very thin keyword set: the substitution queries have low volume but almost no serious competition beyond Новохим, and a page that answers «does switching force re-registration» with real documentation will rank and convert
Yandex Direct on narrow commercial queries - budgets will be tiny because volumes are tiny; useful as a fast test, not a growth engine
Trade exhibitions and conferences where the buyers physically are: Здравоохранение (Russian Healthcare Week), Pharmtech & Ingredients, Аналитика Экспо, Химия, plus surgical and cosmetology congresses
Scientific credibility building: co-authored publications and joint programmes with НМИЦ, ИНЭОС/ИСПМ РАН, ТПУ and medical universities - this is how a material supplier becomes the default in a research tail that later becomes industrial demand
State R&D funding as a customer-acquisition channel: ФСИ programmes, Minpromtorg НИОКР subsidies and НТИ projects that pay RPS to develop a material with a named industrial partner - the partner becomes the customer
Reagent distributors and lab-supply catalogues (Диаэм, Хеликон and similar) to reach the research tail at low cost
Sample-first selling: free 10-50 g evaluation lots with a complete analytical package, because the analytical package is the actual product being sold
A local agent or distributor - decisive, and confirmed as the market norm. Every credible competitor either has one (Evonik via IMCD, exclusively for Turkey since 1 July 2025) or a local entity (Merck). trade.gov records local representation as essential to operating in this market (src-tr-07, src-tr-09). For RPS an agent solves the problem it cannot solve remotely: local technical credibility and physical presence with family-run converters who buy on relationship. It does NOT need to solve a payment problem - RPS's UAE and US entities (src-tr-21) already give the buyer an ordinary hard-currency counterparty - which is a meaningful simplification of the agent brief and of what RPS must offer to attract one
Named-account direct outbound to a target list of roughly 18 industrial converters. With a buying base this small, this is not a marketing channel, it is a business-development list - Dogsan, Katsan, Boz Medikal, TST, Hipokrat, Tipsan and their peers can be approached individually by name
Expomed Eurasia (Istanbul, annual) and MEDICA Dusseldorf, where Turkish converters and their purchasing teams both exhibit and buy - the highest-yield way to convert a cold list into a face-to-face relationship in a market where face-to-face is required
University, TUSEB/TUBITAK institute and teknopark research groups approached directly through academic conferences, published papers and departmental contact - slow, low-value, but the only segment winnable without a supplier-qualification battle, and the source of the technical references that later unlock industrial accounts
Turkish-language technical content: datasheets, degradation-profile selection guides and supplier-qualification documentation packs. Not a lead generator at this search volume, but a credibility requirement once a conversation starts
Sample and trial-lot programmes with free or near-free qualification quantities - the standard mechanism in specialty materials, and the only realistic way past 'has it ever been used in a CE-marked device?'
Veterinary device makers and veterinary suture lines as a deliberate lower-barrier entry route, given the absence of MDR obligations
Deep technical SEO content on the specific grade parameters buyers search on (molecular weight windows, L:D ratio, end-group chemistry, degradation windows) - the only channel that works without a US legal presence and the one that reaches the research tier
Direct scientific outbound to named academic principal investigators and startup formulation leads, opened on technical substance (a degradation dataset, a custom-spec offer) rather than on price
A US- or EU-domiciled distributor or agent that takes title, acts as importer of record, holds the customs bond and appears on the customer's vendor record - practically the only viable route to any organisation with a procurement function
Listing through a third-party research-chemical reseller or catalogue, where the reseller is the vendor of record and the qualification burden on the buyer is near zero
Free sample programmes with full analytical packages, sized so that a lab can evaluate without a purchase order
Peer-reviewed publication and co-authorship with US academic groups - in this category a paper citing a supplier's grade is a durable acquisition asset
Targeted conference presence (Controlled Release Society Annual Meeting, AAPS PharmSci 360, Society For Biomaterials, MD&M West) - though visa and payment logistics make direct exhibition difficult for a Russian entity and argue for going through a partner's booth

§14

The Money Math

Market	Revenue /customer	Cost /customer	Return ratio	Margin	Payback	Entry cost	3-yr return
🇨🇳 China	$12k/year est.^{[cn-12] [cn-13] [cn-20]}	$18k est.	1.3^{[cn-12] [cn-13] [cn-06]}	50% est.^{[cn-12] [cn-13] [cn-20]}	36 mo^{[cn-12] [cn-13] [cn-06]}	$150k est.	-19%^{[cn-12] [cn-13] [cn-06]}
🇮🇳 India	$35k^{[in-05] [in-06] [in-08]}	$15k est.^{[in-20] [in-21] [in-23]}	6.4 ratio^[in-23]	55% est.^{[in-05] [in-06] [in-08] [in-23]}	10 mo^[in-23]	$300k est.^{[in-13] [in-14] [in-20] [in-23]}	15%^[in-23]
🇮🇪 Ireland	$250k est.^[ie-16]	no data	no data	65% est.^[ie-16]	no data	$10M est.^[ie-16]	no data
🇰🇿 Kazakhstan	$45k est.^{[kz-03] [kz-12] [kz-18]}	$12k est.^[kz-18]	11.8 ratio^[kz-18]	45 percent est.^{[kz-12] [kz-18]}	7 mo^[kz-18]	$45k est.^[kz-18]	38 percent^{[kz-03] [kz-12] [kz-18]}
🇷🇺 Russia	$9k est.^{[ru-06] [ru-20]}	$4.5k est.^[ru-20]	4.8 ratio^[ru-20]	60% est.^[ru-20]	28 mo^[ru-20]	$400k est.^{[ru-06] [ru-20]}	35%^{[ru-06] [ru-20]}
🇹🇷 Turkey	$55k^{[tr-14] [tr-18]}	$28k est.^[tr-18]	4.3 ratio^[tr-18]	55 pct est.^{[tr-09] [tr-14] [tr-18] [tr-21]}	29 mo^{[tr-18] [tr-21]}	$128k est.^{[tr-18] [tr-21]}	6 pct^{[tr-18] [tr-21]}
🇺🇸 United States	$28k est.^[us-18]	$18k est.	2 ratio est.^[us-18]	45%^{[us-03] [us-18]}	15 mo^{[us-03] [us-18]}	$700k est.	-120% est.

Return ratio by market

Revenue earned per customer vs cost to win them; the dashed line at 3.0× marks the conventional healthy threshold

§15

Market Trends

Happening now

Long-acting injectable depots are now the demand engine of the whole category: PLGA and PLA microsphere and in-situ-forming implants have moved from experimental excipient to a clinically validated delivery platform in oncology, CNS, hormonal and infectious-disease therapy, and the PLGA excipient line is growing at roughly 12% CAGR against ~11% for the category as a whole. This pulls demand specifically toward high-purity, tightly specified copolymer grades with defined L:G ratio, molecular weight and end-group chemistry rather than toward tonnage.
Aesthetic collagen-stimulating injectables and PDO/PLLA thread lifts are the fastest-moving volume story outside pharma, because the regulatory cycle is measured in months rather than years and the growth is concentrated in Asia, Latin America, the Middle East and the CIS. Kazakh and Russian demand is currently met entirely by finished Korean imports with no domestic material supplier at all.
The post-Absorb reputational hangover still depresses bioresorbable coronary scaffolds: after Abbott withdrew Absorb GT1 from the market in 2017 the segment never recovered the mid-2010s forecasts, and it remains the one sub-segment where actual consumption sits far below what the 2014-2016 projections assumed. The revival that exists is regional and non-Western - Meril's indigenously developed MeRes100 scaffold in India is the clearest example.
Incumbent consolidation and capacity build-out continued through 2023-2025 rather than pausing: Evonik acquired LACTEL Absorbable Polymers from DURECT and commissioned a dedicated advanced-biomaterials production facility, and Ashland announced an expansion of Viatel bioresorbable polymer capacity at Mullingar, Ireland. The merchant market is getting more, not less, capitalised at the top.
Channel consolidation is reshaping how the material is bought: IMCD became Evonik's new RESOMER distributor for medical devices from 1 July 2025, IMCD acquired Signet Excipients in India and Barentz acquired Anshul Life Sciences, so an increasing share of first customer contact runs through two or three global specialty distributors rather than through the producer.

Just starting

GLP-1 and peptide depot formulation is spilling into the resorbable-polyester supply chain: sustained-release and implant formats for metabolic and hormonal peptides raise demand for injectable-grade PLGA with documented residual monomer, residual tin and residual solvent - the analytical package, not the polymer, is the differentiator being bought.
3D-printed patient-specific resorbable implants and medical-grade resorbable filament for FDM/FFF and electrospinning are an identified but barely supplied niche: US demand research found that almost nothing indexes for implant-grade PLLA/PCL filament as distinct from consumer PLA, and no supplier is selling resorbable printing filament into Central Asia at all.
PLCL and other elastomeric resorbable copolymers are moving from research curiosity to specified material for nerve conduits, soft-tissue scaffolds and compliant tubing, and they are thinly represented in both the Chinese domestic catalogue and the Western catalogue relative to PLA and PLGA. Custom comonomer ratio is the request that no catalogue supplier fills.
Buyers are beginning to specify a resorption window rather than a grade code - 'a material that is gone in nine months' rather than 'PLGA 75:25' - which converts the supply relationship from a catalogue purchase into a development engagement and is the emerging shape of the whole custom-synthesis segment.
Domestic-substitution industrial policy is becoming a purchasing criterion in its own right in China (NMPA-era domestic preference), India (Make-in-India local-content preference) and Russia (import substitution), so origin now competes with specification as a selection variable in exactly the markets growing fastest.

Long-term shifts

Supplier requalification is the permanent moat of this industry: changing a resorbable resin supplier forces re-validation of biocompatibility and degradation profile and usually a regulatory file change, giving an 18-36 month design-in cycle for device OEMs and 18-30 months for a pharma excipient tied to a DMF reference. Incumbent grades stay locked in for years, and the only cheap moment to add a supplier is when a file is being written for the first time.
Right of reference to a supplier's FDA Drug Master File or Device Master File is the mechanism that actually creates the lock-in, and it has become table stakes - a supplier without a referenceable master file is not evaluable for a US- or EU-bound filing regardless of how good the polymer is.
Geopolitical fragmentation has become a permanent supply-chain feature rather than a shock: EU Regulation 833/2014 Article 3i with Annex XXI prohibits importing these polymer CN codes of Russian origin and binds the buyer as well as the seller with no medical carve-out and a 'directly or indirectly' clause that defeats transshipment, while the US applies Column 2 rates of duty to Russian-origin polymer. Supplier eligibility is now determined by origin independently of technical merit.
Captive integration removes a large share of headline demand from the buyable market: Ethicon/J&J, Medtronic, Abbott, Stryker, Zimmer Biomet and the largest Chinese suture makers polymerise or fibre-spin significant volumes internally, so the merchant market is estimated at only ~60% of TAM and the largest single line of demand cannot be sold to at any price.
Upstream monomer supply is narrow and concentrated: implant-grade lactide and glycolide come from few sources, which caps how quickly any new polymeriser can scale and exposes the whole tier to raw-material availability and price volatility.
Regulatory regimes are diverging rather than converging - EU MDR, FDA implantable pathways, NMPA excipient bundled review, and the EAEU switch in which national-route medical-device registration ends 31.12.2027 and a single EAEU registration becomes the only route from 01.01.2028 - which multiplies the documentation cost of serving several markets from one manufacturing site.

How AI changes this market. AI is reshaping this market at the two ends where the work is documentary and predictive rather than physical, and leaves the middle untouched. On formulation and polymer design, ML models trained on molecular weight, polydispersity, L:D and L:G ratio, end-group chemistry and crystallinity are starting to predict hydrolytic degradation kinetics and microsphere release profiles well enough to narrow a candidate set before any synthesis happens - which matters commercially because the empirical degradation study is the 6-18 month step that makes every custom specification slow and expensive, and shortening it is what would make 'specify a resorption window, not a grade' a routine purchase rather than a development project. On regulatory documentation, LLM drafting of ISO 10993 biological-evaluation summaries, technical-file sections, DMF modules, certificates of analysis and grade-selection guides genuinely levels a real cost that used to favour large suppliers: a four-person company can now produce a documentation package whose bulk and consistency approximate an incumbent's, which is a meaningful advantage in exactly the small-lot and research tiers where documentation quality is the main non-price differentiator. What AI does not touch is the binding constraint set - wet-lab validation, cleanroom and GMP capability, notified-body and regulator audits of the physical manufacturing site, and the customer's own change-control burden - so it lowers the cost of looking credible without lowering the cost of being qualified. The one clearly adverse effect for a Russian-origin supplier is that AI-assisted supplier screening, sanctions and origin-checking tools have made counterparty due diligence cheaper and more automatic since 2022, so the probability that a Western buyer notices and flags a Ulyanovsk manufacturing site early in the process has gone up, not down.

Money flowing in

Money flowing out

Technologies shaking things up

How buyers are changing

Buyers ask for the analytical package before they ask for a price: residual monomer, residual tin/stannous octoate and residual solvent specifications on the CoA are now the opening question in China, India and Russia alike, because cheap lots fail on documentation rather than on chemistry.
Supplier-origin and sanctions screening has been added to standard supplier-qualification questionnaires since 2022, so country of manufacture is now asked routinely at first contact rather than discovered at audit.
Demand has appeared for single-source traceability from monomer to converted form - the same entity supplying both the resin and the tubing, fibre or film - which Indian OEMs currently cannot get and have to split across two vendors.
Seed-stage device and long-acting-injectable startups are looking for GMP-grade lots under 500 g and finding only 5 g research bottles or full development projects; 'low MOQ GMP PLGA' and 'PLGA supplier without minimum order quantity' are recurring unanswered queries in both the US and India.
Second-source qualification has become a stated procurement objective post-2022 rather than a theoretical one, though the cost of acting on it still exceeds the perceived risk for most programmes - the demand exists and no supplier markets to it directly.

§16

Openings Nobody Is Taking

underserved customers 🇺🇸 🇨🇳 🇮🇳 🇹🇷 🇰🇿 🇷🇺

Small-lot, custom-specification GMP synthesis - 250 g to 20 kg at a written molecular weight, L/D or L/G ratio and end-group chemistry - is the one gap that appeared independently in every single country studied, because catalogue houses sell grades rather than specifications and will not quote a lot this size economically, while the Chinese domestic tier can only supply catalogue ratios.

Segments: Research, tissue engineering and custom small-lot synthesis, Drug-delivery and parenteral formulation

Named as an underserved segment in all seven stage-05 country files in near-identical language: US 'low-MOQ GMP-grade custom polymer... the gap between a 5 g catalogue research bottle and an incumbent's commercial development project'; TR 'custom small-lot synthesis (1-20 kg)... no catalogue supplier serves this, Sigma-Aldrich will not synthesise it, and Chinese suppliers largely offer catalogue ratios only'; IN 'small-lot custom-spec synthesis (250 g - 5 kg)... Western suppliers will not do it economically and Merck only sells catalogue grades'; RU 'the catalogue suppliers sell grades, not specifications'.
The demand is visible as unanswered buyer queries rather than as inference: 'low MOQ GMP PLGA' and 'bioresorbable polymer lead time 2026' in the US, 'PLGA supplier without minimum order quantity India', and 'custom/small-lot resorbable polymer synthesis at 1-20 kg with published turnaround and no catalogue MOQ' in Turkey.
It is also the only pool with essentially no supplier-qualification barrier: research and pre-filing lots carry no regulatory change control, no site audit and no dossier reference, which is precisely why the India research calls it 'the most winnable pool for a Russian supplier' and Turkey calls it 'the only segment RPS can realistically win inside 12 months'.

underserved customers 🇷🇺 🇰🇿 🇮🇳 🇹🇷 🇨🇳 🇺🇸

Converted semi-finished resorbable forms - spun fibre and yarn, extruded tubing, cast anti-adhesion film, microspheres and 3D-printing filament - sold by the same entity that made the resin, which almost nobody offers and which raises value per kilogram far above commodity resin while removing the direct price comparison with Chinese material.

Segments: Absorbable sutures, meshes and soft-tissue barriers, Drug-delivery and parenteral formulation, Research, tissue engineering and custom small-lot synthesis

Russia country research: 'No Russian supplier of these was found while three resin suppliers were' - fibre, yarn, tubing, film, microspheres and medical 3D-printing filament are entirely unserved domestically, and «биорезорбируемое волокно / трубка / плёнка купить в России» and «PLCL PLLA трубка для стента поставщик» return nothing.
India country research: converted forms are listed as an underserved segment because 'Indian OEMs currently have to source from a different vendor than their resin, or make themselves'; Ireland's demand research independently names 'single-source traceability from monomer to form' as an unmet buyer requirement.
US demand research found 'medical-grade resorbable filament for FDM/FFF printing and electrospinning... almost no indexed supply', and Kazakhstan lists resorbable 3D-printing filament as 'a product almost nobody sells into Central Asia'. Note the reachability limit: the near-term winnable version of this gap is research, veterinary and non-implant forms plus RU/EAEU domestic supply, not stent tubing into a CE- or FDA-registered cardiovascular file.

buyers ready, few sellers 🇺🇸

The single largest and best-documented gap in the whole study sits in the United States - very strong demand, high willingness to pay, and six distinct unserved needs including sub-500 g GMP lots, 0.5-5 kg bridge lots, implant-grade printing filament, qualified second-source supply and 3-5 year degradation windows - and it is simultaneously the market this company is structurally least able to reach, which is the honest headline of this stage rather than an opportunity to act on.

Segments: Research, tissue engineering and custom small-lot synthesis, Drug-delivery and parenteral formulation

US market is USD 560M growing ~9% with demand rated very_strong, and its underserved_segments list is the richest of the seven countries: low-MOQ GMP custom polymer for seed-stage startups, kilogram-scale bridge lots for translational and tox work, medical-grade resorbable filament, qualified second-source supply for programmes single-sourced on Evonik or Corbion, non-catalogue PLCL ratios and end-group chemistries, and academic labs that currently synthesise in-house because no supplier will quote a small custom lot.
Every one of the eight US barriers is structural rather than commercial: Column 2 rates of duty on Russian-origin polymer (15.4 cents/kg plus 45%), FDA change control locking incumbents into existing filings, entry difficulty rated very_high, eight established competitors, and a large share of demand captive inside Ethicon, Medtronic, Abbott, Stryker and Zimmer Biomet where no merchant sale is possible at any price.
Ireland is the same story in miniature and should not be read as a second opportunity: its small-lot GMP gap (1-5 kg custom synthesis, fast-turnaround degradation-profile development, converted forms with single-source traceability) is real, is already filled by Ashland manufacturing Viatel inside Mullingar, and is barred outright by EU Regulation 833/2014 Article 3i with Annex XXI, which binds the Irish buyer, contains no medical carve-out, and whose 'directly or indirectly' wording defeats the Dubai and Delaware routing. Ireland's own file records the fourth unmet need as 'EU-origin supply as an explicit de-risking proposition - a real and growing preference, but one RPS is structurally the wrong company to serve.'

pricing gap 🇮🇳 🇹🇷

An empty middle exists between the Chinese commodity floor and the Western premium tier - a documented, batch-consistent, mid-priced suture- and injectable-grade material with a real analytical package - and India's second-tier suture makers and Turkey's converters are the buyers who actually sit in it and currently have nothing to buy.

Segments: Absorbable sutures, meshes and soft-tissue barriers, Drug-delivery and parenteral formulation

India country research states the gap explicitly: 'the gap between the Chinese commodity price floor (USD 100-300/kg, weak documentation) and the Western premium (USD 800-1,500/kg, full dossier): a documented, consistent, mid-priced suture-grade PGA/PGLA has a real buyer in India's second-tier suture makers'.
Turkey's competitive structure is described as 'concentrated at the top and fragmented at the bottom, with essentially nothing in the middle - which is where RPS is trying to sell', and Turkish buyers report that no supplier in the market publishes kilogram-scale prices at all.
The recurring purchase trigger is documentation rather than price: 'PLGA CoA residual monomer tin content specification' in India and '低残留单体低锡 PLGA 注射级 COA - injectable-grade purity documentation, the recurring failure point of cheap domestic lots' in China both show buyers rejecting the cheap tier on analytics, not on chemistry.

underserved country 🇰🇿

Kazakhstan is not a crowded market but a vacuum with a price floor - none of Evonik, Corbion, Ashland or Poly-Med has any in-country presence and none will contest an account of this size - and it is the only studied market where Russian origin is an advantage rather than a disqualifier, though the whole country is worth roughly USD 0.6M.

Segments: Absorbable sutures, meshes and soft-tissue barriers, Aesthetic and dermatology injectables, Research, tissue engineering and custom small-lot synthesis

Kazakhstan country research: 'None of Evonik, Corbion, Poly-Med or Ashland has any presence in the country; they reach it, if at all, by direct export or an EU distributor, and none of them will fight for an account of this size.' Four meaningful competitors, entry difficulty rated low.
EAEU membership removes the frictions that block every other market: no customs border with Russia, days rather than weeks of transit, ruble-adjacent settlement, and a Russian-language technical and regulatory dialogue that every Western competitor must translate into. The EAEU single-registration deferral to 01.01.2028 means one Russian-language documentation package becomes a five-country asset.
Two named greenfield openings rather than share fights: the single domestic absorbable-suture converter that 'no supplier services with local technical attention, Russian-language documentation or plant visits', and aesthetic thread conversion, 'a segment with real end-market demand met entirely by finished Korean imports and no domestic converter'. The honest counterweight is scale - USD 0.6M market, demand rated weak - and the structural risk that Kazakhstan simply keeps importing finished suture and threads, in which case no polymer is bought domestically by anyone.

search-content gap 🇷🇺 🇰🇿 🇹🇷

The authoritative technical and regulatory content in this category exists only in English, so Russian- and Turkish-language answers to the two questions buyers actually ask - what a supplier change does to an already-registered device, and how to read an inherent-viscosity and end-group specification - are simply absent, and whoever publishes them owns the discovery layer in those markets.

Segments: Absorbable sutures, meshes and soft-tissue barriers, Research, tissue engineering and custom small-lot synthesis, Orthopaedic, spinal, dental and craniomaxillofacial fixation

Kazakhstan's underserved queries are literally this gap: 'Russian-language technical datasheets giving inherent viscosity, weight-average molecular weight, L/D ratio, end-group chemistry, residual monomer and residual solvent - Western suppliers publish these in English only', plus «Как заменить поставщика полимера в зарегистрированном медицинском изделии» and what a raw-material supplier must give a device maker for an EAEU versus national dossier.
Russia repeats it independently: «замена Resomer без перерегистрации медизделия», «сертификат анализа PLGA остаточный мономер остаточное олово», and «PLGA фармакопейного качества для депо-форм ГФ РФ» - the last returns nothing authoritative because no Russian pharmacopoeial monograph exists. The Russian file names the resulting position: 'Own the missing regulatory infrastructure - whoever makes switching regulatorily cheap wins.'
Turkey: 'Turkish-language technical content on selecting L/D ratio and molecular weight for a target degradation profile - essentially all authoritative material is English', and Turkish-language technical support 'is a real differentiator rather than a requirement, because no incumbent provides it'.

overlooked niche 🇹🇷 🇰🇿 🇷🇺 🇮🇳

Two adjacent niches sit entirely outside the regulatory machinery that blocks everything else - veterinary-grade resorbable material, which falls outside EU MDR completely, and brand-new product lines whose bill of materials is not yet frozen, where specifying a new supplier costs nothing in change control because there is no existing file to amend.

Segments: Aesthetic and dermatology injectables, Research, tissue engineering and custom small-lot synthesis, Absorbable sutures, meshes and soft-tissue barriers

Turkey country research names both: veterinary-grade material is 'under-marketed by every competitor', with Katsan's own 2025 catalogue confirming Turkish production for veterinary as well as human use, and veterinary devices sitting outside MDR entirely; and 'new product lines where the bill of materials is not yet frozen - an orthopaedic maker launching a resorbable anchor line, or an aesthetics manufacturer starting PDO thread or PLLA biostimulator production. Specifying RPS costs nothing in change control when there is no existing file to amend, which converts the single largest obstacle into a non-issue.'
Aesthetic injectables are the clearest unfrozen-BOM opening across the reachable markets: India lists 'aesthetic-injectable and thread-lift manufacturers formulating in India, an emerging buyer group with no dedicated supplier attention', Russia lists 'contract development for aesthetics manufacturers who currently import finished Korean thread and have no domestic material partner', and Kazakhstan's aesthetic thread demand is met entirely by finished Korean imports.
The timing is specific rather than open-ended: the EAEU transition, with national-route registration ending 31.12.2027 and single EAEU registration mandatory from 01.01.2028, forces a wave of dossier rewriting through 2026-2027 - the Russian file calls this 'the moment when adding a supplier costs the customer least'.

distribution gap 🇮🇳

India offers the only distribution route in the study that reaches sanctioned-off markets lawfully and without any registration by the supplier: qualify the material into an Indian suture maker's or CDMO's product and it travels to 60+ export destinations inside their finished device, reaching sponsors who would never have qualified a Russian supplier directly.

Segments: Absorbable sutures, meshes and soft-tissue barriers, Drug-delivery and parenteral formulation, Research, tissue engineering and custom small-lot synthesis

India country research: 'Indian suture and generic-injectable makers ship to 60+ countries in Africa, LatAm, SE Asia and the Middle East, so material qualified into an Indian product reaches those markets without RPS registering anywhere - the highest-leverage form of distribution available to a sanctioned-adjacent supplier', plus 'Indian CDMOs as an indirect channel into their global clients'.
The winnable slice is bounded and named: US/EU-bound filings require a referenceable FDA Type IV or EU master file that a Ulyanovsk SME cannot provide, so the addressable pool is domestic-market-only Indian filings, research work and pre-filing R&D - and 'resorbable polymer supplier for domestic-market-only product filing' is itself one of the recorded unanswered buyer queries.
The offsetting facts belong in the same gap: Nomisma Healthcare is a domestic Indian manufacturer offering the identical pitch - custom molecular weight, molar ratio and end-group tailoring, tin-free, small lots, Indian prices - with none of the payment, freight or sanctions friction; and rupee vostro settlement works but leaves hard-to-repatriate INR balances.

§17

Risk Analysis

Risk	How bad if it happens	How likely
regulatoryThe origin and sanctions exposure is structural, not a temporary condition to be waited out. EU Regulation 833/2014 Article 3i with Annex XXI is an import prohibition on the relevant polymer CN codes of Russian origin: it binds the EU buyer rather than only the Russian seller, contains no medical or humanitarian carve-out for these goods, and its 'directly or indirectly' wording defeats transshipment. The United States applies Column 2 rates of duty (15.4 cents/kg plus 45% on the relevant headings) to Russian-origin polymer. The Dubai (Meydan) and Delaware entities solve contracting, invoicing and payment - which was never the binding constraint - and leave untouched the two things that are: the goods-origin bar at customs and the manufacturing-site audit at supplier qualification. Any plan that routes an EU or US sale through those entities while shipping from Ulyanovsk misdeclares origin, engages the anti-circumvention prohibition, and fails at the site audit. Because these instruments are tied to the underlying political situation rather than to any product characteristic, no amount of technical quality, pricing or relationship-building moves them, and successive sanctions packages have tightened rather than loosened the perimeter. What we'd do: Plan the business around the perimeter rather than against it: treat the EU, US, UK, Canada, Australia, New Zealand and Japan as unavailable for goods and price no revenue from them. Concentrate on RU, EAEU, India, Turkey (non-CE segments only), China, Iran, the Gulf and SE Asia. Where EU or US access is a genuine long-term objective, the only lawful routes are (a) licensing polymer chemistry and know-how to a manufacturer that produces the material itself, so origin is conferred by real substantial transformation, or (b) relocating polymerisation to a non-Russian jurisdiction (Kazakhstan, UAE, Turkey, India) to obtain a non-Russian certificate of origin and banking relationship. Both are corporate-structure decisions, not go-to-market ones. Maintain English-language technical documentation to preserve optionality at near-zero cost.
operationalThe company is too small to survive the qualification cycle its own strategy requires. Four employees, roughly 1.6M RUB of revenue and a negative 24M RUB result in 2025 must be carried against a design-in cycle of 18-36 months for a device OEM, 18-30 months for a pharma excipient tied to a master-file reference, and 12-30 months to be qualified into an already-registered Russian dossier. The cash burn is therefore front-loaded into a period during which almost no qualified revenue can arrive by construction, and the burn is roughly fifteen times current revenue. A single key-person departure among four people, or one failed funding round, ends the qualification programmes already in flight and forfeits the sunk documentation cost. This risk compounds with the sanctions risk: the only markets reachable inside the runway (research lots, KZ, RU domestic) are also the smallest, so the revenue that arrives early is too small to fund the qualification work that would unlock the larger pools later. What we'd do: Sequence deliberately toward cash-positive, short-cycle work: paid contract R&D, research and custom-synthesis lots, and veterinary and non-implant material, all of which close in 1-6 months and carry no qualification burden, rather than pursuing industrial design-ins that cannot pay inside the runway. Use funded development (Minpromtorg NIOKR subsidies, FSI, NTI) so that qualification work is paid for by a third party and the industrial partner is attached before any supply contract exists. Deliberately limit the number of simultaneous long-cycle qualifications to what four people can actually document, and treat every long-cycle programme as a call option that must not be funded from operating cash.
competitiveIn every target market a domestic substitute already occupies the exact position being aimed at, usually with the identical pitch and none of the friction. In Russia, НПК «Новохим» already holds the import-substitution narrative and sells resorbable resin domestically. In India, Nomisma Healthcare is a domestic manufacturer offering custom molecular weight, molar ratio and end-group tailoring, tin-free, in small lots at Indian prices, with no payment, freight or sanctions problem - which means a Russian supplier cannot win India on 'cheaper than Evonik' alone. In Ireland, Ashland manufactures Viatel inside Mullingar and fills the small-lot custom gap from a position that also confers EU origin. In China, a broad domestic base (Jinan Daigang, Shandong institute-linked producers, Chengdu and Shenzhen suppliers) plus captive production inside the large converters has already taken the volume tiers. The differentiation being counted on - custom specification, small lots, flexibility - is not unique anywhere except Kazakhstan, and even there the incumbent is Chinese landed cost. What we'd do: Compete on the axes the domestic substitutes do not hold rather than on the shared pitch: specifications absent from every domestic catalogue (PLCL and other elastomeric copolymers, high-IV extrusion and fibre grades, defined end-group PLGA, long 3-5 year degradation windows), converted semi-finished forms rather than resin, Russian-language regulatory documentation and technical service in the EAEU, and paid contract R&D that attaches the customer's programme to the chemistry before any supplier is named. Where a domestic incumbent is structurally advantaged (Nomisma in India, Ashland in Ireland), do not contest the same ground - go around it via CDMO and export-piggyback channels or, in Ireland's case, do not go at all.
economicChinese producers set a price floor that a Ulyanovsk SME cannot reach once duty, VAT, freight and an agent's margin are added, and that floor is being reset downward by domestic-substitution capacity build-out. The category has hardened into commodity material at roughly USD 100-300/kg with weak documentation against a Western premium tier at roughly USD 800-1,500/kg with a full dossier, and a new entrant lands between the two with neither advantage - unable to match domestic Chinese landed cost, and without the referenceable master file and audit history that justify the premium. In Kazakhstan the realistic incumbent for the one account that matters is Chinese braided PGA/PGLA yarn competing purely on landed cost; in India the entire tonnage economy is priced off China; in China itself the domestic cost advantage is most absolute in exactly the largest segment. Gross-margin assumptions for the category (~62% for an established GMP polymeriser) do not transfer to a supplier who has to discount to compensate for origin risk. What we'd do: Refuse the price fight structurally rather than tactically: sell converted semi-finished forms and development services where value per kilogram is higher and the Chinese comparison is not direct, avoid commodity absorbable-suture resin at scale, and compete on the documented analytical package (residual monomer, residual tin, residual solvent) which is the recorded failure point of the cheap tier in China, India and Russia alike. Target the empty middle explicitly - documented, batch-consistent, mid-priced material - rather than trying to be either tier.
operationalEverything depends on one manufacturing site in Ulyanovsk, and that single point of failure is compounded upstream and downstream. Upstream, implant-grade lactide and glycolide monomer comes from a narrow, concentrated global supply base, exposing the site to raw-material availability and price volatility that a small buyer has no leverage over. Downstream, a Russian-domiciled site has restricted access to Western analytical services, sterilisation capacity, notified-body assessment and reference-standard supply, so parts of the quality infrastructure a customer expects cannot be sourced locally. The site is also the object of the customer audit that sanctions exposure makes decisive, and it is what fixes the country of origin on every shipment. A single interruption - equipment, licensing, staffing, monomer supply, or logistics - stops all revenue in every market simultaneously, with no second site to shift to. What we'd do: Qualify at least two monomer sources and hold buffer stock of implant-grade lactide and glycolide sized to the longest realistic lead time. Contract analytical and sterilisation services in non-sanctioning jurisdictions (Turkey, UAE, India, Kazakhstan) and validate them in parallel with domestic providers. Treat a second production or conversion location - a Kazakh, UAE, Turkish or Indian converting or repacking arrangement - as both business-continuity insurance and the origin fix, since it addresses the tariff, the payment routing and the single-site risk with one decision.
demandThe headline market overstates what is actually buyable. Roughly 40% of the USD 1,950M TAM never reaches the merchant market at all because Ethicon/J&J, Medtronic, Abbott, Stryker, Zimmer Biomet and the largest Chinese suture makers polymerise or fibre-spin internally, and within the remaining merchant market the high-volume standard-grade resin under multi-year framework contracts is locked to incumbent catalogue codes referenced in existing regulatory files. Two of the six segments - s-cardiovascular-scaffolds and s-orthopedic-fixation - are additionally judged out of reach inside three years on qualification grounds alone, and the cardiovascular segment has not recovered its mid-2010s trajectory since the Absorb withdrawal. The realistic near-term demand is therefore concentrated in the two smallest and least profitable pools: research and custom-synthesis micro-orders, and Russian and EAEU domestic import substitution. What we'd do: Plan against the reachable pool (stage 03 estimates ~USD 50M reachable within 36 months, versus USD 660M SAM and USD 1,950M TAM) rather than against the headline. Treat research and custom-synthesis revenue as a credibility and lead-generation engine that funds the qualification work rather than as the profit centre, and measure progress in qualified design-in positions and published citations rather than in addressable market captured.

What would kill this plan

Any tightening of sanctions or origin enforcement that extends the EU/US pattern into the currently reachable markets - secondary-sanctions pressure on Turkish, Kazakh, Indian or Chinese banks and counterparties has already produced account closures and payment refusals, and a further step would close the payment routing on which every non-EAEU sale depends.
Russian domestic import substitution turning out to be a smaller and slower opportunity than assumed: the Russian country research found no evidence that Western supply actually stopped, so parallel import remains a live competitor, and if Evonik and Corbion material keeps arriving through intermediaries the domestic substitution pitch loses its urgency and its price umbrella.
Chinese capacity expansion pushing the commodity floor low enough that the 'documented mid-priced' position disappears - if domestic Chinese and Indian producers close the documentation gap while keeping their cost advantage, the empty middle that the whole strategy targets stops existing.
Failure to convert any research or custom-synthesis relationship into a qualified industrial supply position within the runway, which would leave the company permanently in a segment whose total reachable value (est. USD 8-12M globally) cannot support a polymerisation plant.
A domestic Russian or EAEU competitor forward-integrating into converted semi-finished forms first - fibre, tubing, film, microspheres, filament - since that is the one clearly unoccupied position and its defensibility rests entirely on nobody else having taken it yet.
Loss of the manufacturing site's ability to source implant-grade lactide and glycolide monomer, or to obtain the analytical and sterilisation services a customer's quality agreement requires, either of which removes the ability to supply implant-grade material at all regardless of demand.

Our shakiest assumptions

Which legal entity actually invoices a given customer, and from where the goods physically ship, is unverified. The company has contracting entities in Dubai (Meydan free zone) and Delaware and manufacturing in Ulyanovsk, but no shipping documents, invoices or customs entries were seen in this run. The entire tariff, origin-declaration and sanctions analysis depends on the assumption that goods move from Ulyanovsk under Russian origin while payment is contracted offshore; if in practice some material is produced, blended or substantially transformed elsewhere, several country conclusions change materially. This should be verified from actual commercial documents before any of it is acted on.
All market sizes in this run are triangulated, not reported. The USD 1,950M TAM is a scope-adjusted centre of a 2025-2026 report cluster (TBRC, FMI, MRFR, Grand View, Coherent, Verified) rather than a figure any single source publishes for the defined scope, and the widest like-for-like spread found was 1.97x (Coherent USD 1,220M for 2026 against Verified USD 2,400M for 2025). Every country-level figure is a derived share of that number, not a reported national statistic.
The SAM decomposition rests on two analyst judgements that no source states: that the merchant (non-captive) share is ~60% of TAM, and that the custom-spec, mid-volume, converted-form and contract-development slice is ~56% of that merchant market. Both percentages are reasoned rather than measured, and the SAM of USD 660M moves proportionally with either.
Not a single competitor market share could be established. Every est_market_share_pct in all seven country files is deliberately null because no source publishes revenue splits for medical-grade bioresorbable polymer at country level; the competitive ordering in this study is qualitative inference from product ranges, manufacturing locations and distribution announcements.
The ~62% typical gross margin for an established GMP polymeriser is low-confidence and inferred: Evonik does not break out RESOMER, Corbion does not separately margin its biomaterials line, and Poly-Med is private. The band used is 55-70%, and the company's own realistic margin in its addressable tiers is unknown.
The brief's premise that Western supply to Russia was cut off is not evidenced and was contradicted by the Russian country research. Searches for Evonik/Corbion supply restrictions, price increases or lead-time changes to Russian buyers returned nothing specific; Evonik, Corbion and Total Corbion PLA all still appear in a Russian polymer supplier directory, Evonik with a Moscow entry, and medicines and medical devices are broadly exempted on humanitarian grounds. The honest reading is friction rather than absence - which means the size of the domestic import-substitution opportunity, the single largest line in the reachable pool, may be substantially overstated. This is the weakest load-bearing assumption in the run.
The 12-30 month Russian dossier requalification window and the 18-36 month device design-in cycle are analyst estimates drawn from category norms rather than from observed cases at this company or its named customers, and the whole runway argument in the operational risk above is sensitive to them.
Willingness-to-pay ratings and demand strength for every country are qualitative judgements built from buyer queries and industry structure, with no pricing survey, no win/loss data and no customer interviews behind them.

§18

Best / Expected / Worst Case

What we could earn — India (Research, tissue engineering and custom small-lot synthesis)

USD; the assumptions behind each case are in the table below

Case	Customers yr 1	Deal size	Cost /customer	Revenue yr 1	Revenue yr 3	Earn-back	3-yr return
Cautious Indian buyers keep Resotech in the sampling stage because every serious volume order is tied to a US/EU-bound filing that requires a DMF, so the account list never grows past a handful of academic and early-R&D labs.	1	$28k	$20k	$28k	$168k	17 mo	-38%
Expected Resotech sells into the domestic-only slice of Indian bioresorbables — custom synthesis, research grades and pre-filing R&D — winning roughly one in six of the buyers it can actually serve while export-bound programmes stay closed.	3	$35k	$15k	$105k	$420k	10 mo	15%
Optimistic A single Indian CDMO reference account turns Resotech from an unknown Russian supplier into a shortlisted second source for domestic filings, and word of mouth inside the Hyderabad cluster does the prospecting that four employees could not.	5	$37k	$13k	$185k	$814k	8 mo	58%

What we could earn — Kazakhstan (Absorbable sutures, meshes and soft-tissue barriers)

USD; the assumptions behind each case are in the table below

Case	Customers yr 1	Deal size	Cost /customer	Revenue yr 1	Revenue yr 3	Earn-back	3-yr return
Cautious RuMa Farm keeps its incumbent glycolide/L-lactide resin rather than reopening the Rumacryl dossier, and Kazakhstan collapses to a couple of small academic orders that never repay even the modest entry cost.	1	$12k	$16k	$12k	$24k	39 mo	-72%
Expected One exact chemistry match carries the whole country: RuMa Farm adds Resotech as an alternate resin supplier for its registered suture, and the low entry cost makes even a single account profitable.	1	$45k	$12k	$45k	$135k	7 mo	38%
Optimistic RuMa Farm qualifies fast, moves most of its suture yarn onto Resotech resin, and becomes the EAEU reference that makes three neighbouring converters willing to open a dossier amendment.	1	$52k	$10k	$52k	$208k	5 mo	96%

What we could earn — Russia (Aesthetic and dermatology injectables)

USD; the assumptions behind each case are in the table below

Case	Customers yr 1	Deal size	Cost /customer	Revenue yr 1	Revenue yr 3	Earn-back	3-yr return
Cautious Parallel-import channels for Western PLLA stay open and Новохим wins the import-substitution framing first, so Resotech is left discounting into small filler and microsphere accounts that never cover the $400k+ of domestic entry cost.	4	$7.2k	$5.8k	$29k	$187k	39 mo	-47%
Expected Resotech wins about a quarter of the addressable Russian aesthetic-injectable and microsphere buyers on low ticket sizes, growing volume steadily while sharing the import-substitution story with Новохим.	8	$9k	$4.5k	$72k	$495k	28 mo	35%
Optimistic Procurement localisation rules bite and parallel imports thin out, so Russian injectable makers have to qualify a domestic resin quickly, and Resotech's wider grade range beats Новохим's narrower catalogue in head-to-head evaluations.	12	$9.9k	$4k	$119k	$891k	21 mo	82%

§19

Top Market Recommendations

№1

🇷🇺 Russia — Aesthetic and dermatology injectables

Why this market

The only market where Russian goods origin is not a liability: no tariff, no origin declaration, no foreign ISO 13485 site audit, and ~210 realistic buyers against ~6 in Kazakhstan. Weak-competition scores 77.6, the highest of the seven.

Why now

There is no evidence Western supply stopped, so the import-substitution window is open but not exclusive - NPK Novokhim is already selling into it. Positions taken before parallel-import channels re-normalise are worth more than positions taken after.

Why these customers

It is the highest-scoring country x segment cell in the entire analysis at 79.9. Aesthetic injectables use PLLA and PCL microspheres and suspensions in small lots, which fits a four-person operation, and the regulatory path is materially lighter than the registered-device dossier route that gates sutures and drug delivery.

Why we can win

RPS makes both the base polymers (PLLA, PCL, PDLLA) and the converted microsphere form in-house, so it can quote a finished semi-finished input rather than a raw resin - one of the identified cross-country gaps. Small-lot custom GMP synthesis at 250 g-20 kg sits below incumbent MOQs, and Russian-language technical content is a documented gap that a domestic supplier fills for free.

How to enter

Direct technical selling from Ulyanovsk with a Russian-entity invoice, led by contract R&D: sell a paid formulation study or sample lot first, then convert to supply. Build Russian-language technical datasheets and a microsphere spec sheet as the primary sales asset.

What it will cost

Part of the RU $400k entry envelope, staged across the qualification cycle rather than committed up front; the aesthetics track is the cheapest slice because it does not require funding a full registered-dossier qualification before first revenue.

What we can make

Ceiling arithmetic on the given figures: $9k ACV x ~210 realistic buyers across all RU segments; the aesthetics slice is a fraction of that pool. With CAC at $4.5k and LTV/CAC 4.8, each account returns on a 28-month payback, so this is a compounding annuity, not a fast one.

What could go wrong

NPK Novokhim (Tomsk) beats us to the same accounts with Russian excipient certification we do not yet hold. Parallel import keeps Western material flowing at credible prices, so the import-substitution argument never becomes urgent. And at $9k ACV with a 28-month payback, a four-person company with a -24M RUB result may run out of runway before the annuity matures.

Next steps

Map the Russian aesthetic-injectable manufacturers and formulators against our PLLA and PCL microsphere grades, and rank by whether their BOM is already frozen.
Publish Russian-language technical datasheets and a microsphere specification pack - the documented language gap is the cheapest differentiator available.
Close two paid contract-R&D formulation studies as the entry wedge, priced to cover cost, with supply rights on the resulting spec.
Obtain or scope the Russian excipient certification that NPK Novokhim uses as its qualification advantage.
Stage the RU $400k against qualification milestones so that no tranche is spent before a named account has accepted a sample lot.

№2

🇰🇿 Kazakhstan — Absorbable sutures, meshes and soft-tissue barriers

Why this market

It is the cheapest and fastest test the company can run, and the only entry it can fund without new capital: ~$45k, no customs border inside the EAEU, Russian as the working language, and no product registration required for a raw material. Note the deviation - KZ x absorbable-sutures-meshes is not in the computed top-8 cells and Kazakhstan's demand score is 27.0, the weakest of the seven. It earns a place here on economics and on an exact chemistry match, not on market size.

Why now

EAEU-only device registration was deferred to 01.01.2028, so a raw-material supply relationship can be established before that regime tightens. Bank de-risking is already solved by the Dubai entity, and both invoicing routes can be quoted today.

Why these customers

TOO RuMa Farm's registered Rumacryl suture is glycolide 90 / L-lactide 10 - an exact match to what RPS already makes in PGA and PLGA, and to the spun fibre and yarn it already converts. This is not a segment hypothesis; it is one identified product at one identified account.

Why we can win

We supply both the polymer and the spun fibre form, so we can compete for either the resin or the converted yarn position. There is no customs border, no duty, no origin declaration problem and no FX friction inside the EAEU, and a Kazakh price floor with no domestic producer leaves room above the Chinese commodity level.

How to enter

Single named-account pursuit of TOO RuMa Farm (Almaty): technical qualification sample of glycolide 90 / L-lactide 10 against their Rumacryl specification, quoted twice - once from the Russian entity to preserve EAEU indirect-tax treatment, once from Dubai for bank comfort - and let them choose.

What it will cost

~$45k, against CAC of $12k per account. This is the only entry in the analysis a company with ~1.6M RUB revenue can commit unaided, and the maximum loss is bounded at roughly that figure.

What we can make

$45k ACV x ~6 realistic buyers is the honest ceiling, and the case is really $45k x 1 anchor. Against that: LTV/CAC 11.8, 7-month payback and 38% three-year ROI - the best returns in the set. If RuMa Farm declines, the residual is roughly $50k of academic sales.

What could go wrong

RuMa Farm declines, is already locked to an incumbent supplier, or fails our qualification - and there is no second account to fall back on, only ~$50k of academic demand. Choosing the Dubai invoicing route to please the bank forfeits EAEU indirect-tax treatment and hands back part of the price advantage. Demand scoring 27.0 means nothing here scales.

Next steps

Open a direct technical conversation with TOO RuMa Farm (Almaty) and obtain the Rumacryl input specification.
Produce and ship a qualification lot of glycolide 90 / L-lactide 10 in both resin and spun-fibre form.
Quote both invoicing routes side by side - Russian entity with EAEU indirect-tax treatment, Dubai entity for bank de-risking - and let the customer price the difference.
Set a hard decision gate: if no qualification lot is accepted within two quarters, cap KZ spend and redirect to the RU tracks.
Identify and contact the remaining ~5 realistic buyers plus the academic accounts, so the market is not a single point of failure by default.

№3

🇷🇺 Russia — Research, tissue engineering and custom small-lot synthesis

Why this market

Home ground with no origin barrier and the largest buyer pool, and the segment where the company's smallest structural weakness - being a four-person operation - becomes an advantage rather than a liability.

Why now

This is the only track that generates cash inside the 12-36-month supplier-qualification cycles the company must survive. Every other opportunity here pays back in 28 months or relies on a single account; research work bills now and funds the rest.

Why these customers

Computed cell at 64.6, and it answers the top cross-country gap: small-lot custom GMP synthesis at 250 g-20 kg that incumbent MOQs simply ignore. Crucially it carries no regulatory gate - no registered dossier, no 12-30-month qualification, no site audit by a foreign notified body - so revenue is not hostage to the approval clock.

Why we can win

The full polymer family (PLLA, PDLLA, PGA, PLGA, PCL, PLCL) plus fee-based contract R&D is exactly the offer this segment buys, and the Russian-language technical content gap means domestic researchers currently get nothing readable from Western suppliers. Weak-competition scores 77.6 in RU.

How to enter

Productise contract R&D: a published small-lot price list at 250 g-20 kg, a standing catalogue of the six polymer grades, and Russian-language technical notes. Sell directly to institutes, university groups and R&D departments, and use each engagement as the pre-qualification step for later supply into the aesthetics and suture tracks.

What it will cost

The lowest-cost track in the plan - it consumes existing capacity and the existing four-person team, and draws only the front tranche of the RU $400k envelope, since it needs no dossier qualification funding.

What we can make

Modest per order but fast: RU CAC is $4.5k, the lowest of any market, so small-lot orders can be won economically. Against $9k ACV and ~210 realistic buyers across RU segments, this is a working-capital engine rather than a growth market - its job is to fund the 28-month paybacks elsewhere.

What could go wrong

Research revenue is small, lumpy and grant-cycle dependent, and it can absorb all four employees' time without ever converting into supply contracts - a busy company that never qualifies into a dossier. It also does not scale: winning it does not by itself change the -24M RUB result.

Next steps

Publish a small-lot price list and lead time for 250 g-20 kg quantities across all six polymer grades.
Build the Russian-language technical documentation set once and reuse it across the aesthetics, suture and research tracks.
Route every contract-R&D engagement toward a named downstream supply opportunity, and track conversion rate as the primary metric.
Extend the same small-lot catalogue to Kazakh academic accounts, where it costs nothing extra inside the EAEU.

№4

🇷🇺 Russia — Absorbable sutures, meshes and soft-tissue barriers

Why this market

Same home-ground logic - ~210 realistic buyers, weak-competition 77.6, no tariff or origin exposure - applied to the segment with the deepest and most repeatable volume.

Why now

Dossier qualification takes 12-30 months, so the clock has to start now for revenue to exist in 2028. Starting later does not make it cheaper; it only pushes the annuity further out.

Why these customers

Computed cell at 72.7, third highest overall. RPS already makes PGA, PLGA and spun fibre and yarn, so the converted semi-finished form gap identified in RU applies directly, and the same glycolide/lactide chemistry qualified for Kazakhstan serves here without change.

Why we can win

One chemistry serves both the KZ anchor account and the RU suture manufacturers, so qualification work is shared across two markets. Domestic origin removes the customs, duty and origin-declaration frictions that any importing competitor carries.

How to enter

Qualify into registered dossiers at Russian suture and mesh manufacturers, entering as a second-source or import-substitution supplier of PGA and PLGA resin and spun yarn. Expect the long cycle and price the relationship, not the first order.

What it will cost

The main consumer of the RU $400k envelope, and the reason that figure must be staged against qualification milestones rather than committed as a single cheque given ~1.6M RUB revenue and a -24M RUB result.

What we can make

The largest ceiling available: $9k ACV against ~210 realistic buyers, with 3-year ROI of 35%. Treat the buyer count as a ceiling, not a forecast - each account takes 12-30 months to qualify and pays back over 28 months.

What could go wrong

NPK Novokhim holds the import-substitution position with Russian excipient certification we lack. Parallel import means incumbent BOMs never actually broke, so there is no forced re-qualification event to exploit. And 28-month payback against a 12-30-month qualification cycle means roughly four years from first call to positive return - the single largest survival risk in this plan.

Next steps

Shortlist Russian suture and mesh manufacturers whose registered dossiers list an imported PGA or PLGA source, and target those BOMs first.
Reuse the KZ glycolide 90 / L-lactide 10 qualification package here rather than running a second programme.
Close the excipient-certification gap against NPK Novokhim before pitching regulated accounts.
Fund this track from contract-R&D and Kazakh cash flow, not from a standing commitment, and review the tranche every quarter.

§20

Market Entry Strategy

Opportunity order is not funding order. Write one cheque first: Kazakhstan at ~$45k, aimed at the single named account TOO RuMa Farm, because it is the only entry a company with ~1.6M RUB revenue and a -24M RUB result can commit unaided, it has a 7-month payback and 38% three-year ROI, and its downside is bounded at the entry cost. In parallel and at near-zero incremental cost, run the two Russian tracks that need no approval clock - contract R&D and small-lot custom synthesis at 250 g-20 kg, plus the aesthetic-injectables cell at 79.9 - because they bill inside the 12-36-month qualification cycles the company must survive and they build the Russian-language technical content that every other track reuses. Start the Russian absorbable-sutures-meshes qualification now, since 12-30 months of dossier work plus a 28-month payback means nearly four years to return, but stage the $400k RU envelope tranche by tranche against named accounts accepting sample lots rather than committing it up front. Explicitly deferred: India, despite ranking first at 55.1, until Kazakh and Russian cash covers the $300k entry and the DMF-gated pool is re-sized against Nomisma Healthcare - revisit no earlier than Q4 2027. Turkey stays a watching brief at $128k and 6% ROI, probed only through research, veterinary and not-yet-frozen BOM enquiries that cost nothing to answer. Ireland, the United States and China are closed for the life of this plan and should not consume management attention: IE because importing these CN codes of Russian origin is prohibited outright, US because Column 2 duty of 15.4c/kg + 45% produces -120% three-year ROI, CN because a published $8-30/g domestic floor leaves profitability at 33.1. If RuMa Farm declines and no second Kazakh account qualifies within two quarters, cap KZ spend and consolidate entirely on the Russian home market.

§21

What To Do, In Order

1Open TOO RuMa Farm (Almaty) directly and ship a qualification lot of glycolide 90 / L-lactide 10 in resin and spun-fibre form, quoting both the Russian-entity route (EAEU indirect-tax treatment) and the Dubai route (bank de-risking). Cap total KZ commitment at ~$45k.Q4 2026
2Launch the RU contract-R&D and small-lot custom-synthesis offer: published 250 g-20 kg price list across all six polymer grades, Russian-language technical datasheets, and two paid formulation studies closed as the cash engine that funds every longer track.Q4 2026 - Q1 2027
3Attack RU aesthetic-injectables (computed cell 79.9) with the PLLA and PCL microsphere converted form, targeting formulators whose BOM is not yet frozen, and close the Russian excipient-certification gap that NPK Novokhim currently uses as its qualification advantage.Q1 - Q2 2027
4Start RU absorbable-sutures-meshes dossier qualification at manufacturers currently sourcing imported PGA/PLGA, reusing the Kazakh qualification package, with the $400k RU envelope released tranche by tranche against accepted sample lots.Q2 - Q4 2027
5Decision gate on Kazakhstan and on the deferred India entry: if no KZ qualification lot has been accepted, cap KZ spend and consolidate on RU; re-size the DMF-gated Indian pool against Nomisma Healthcare and the INR repatriation constraint before releasing any part of the $300k.Q4 2027
6Keep Turkey as a zero-cost watching brief limited to research, veterinary (outside MDR) and not-yet-frozen-BOM enquiries; take no position against IMCD's Evonik exclusivity and commit none of the $128k while three-year ROI stands at 6%.Ongoing from Q1 2027

§22

Sources Behind the Numbers

These are the citations. Wherever a number in this report carries a small blue marker like [gm-01], it links to a row here — the report, article or database the number came from. Rows typed "llm knowledge" mean the analysis synthesized the point without a single external document.

Ref	Title	Publisher	Type	Published	Checked
`src-in-01`	Resotech Polymer Solutions - biodegradable medical polymers (homepage)	Resotech Polymer Solutions	company	unknown	2026-09-01
`src-in-02`	Polymers - grades, compositions, molecular weights and mechanical properties	Resotech Polymer Solutions	company	unknown	2026-09-01
`src-in-03`	Solutions - fibres and surgical threads, tubes, films, microspheres, 3D-printing materials	Resotech Polymer Solutions	company	unknown	2026-09-01
`src-in-04`	Services - staged medical device development from technical specification to serial production	Resotech Polymer Solutions	company	unknown	2026-09-01
`src-in-05`	Company (RU) - team, patents, publications, endovascular device plants in Russia	Resotech Polymer Solutions	company	unknown	2026-09-01
`src-in-06`	About Resotech Polymer Solutions (EN)	Resotech Polymer Solutions	company	unknown	2026-09-01
`src-in-07`	Contact - Ulyanovsk, Russia address, phone, email	Resotech Polymer Solutions	company	unknown	2026-09-01
`src-in-08`	Resotech Polymer Solutions (RU mirror) - product lines and legal entity OOO INTEKHNOBIOMED, INN 7326043718, OGRN 1137326001009	Resotech Polymer Solutions	company	unknown	2026-09-01
`src-in-09`	Resotech - Bioresorbable Self-expanding Scaffold (affiliated business, Dubai UAE and Nur-Sultan KZ)	Resotech	company	unknown	2026-09-01
`src-in-10`	Industry knowledge of medical-grade bioresorbable polymer suppliers (PLA/PLGA/PGA/PCL) used to populate known_competitors	model knowledge	llm knowledge	unknown	2026-09-01
`src-in-11`	viatel bioresorbable polymers - competitor product line verification	Ashland Inc.	company	unknown	2026-09-01
`src-in-12`	OOO 'Meditsinskie Polimery', Skolkovo Innovation Centre (INN 9731152478) - registry record	Rusprofile	database	unknown	2026-09-01
`src-in-13`	Resotech Polymer Solutions — Contact (UAE and USA addresses)	Resotech Polymer Solutions	company	unknown	2026-09-01
`src-md-01`	Bioresorbable polymer portfolio — PURASORB	Corbion N.V.	company	unknown	2026-09-01
`src-md-02`	PURASORB bioresorbable polymers for medical devices	Corbion N.V.	company	unknown	2026-09-01
`src-md-03`	PURASORB bioresorbable polymers for controlled drug delivery	Corbion N.V.	company	unknown	2026-09-01
`src-md-04`	RESOMER bioresorbable polymers for medical devices	Evonik Industries AG	company	unknown	2026-09-01
`src-md-05`	RESOMER and LACTEL bioresorbable polymers for parenteral controlled release	Evonik Industries AG	company	unknown	2026-09-01
`src-md-06`	RESOMER MD biodegradable polymers receive ISO 13485 certification	Evonik Industries AG	company	unknown	2026-09-01
`src-md-07`	RESOMER biodegradable polymers for medical device applications and research	Merck KGaA / Sigma-Aldrich	company	unknown	2026-09-01
`src-md-08`	Bioresorbable scaffolds: advances, challenges, and future directions	Annals of Medicine and Surgery	academic	2025-07-01	2026-09-01
`src-md-09`	Российский рынок полимеров для медицины зависит от импорта на 70% (Russian medical polymer market is 70% import-dependent)	Plastinfo / MRC	news	2024-10-28	2026-09-01
`src-md-10`	Анализ рынка полилактида (полимолочной кислоты) в России — no domestic PLA production, imports led by Germany	Re-port.ru (market research digest)	industry report	unknown	2026-09-01
`src-md-11`	Bioresorbable Polymers Market Size & Growth Report	IMARC Group	industry report	unknown	2026-09-01
`src-md-12`	U.S. PLLA Filler Market Driven by Non-Surgical Aesthetic Demand	Towards Healthcare	industry report	unknown	2026-09-01
`src-md-13`	Long-acting PLGA microspheres: advances in excipient and product analysis toward improved product understanding	Advanced Drug Delivery Reviews (Elsevier)	academic	unknown	2026-09-01
`src-md-14`	Resotech Polymer Solutions — product and service scope (stage 01 company research)	OOO INTEKHNOBIOMED (Resotech Polymer Solutions)	company	unknown	2026-09-01
`src-md-15`	General domain knowledge: bioresorbable polyester chemistry, device qualification practice (ISO 13485/10993, ICH Q7, master files), and competitive structure of the medical resorbable polymer supply base	LLM background knowledge	llm knowledge	unknown	2026-09-01
`src-gm-01`	Bioresorbable Medical Material Global Market Report 2026 - Size, Forecast to 2030	The Business Research Company	industry report	2026-01	2026-09-01
`src-gm-02`	Bioresorbable Polymers Market Growth & Forecast, 2025-2035	Future Market Insights	industry report	2025	2026-09-01
`src-gm-03`	Bioresorbable Polymers Market Size, Share, Growth Report 2035	Market Research Future	industry report	2025	2026-09-01
`src-gm-04`	Bioresorbable Polymers Market Size to Hit USD 2.46 Billion by 2033	Coherent Market Insights	industry report	2026	2026-09-01
`src-gm-05`	Bioresorbable Polymers Market Size & Share Report, 2030	Grand View Research	industry report	2023	2026-09-01
`src-gm-06`	Resorbable Polymers Market Size & Share Analysis - Growth Trends and Forecasts (2025-2030)	Mordor Intelligence	industry report	2025	2026-09-01
`src-gm-07`	PLGA Market Size & Share 2026-2032	360iResearch	industry report	2026	2026-09-01
`src-gm-08`	RESOMER bioresorbable polymers for medical devices	Evonik Industries AG	company	2025	2026-09-01
`src-gm-09`	PURASORB bioresorbable polymer portfolio	Corbion N.V.	company	2025	2026-09-01
`src-gm-10`	Analyst judgement on supplier requalification cycles, sanctions exposure and Russian import-substitution demand for medical-grade resorbable polymers	Model knowledge	llm knowledge	2026-05	2026-09-01
`src-sc-01`	Selected General Licenses Issued by OFAC (Russia-related GL 6D — medicine and medical devices)	US Treasury, Office of Foreign Assets Control	official statistics	unknown	2026-09-01
`src-sc-02`	FAQs on EU sanctions against Russia — Medicines and medical devices	European Commission, DG FISMA	official statistics	2023-02	2026-09-01
`src-sc-03`	Must-Know Legislation for Medical Device Registration in the EAEU	Biomapas	industry report	unknown	2026-09-01
`src-sc-04`	Kazakhstan Medical Device Registration: Unified EAEU Certificate vs. Neighbouring Systems	OMC Medical	industry report	unknown	2026-09-01
`src-sc-05`	Costa Rica Strengthens Its Global Leadership in Medical Devices, Exporting Innovation to the World	Ortho Spine News	news	2026-01-02	2026-09-01
`src-sc-06`	Precision in paradise: the Dominican Republic emerges as Latin America's medtech hub	Medical Technology (NRI Digital)	news	2025-09	2026-09-01
`src-sc-07`	General knowledge of medical-device and pharmaceutical manufacturing clusters, EAEU/CIS trade arrangements, correspondent-banking de-risking of Russian exporters, and supplier-qualification practice in regulated medical supply chains	Model internal knowledge	llm knowledge	unknown	2026-09-01
`src-seg-01`	Synthesis of stage-05 country research in this run	market-audit pipeline	llm knowledge	2026-09-01	2026-09-01
`src-tr-01`	Bioresorbable Medical Material Global Market Report 2026 - Size, Forecast to 2030	The Business Research Company	industry report	2026	2026-09-01
`src-tr-02`	Resorbable Polymers Market Size & Share Analysis - Growth Trends and Forecasts (2025-2030)	Mordor Intelligence	industry report	2025	2026-09-01
`src-tr-03`	Bioresorbable Polymers Market to Reach USD 867.2 Million by 2029, Growing at a CAGR of 11.6% - MarketsandMarkets	GlobeNewswire / MarketsandMarkets	industry report	2026-08-17	2026-09-01
`src-tr-04`	PLGA Market Size & Share 2026-2032	360iResearch	industry report	2026	2026-09-01
`src-tr-05`	Evonik to acquire Birmingham-based LACTEL Absorbable Polymers from DURECT Corporation	Evonik Health Care	company	unknown	2026-09-01
`src-tr-06`	Evonik commissions advanced biomaterials production facility for pharmaceutical and medical applications	Evonik Health Care	company	unknown	2026-09-01
`src-tr-07`	Ashland announces expansion of Viatel bioresorbable polymers	Ashland	company	unknown	2026-09-01
`src-tr-08`	IMCD becomes new distributor for Evonik's RESOMER medical device polymers	Evonik	company	2025-07	2026-09-01
`src-tr-09`	Meril Life Sciences unveils indigenously developed bioresorbable scaffold MeRes100 in India	Medical Dialogues	news	unknown	2026-09-01
`src-tr-10`	Registration of medical devices under national rules will end by 2028	Eurasian Economic Commission	official statistics	unknown	2026-09-01
`src-tr-11`	IMCD buys India's Signet Excipients	CHEManager	news	unknown	2026-09-01
`src-tr-12`	Barentz acquires Indian chemical distributor Anshul Life Sciences	Borderless	news	unknown	2026-09-01
`src-tr-13`	Materials firms pulling some business from Russia as Ukraine conflict continues	Plastics News	news	unknown	2026-09-01
`src-tr-14`	Council Regulation (EU) No 833/2014 concerning restrictive measures in view of Russia's actions destabilising the situation in Ukraine (consolidated)	EUR-Lex / Council of the European Union	official statistics	unknown	2026-09-01
`src-tr-15`	Russia Column 2 Rates of Duty	U.S. Customs and Border Protection	official statistics	unknown	2026-09-01
`src-tr-16`	RESOMER biodegradable polymers for drug delivery - technical article	Merck / Sigma-Aldrich	company	unknown	2026-09-01
`src-tr-17`	Analyst knowledge: withdrawal of Abbott's Absorb GT1 bioresorbable vascular scaffold in 2017 and the persistent depression of the resorbable coronary scaffold sub-segment relative to mid-2010s forecasts	Market-audit pipeline (stage 07 synthesis)	llm knowledge	unknown	2026-09-01
`src-tr-18`	Analyst knowledge: application of machine learning to resorbable-polyester degradation kinetics and microsphere release prediction, and LLM-assisted regulatory documentation (ISO 10993 summaries, technical files, master-file modules) in specialty medical materials	Market-audit pipeline (stage 07 synthesis)	llm knowledge	unknown	2026-09-01
`src-tr-19`	Analyst synthesis of stage-05 country research: two-tier price structure (Chinese commodity USD 100-300/kg vs Western premium USD 800-1,500/kg), minimum-order-quantity behaviour of catalogue suppliers, captive integration at large device OEMs, and the 18-36 month supplier-requalification cycle	Market-audit pipeline (stages 03 and 05)	llm knowledge	2026-09-01	2026-09-01
`src-og-01`	Analyst synthesis of the seven stage-05 country files (US, CN, IE, IN, RU, TR, KZ): underserved_segments, underserved_queries and competition notes, cross-tabulated to identify gaps recurring in more than one market	Market-audit pipeline (stage 05)	llm knowledge	2026-09-01	2026-09-01
`src-og-02`	Council Regulation (EU) No 833/2014, Article 3i and Annex XXI - prohibition on import of listed goods of Russian origin (consolidated)	EUR-Lex / Council of the European Union	official statistics	unknown	2026-09-01
`src-og-03`	FAQs on sanctions adopted following Russia's military aggression against Ukraine - medical sector	European Commission, DG FISMA	official statistics	2023-02	2026-09-01
`src-og-04`	Russia Column 2 Rates of Duty	U.S. Customs and Border Protection	official statistics	unknown	2026-09-01
`src-og-06`	Viatel ultrapure bioresorbable polymers	Ashland	company	unknown	2026-09-01
`src-og-07`	Nomisma Healthcare - company profile and product range (custom PLGA/PLA synthesis)	IndiaMART	company	unknown	2026-09-01
`src-og-08`	НПК «Новохим» - biopolymers (Russian domestic resorbable polymer range)	NPK Novokhim	company	unknown	2026-09-01
`src-og-09`	Katsan 2025 catalogue - absorbable suture range including veterinary production	Katsan (Turkey)	company	2025-02	2026-09-01
`src-og-10`	Registration of medical devices under national rules extended (transition to single EAEU registration from 01.01.2028)	Eurasian Economic Commission	official statistics	unknown	2026-09-01
`src-og-11`	Types of Drug Master Files (DMFs)	U.S. Food and Drug Administration	official statistics	unknown	2026-09-01
`src-og-13`	Analyst knowledge: medical-grade resorbable polymer price bands (Chinese commodity USD 100-300/kg, Western premium USD 800-1,500/kg), catalogue minimum-order-quantity practice, and the absence of published kilogram-scale pricing from any supplier in the seven studied markets	Market-audit pipeline (stages 03 and 05)	llm knowledge	2026-09-01	2026-09-01
`src-gr-01`	Council Regulation (EU) No 833/2014, Article 3i and Annex XXI - prohibition on import of listed goods of Russian origin (consolidated)	EUR-Lex / Council of the European Union	official statistics	unknown	2026-09-01
`src-gr-02`	FAQs on sanctions adopted following Russia's military aggression against Ukraine - medical sector	European Commission, DG FISMA	official statistics	2023-02	2026-09-01
`src-gr-03`	FAQs on sanctions adopted following Russia's military aggression against Ukraine - listed goods (Annex XXI)	European Commission, DG FISMA	official statistics	2023-10	2026-09-01
`src-gr-04`	Russia Column 2 Rates of Duty	U.S. Customs and Border Protection	official statistics	unknown	2026-09-01
`src-gr-05`	19th package of sanctions against Russia: EU targets Russian energy, third-country banks and crypto providers	Council of the European Union	news	2025-10-23	2026-09-01
`src-gr-06`	EU adopts 21st Russia sanctions package	Baker McKenzie Sanctions News	news	unknown	2026-09-01
`src-gr-07`	Turkish banks close Russian corporate accounts over secondary sanctions	The Moscow Times	news	2024-02-01	2026-09-01
`src-gr-08`	More Central Asian banks sanctioned by the EU	The Diplomat	news	2025-10	2026-09-01
`src-gr-09`	Materials firms pulling some business from Russia as Ukraine conflict continues	Plastics News	news	unknown	2026-09-01
`src-gr-10`	НПК «Новохим» - biopolymers (Russian domestic resorbable polymer range)	NPK Novokhim	company	unknown	2026-09-01
`src-gr-11`	Nomisma Healthcare - company profile and product range (custom PLGA/PLA synthesis)	IndiaMART	company	unknown	2026-09-01
`src-gr-12`	Viatel ultrapure bioresorbable polymers (manufactured at Mullingar, Ireland)	Ashland	company	unknown	2026-09-01
`src-gr-13`	Resorbable Polymers Market Size & Share Analysis - Growth Trends and Forecasts (2025-2030)	Mordor Intelligence	industry report	2025	2026-09-01
`src-gr-14`	Company registry record - revenue, financial result and headcount	Rusprofile	database	unknown	2026-09-01
`src-gr-15`	Registration of medical devices under national rules will end by 2028	Eurasian Economic Commission	official statistics	unknown	2026-09-01
`src-gr-16`	Analyst synthesis of stages 03 and 05: TAM triangulation and its 1.97x spread, merchant/captive and custom-slice splits behind the SAM, null competitor market shares in all seven country files, inferred gross-margin band, and supplier requalification cycle estimates	Market-audit pipeline (stages 03 and 05)	llm knowledge	2026-09-01	2026-09-01
`src-gr-17`	Analyst knowledge: Chinese domestic resorbable-polyester producer landscape and price floor, captive polymerisation inside large device OEMs, and the concentrated upstream supply of implant-grade lactide and glycolide monomer	Market-audit pipeline (stage 09 synthesis)	llm knowledge	2026-09-01	2026-09-01
`src-cn-01`	Bioresorbable Medical Material Global Market Report 2026 - Size, Forecast to 2030	The Business Research Company	industry report	2026	2026-09-01
`src-cn-02`	Resorbable Polymers Market Size & Share Analysis - Growth Trends and Forecasts (2025-2030)	Mordor Intelligence	industry report	2025	2026-09-01
`src-cn-03`	Bioresorbable Polymers Market Size & Share Report, 2030 (USD 1.30bn in 2022, 13.8% CAGR)	Grand View Research	industry report	unknown	2026-09-01
`src-cn-04`	RESOMER bioresorbable polymers for medical devices — grades, forms and ASTM F2313 compliance	Evonik Industries AG	company	unknown	2026-09-01
`src-cn-05`	PURASORB bioresorbable polymer portfolio — device and drug-delivery grades, Shanghai office	Corbion N.V.	company	unknown	2026-09-01
`src-cn-06`	Analyst knowledge: unit economics of specialty medical-materials supply, qualification cycle length, programme mortality in pre-filing device and pharma development, and captive integration in absorbable-device converters	Model knowledge	llm knowledge	unknown	2026-09-01
`src-cn-07`	Analyst knowledge: NMPA regulatory pathways for medical device raw materials — Medical Device Master File registration, excipient bundled review (关联审评审批), and licence-item change control on registered devices. NOTE: NMPA and CMDE registries were unreachable from this network, so no registration number for any supplier could be verified	Model knowledge	llm knowledge	unknown	2026-09-01
`src-cn-08`	Analyst knowledge: Russia-China settlement conditions, secondary-sanctions caution among Chinese banks since 2024, and the effect of a UAE/Delaware contracting entity on counterparty banking versus goods-origin exposure	Model knowledge	llm knowledge	unknown	2026-09-01
`src-cn-09`	Analyst knowledge: China B2B digital channel gating — Baidu paid search advertiser licensing, ICP filing requirements for China-hosted sites, and 1688 domestic-seller eligibility versus Alibaba.com international	Model knowledge	llm knowledge	unknown	2026-09-01
`src-cn-10`	PLGA Market Size & Share 2026-2032	360iResearch	industry report	2026	2026-09-01
`src-cn-11`	Bioresorbable Polymers Market Growth & Forecast, 2025-2035	Future Market Insights	industry report	2025	2026-09-01
`src-cn-12`	Evonik RESOMER RG 502 H (PLGA 50:50, acid-terminated) catalogue pricing — USD 109/1 g, USD 350/5 g; companion pages 719900 (RG 504 H), 719870 (RG 503 H), 719854 (RESOMER L 206 S PLLA)	Krackeler Scientific (authorised Sigma-Aldrich distributor)	database	unknown	2026-09-01
`src-cn-13`	Corbion PURASORB and Ashland Viatel price list — USD 30/g at 1-9 g, USD 20/g at 50 g+; PLC 7015 PLCL USD 35/g; PDLG 5505G USD 200/g	Akina Inc / PolySciTech	company	unknown	2026-09-01
`src-cn-14`	济南岱罡生物工程有限公司 (Jinan Daigang Biomaterial) — bioresorbable monomer, polymer and converted-form catalogue with QC specification; ICP 鲁ICP备11027909号-1	Jinan Daigang Biomaterial Co., Ltd.	company	unknown	2026-09-01
`src-cn-15`	深圳市博立生物材料有限公司 (Shenzhen Polymtek Biomaterial) — PGA, PLLA, PDLLA, PDLA, PLGA, PCL, PDO, PTMC resin range; import-substitution positioning; ICP 粤ICP备2022096756号	Shenzhen Polymtek Biomaterial Co., Ltd.	company	unknown	2026-09-01
`src-cn-16`	惠州华阳医疗器械有限公司 (Foryou Medical) — FORUSORB®/华素宝® monomer and polymer raw-material brand (glycolide, L-lactide, DL-lactide, p-dioxanone, TMC, PGA, PLGA); ISO 13485 and CE claims; ICP 粤ICP备15063100号	Foryou Medical Devices Co., Ltd.	company	unknown	2026-09-01
`src-cn-17`	汉商集团 Hanshang Group 2024 Annual Report — Chengdu Dikang Zhongke PDLLA/PLLA raw-material sales, absorbable bone screw Class III registration, medical device segment revenue RMB 82.57M	Hanshang Group Co., Ltd. (SSE: 600774)	official statistics	2025-05-16	2026-09-01
`src-cn-18`	长春圣博玛生物材料有限公司 (Changchun Sinobiomaterials) — medical-grade PLA, PLGA, PCL and mPEG-PLGA producer; maker of 艾维岚, China's first approved PLLA facial injectable (2021)	Changchun Sinobiomaterials Co., Ltd.	company	unknown	2026-09-01
`src-cn-19`	山东省生物医药科学院有限公司 (Shandong Institute of Biomedicine, spun off from 山东省药学科学院 in 2019) — PLLA/PDLA/PDLLA, PGA, PEG/mPEG, PCL, PTMC, PPDO for anti-adhesion membrane, stent material and embolisation agents	Shandong Institute of Biomedicine Co., Ltd.	company	unknown	2026-09-01
`src-cn-20`	ChemicalBook Chinese PLGA supplier listings with quoted prices — 青岛泛太化学 PLGA RMB 20,001/kg; 上海紫一试剂厂 PLGA RMB 2,680/50 g; companion PCL listing CB9498981 at RMB 4,000/100 g	ChemicalBook	database	unknown	2026-09-01
`src-cn-21`	中国缝合线行业市场规模 — China suture market RMB 4.39bn (2015) to RMB 8.62bn (2022), absorbable share ~79%, J&J Ethicon ~50% share	智研咨询 (Zhiyan Consulting)	industry report	unknown	2026-09-01
`src-cn-22`	Rimless Industry / Reborn PLLA — medical PLLA, PDLLA and PCL resin at USD 10-15/g and PLLA/PCL microspheres at USD 25-30/g, 100 g MOQ (trading company, stated capacity 1 kg/month)	Rimless Industry Co., Ltd.	company	unknown	2026-09-01
`src-cn-23`	成都市南丁医用材料有限公司 (Chengdu Nanding) — ISO 13485, class 10k/100k/300k cleanrooms, ~100 kg/month surgical-implant-grade PLA, PDLLA/PLLA microspheres meeting YY/T 0661 and YY/T 0510	bio-equip.com	database	unknown	2026-09-01
`src-cn-24`	China regenerative aesthetic injectables — market to RMB 11.52bn by 2027 at 54.7% CAGR 2021-25 (头豹研究院); 艾维岚 213,300 vials cumulative to April 2024; Imeik 濡白天使 893,600 vials FY2024 with units down 11.2% YoY	21世纪经济报道 (21st Century Business Herald), citing 头豹研究院 and company filings	news	2024	2026-09-01
`src-cn-26`	《政府采购进口产品审核指导标准（2021年版）》财库便函〔2021〕551号 (Ministry of Finance with MIIT, ~2021-10-12) — 137 medical device categories at 100% domestic procurement, 12 at 75%, 24 at 50%, 5 at 25%. NO DIRECT URL: this is a 便函, an internal circular issued to provincial finance departments and public institutions rather than a publicly published regulation; the document number and the device-category breakdown were verified through Chinese medtech commentary, but the governing text itself is not publicly retrievable	中华人民共和国财政部 (Ministry of Finance) with 工业和信息化部 (MIIT)	other	2021-10-12	2026-09-01
`src-cn-25`	中国生物医用材料行业市场规模 — RMB 173bn (2016) to RMB 485.7bn (2021), CAGR 22.9% (all biomedical materials, far broader than bioresorbable polymer scope)	观研报告网 (Chinabaogao)	industry report	unknown	2026-09-01
`src-cn-28`	国家药监局公告 2021年第36号 — 医疗器械主文档登记 (Medical Device Master File) scheme; scope covers 原材料; registration is voluntary (自愿行为); imported master file owners must file through a Chinese agent (境内代理机构); no review occurs at registration	国家药品监督管理局 (NMPA) via gov.cn	official statistics	2021-03-05	2026-09-01
`src-cn-29`	CMDE 主文档登记信息公示 — public master file registry, 1,555 entries, latest M2026337-000 dated 2026-08-21. Independently re-verified in this run: Evonik Operations holds exactly one master file and it is bone-conductive PEEK (M2024162-000), Corbion/普拉克 appears nowhere, while ~10 Chinese firms hold bioresorbable polymer files including injectable-grade PLGA. Page disclaimer: registration does not mean the file has been reviewed or used in a marketed device	国家药品监督管理局医疗器械技术审评中心 (CMDE)	database	2026-08-21	2026-09-01
`src-cn-30`	国家药监局公告 2019年第56号 — 原辅包与制剂关联审评审批; overseas excipient suppliers may register via a resident representative office or Chinese agent with a Chinese-language dossier and joint liability; only APIs get standalone review, so an excipient registration stays at status 'I' until a customer's drug application pulls it to 'A'	国家药品监督管理局 (NMPA)	official statistics	2019-07-16	2026-09-01
`src-cn-31`	CDE 原辅包登记平台 public list — 19,845 registrations; prefixes Y (API), F (excipient), B (packaging); columns include 与制剂共同审评审批结果 A\|I. No PLGA excipient F-number for any supplier could be queried — the database is JS-driven and not query-addressable	国家药品监督管理局药品审评中心 (CDE)	database	unknown	2026-09-01
`src-cn-32`	《无源医疗器械产品原材料变化评价指南》(CMDE) — raw-material changes fall into four categories, with supplier change (供应商、牌号) in the lowest-risk bucket ④; the registrant performs a risk assessment and decides whether 变更注册 or 首次注册 is required	CMDE guideline, via Osmunda	industry report	unknown	2026-09-01
`src-cn-33`	《医疗器械注册与备案管理办法》(市场监管总局令第47号) 许可事项变更 analysis — the enumerated triggers are 产品名称、型号规格、结构及组成、适用范围、产品技术要求、进口医疗器械的生产地址; raw-material supplier is NOT among them	CIRS Group	industry report	unknown	2026-09-01
`src-cn-34`	《新化学物质环境管理登记办法》生态环境部令第12号 (effective 2021-01-01) — Art. 2 scope covers research, production, import and processing; the exclusion list covers pharmaceuticals including APIs, pesticides, cosmetics and food but NOT medical devices and NOT excipients; Art. 10 tiers 常规登记 ≥10 t/y, 简易登记 1-10 t/y, 备案 <1 t/y or low-concern polymer; Art. 11 allows a foreign entity to hold the registration via a PRC agent	中华人民共和国生态环境部 (MEE)	official statistics	2020-05-07	2026-09-01
`src-cn-35`	New polymer registration under China MEE Order 12 — degradable/unstable polymers are expressly excluded from the low-concern polymer record-filing (备案) route above 1 tonne/year and must instead apply for 简易登记 or 常规登记; ChemLinked separately confirms medical devices are absent from the Order 12 exclusion list	ChemLinked	industry report	unknown	2026-09-01
`src-cn-36`	环境保护部公告2013年第1号 — 中国现有化学物质名录 (IECSC) 2013 public base list. Text-searched in this research: PCL (CAS 24980-41-4), a PDLLA/lactide copolymer (9051-89-2), ε-caprolactone, glycolide and lactic acid are present; PLA/PLLA (26100-51-6), PGA (26124-68-5) and PLGA (26780-50-7, 34346-01-5) were NOT found. Caveat: this is the 2013 public base list only, later supplements and a confidential portion are not published, so absence is not proof a substance is new	中华人民共和国环境保护部 (now MEE)	official statistics	2013-01-31	2026-09-01
`src-cn-37`	《关于在政府采购中实施本国产品标准及相关政策的通知》国办发〔2025〕34号 — MOF explanatory Q&A. Effective 2026-01-01. 本国产品 status turns on attribute change (属性改变) occurring inside China's customs territory; domestic component-cost ratios and key-component rules are to be set per product category within five years; qualifying products receive a 20% price deduction for evaluation purposes only	中国政府采购网 / 财政部 (Ministry of Finance)	official statistics	2025-09-30	2026-09-01
`src-cn-38`	China HS tariff lines for bioresorbable polymer forms — PLA resin 3907700000 (MFN 6.5%); PGA/PLGA/PCL/PLCL resin 3907999990 (MFN 6.5%); monofilament/3D-print filament 3916909000 (MFN 10%); tubing 3917390000 (MFN 6.5%); film 3920999090 (MFN 6.5%); import VAT 13% on all lines	HS编码网 (hsbianma.com)	database	unknown	2026-09-01
`src-cn-39`	《2026年关税调整方案》(税委会公告2025年第11号, effective 2026-01-01) — checked directly: no 暂定税率 (interim reduced duty) applies to any of the relevant Chapter 39 lines, and Russia/EAEU are absent from both the 协定税率 (24 FTAs, 34 partners) and 特惠税率 annexes, confirming Russian goods pay the MFN column with no preference	中华人民共和国商务部 (MOFCOM) / 国务院关税税则委员会	official statistics	2025	2026-09-01
`src-cn-40`	China's 2025 trade with Russia posts first decline in five years — US$228.1bn, down 6.9% year on year	Reuters	news	2026-01-14	2026-09-01
`src-cn-41`	China-Russia payment frictions — Sberbank at SPIEF (June 2026): payment routes require additional intermediary banks which often reject payments without explanation; context of EU listing of Chinese banks in the 18th (July 2025) and 19th (October 2025) packages	South China Morning Post	news	2026-06	2026-09-01
`src-in-01`	India Surgical Sutures Market Size, Share & Analysis 2034	IMARC Group	industry report	2025	2026-09-01
`src-in-02`	PLGA Companies — Evonik (Germany), Corbion NV (Netherlands) and Nomisma Healthcare Pvt. Ltd. (India)	MarketsandMarkets	industry report	unknown	2026-09-01
`src-in-03`	Nomisma Healthcare Private Limited — company profile, PLGA and PLA product range	IndiaMART / Nomisma Healthcare	company	unknown	2026-09-01
`src-in-04`	Nomisma Healthcare — company profile, founding, headcount and financials	Tracxn	database	2026	2026-09-01
`src-in-05`	PURASORB bioresorbable polymer portfolio	Corbion	company	unknown	2026-09-01
`src-in-06`	RESOMER bioresorbable polymers for medical devices	Evonik Industries	company	unknown	2026-09-01
`src-in-07`	RESOMER biodegradable polymers for medical device applications — research grades and catalogue	Merck / Sigma-Aldrich	company	unknown	2026-09-01
`src-in-08`	How much does PLGA polymer cost? — catalogue and bulk price observations for RESOMER and PURASORB	Polylactide.com	other	unknown	2026-09-01
`src-in-09`	Russia trade guide 2026: opportunities, payment challenges and compliance for Indian firms	Pazago	other	2026	2026-09-01
`src-in-10`	Russian banks open vostro accounts in India — Special Rupee Vostro Account mechanism explained	Drishti IAS	other	unknown	2026-09-01
`src-in-11`	How India became a global leader in generic injectables	India Brand Equity Foundation (IBEF)	industry report	unknown	2026-09-01
`src-in-12`	Growing complex injectable portfolio — Indian depot, long-acting injectable and PLGA microsphere programmes	Pharma Focus Asia	industry report	unknown	2026-09-01
`src-in-13`	Types of Drug Master Files (DMFs) — Type IV excipient DMF	US Food and Drug Administration	official statistics	unknown	2026-09-01
`src-in-14`	CDSCO MD-15 licence for importing medical devices into India, and treatment of raw materials and components	Pharmadocx Consultants	other	unknown	2026-09-01
`src-in-15`	Meril Life Sciences unveils indigenously developed bioresorbable scaffold MeRes100 in India	Medical Dialogues	news	unknown	2026-09-01
`src-in-16`	MeRes100 — 100 micron thin-strut sirolimus-eluting PLLA bioresorbable vascular scaffold	Meril Life Sciences	company	unknown	2026-09-01
`src-in-17`	Polyglycolic acid (PGA) sutures — Petcryl, first Indian PGA suture brand	Dolphin Sutures / Futura Surgicare Pvt. Ltd.	company	unknown	2026-09-01
`src-in-18`	India surgical sutures market — industry growth, size and forecast	Mordor Intelligence	industry report	unknown	2026-09-01
`src-in-19`	India to begin formal FTA negotiations with Russia-led Eurasian Economic Union — Terms of Reference signed 20 August 2025, 18-month roadmap	News On Air (Prasar Bharati)	news	2025-08	2026-09-01
`src-in-20`	IMCD acquires India's Signet Excipients — consolidation of Indian pharma-excipient distribution	CHEManager	news	unknown	2026-09-01
`src-in-21`	Barentz acquires Indian chemical distributor Anshul Life Sciences (August 2024)	Borderless	news	2024-08	2026-09-01
`src-in-22`	India paid USD 14.6 billion of imports in rupees over March-May 2026 — rupee settlement volumes with Russia	EcoNiti Daily Brief	news	2026-07-25	2026-09-01
`src-in-23`	Analyst derivation — bottom-up sizing, unit economics, CAC and go-to-market cost model for India built from the price, market and channel sources in this registry	—	llm knowledge	2026-09-01	2026-09-01
`src-in-24`	Indian banks approved for Special Rupee Vostro Accounts for trade with Russia (UCO, Indian Bank, HDFC, YES, IndusInd, IDBI, Canara, Union Bank, SBI)	Business Standard	news	unknown	2026-09-01
`src-in-25`	GST rate and HSN code for plastics and articles thereof — Chapter 39	ClearTax	other	unknown	2026-09-01
`src-ie-01`	Council Regulation (EU) 2022/1904 of 6 October 2022 amending Regulation (EU) No 833/2014 (8th sanctions package) - Annex VI replacing Annex XXI, and amendments to Article 3i	Official Journal of the European Union / EUR-Lex	other	—	2026-09-01
`src-ie-02`	Council Regulation (EU) No 833/2014 concerning restrictive measures in view of Russia's actions destabilising the situation in Ukraine	Official Journal of the European Union / EUR-Lex	other	—	2026-09-01
`src-ie-03`	Frequently asked questions on sanctions adopted following Russia's military aggression against Ukraine - Medicines and Medical Devices	European Commission, DG FISMA	other	—	2026-09-01
`src-ie-04`	Frequently asked questions on sanctions adopted following Russia's military aggression against Ukraine - Import, Purchase and Transfer of Listed Goods	European Commission, DG FISMA	other	—	2026-09-01
`src-ie-05`	EU adopts 21st package of Russia sanctions (23 July 2026) - law firm analyses	Baker McKenzie Sanctions News; Bird & Bird; Covington & Burling	news	—	2026-09-01
`src-ie-06`	Irish Medtech Awards launched as sector reaches EUR 20 billion in exports with 50,000 employed	Ibec / Irish Medtech Association	industry report	—	2026-09-01
`src-ie-07`	MedTech Sector: Shaping the Future; and Ireland's Rise as a Global Life Sciences Hub	IDA Ireland	official statistics	—	2026-09-01
`src-ie-08`	Ashland announces and completes expansion of Viatel bioresorbable polymers manufacturing and R&D capabilities in Mullingar, Ireland	Ashland Inc. (investor relations) and IDA Ireland	company	—	2026-09-01
`src-ie-09`	Viatel bioresorbable polymers - product portfolio	Ashland Inc.	company	—	2026-09-01
`src-ie-10`	PURASORB bioresorbable polymer portfolio - lactide, glycolide, caprolactone and PEG (co-)polymers	Corbion	company	—	2026-09-01
`src-ie-11`	RESOMER biodegradable polymers for medical device and drug delivery applications	Evonik Health Care / Merck (Sigma-Aldrich)	company	—	2026-09-01
`src-ie-12`	Aran Biomedical (formerly Proxy Biomedical), Galway - resorbable implants, medical textiles and stent encapsulation	Aran Biomedical	company	—	2026-09-01
`src-ie-13`	Medtech Ireland: Galway, EUR 20bn in exports and 50,000 jobs	Enable Research	industry report	—	2026-09-01
`src-ie-14`	Ireland's MedTech Ecosystem - Ireland Market Insights 2025	Flanders Investment and Trade	industry report	—	2026-09-01
`src-ie-15`	Stage 03 global market analysis - medical-grade bioresorbable polymers (internal)	Market audit pipeline, 03-global-market.json	other	—	2026-09-01
`src-ie-16`	Analyst assessment - bioresorbable polymer pricing, ISO 13485 supplier qualification practice, EU banking and freight de-risking, and Irish medtech site composition	LLM analyst knowledge	llm knowledge	—	2026-09-01
`src-ie-17`	Resotech Polymer Solutions - contact page (UAE and US addresses; no Russian address listed)	Resotech Polymer Solutions / medical-polymer.com	company	—	2026-09-01
`src-kz-01`	Регистрация медицинских изделий по национальным правилам завершится к 2028 году	Eurasian Economic Commission (ЕЭК)	official statistics	2025-12-30	2026-09-01
`src-kz-02`	Регистрация медицинских изделий по национальным правилам завершится к 2028 году — Новости Евразийского экономического союза	Альта-Софт	news	2025-12-30	2026-09-01
`src-kz-03`	RuMa Farm — О компании: современный шовный материал, хирургическая нить	RuMa Farm (ТОО)	company	2026	2026-09-01
`src-kz-04`	Инструкция по медицинскому применению: хирургический стерильный синтетический рассасывающийся шовный материал Ruma Farm (Румакрил — гликолид 90% + L-лактид 10%; полигликолид; кетгут)	Комитет контроля медицинской и фармацевтической деятельности МЗ РК / ПРГ	official statistics	2016-11-21	2026-09-01
`src-kz-05`	Отечественная продукция на фармрынке Казахстана занимает 40,3%	Kapital.kz — Центр деловой информации	news	2026-08-28	2026-09-01
`src-kz-06`	Казахстан нарастил производство лекарств	365info.kz	news	2026-05	2026-09-01
`src-kz-07`	National Bank comments on sanctions against VTB Kazakhstan	Tengrinews	news	2025-10-31	2026-09-01
`src-kz-08`	19th package of sanctions against Russia: EU targets Russian energy, third-country banks and crypto providers	Council of the European Union	official statistics	2025-10-23	2026-09-01
`src-kz-09`	More Central Asian Banks Sanctioned by the EU	The Diplomat	news	2025-10-24	2026-09-01
`src-kz-10`	Рынок медицинского оборудования в России и СНГ 2025: тенденции и перспективы	Luminorica	industry report	2025-04-11	2026-09-01
`src-kz-11`	Macroporous 3D Printed Structures for Regenerative Medicine Applications	Nazarbayev University Research Portal	academic	2024	2026-09-01
`src-kz-12`	Bioabsorbable polymers — price evidence (Evonik RESOMER, Corbion PURASORB, medical grade)	IndexBox	database	2026	2026-09-01
`src-kz-13`	Формат НС — шовные хирургические материалы в Казахстане (официальный дистрибьютор «Футберг», Беларусь и «МЗКРС шовные материалы», Россия)	Формат НС (Астана)	company	2026	2026-09-01
`src-kz-14`	Купить мезонити в Казахстане — цены, оптом и в розницу с доставкой в клинику	Origomed	company	2026	2026-09-01
`src-kz-15`	Polpharma-SANTO (Химфарм, Шымкент) — о компании и производстве	SANTO / Polpharma	company	2026	2026-09-01
`src-kz-16`	Nobel Almaty Pharmaceutical Factory — company and production capacity profile (350m tablets, 150m capsules, 20m bottles of syrup, 10m tubes of creams)	Nobel AFF (profile document)	company	2024	2026-09-01
`src-kz-17`	Abdi Ibrahim Global Pharm — corporate profile	Abdi Ibrahim Global Pharm (Almaty)	company	2026	2026-09-01
`src-kz-18`	LLM domain knowledge: EAEU customs and indirect-tax mechanics for Russia-to-Kazakhstan supply, Kazakhstani local-content (СТ-KZ) regime, medical-polymer supply-chain economics and qualification practice, Kazakh B2B sales culture	Model internal knowledge (Claude)	llm knowledge	2026	2026-09-01
`src-kz-19`	LLM estimate — no keyword API connected: Kazakhstan search volumes and CPC for Russian- and Kazakh-language bioresorbable-polymer terms	Model internal knowledge (Claude)	llm knowledge	2026	2026-09-01
`src-kz-20`	Most Kazakh banks not servicing Russian Mir cards due to sanctions	Interfax	news	2024-04-03	2026-09-01
`src-kz-21`	ТОО «Ультрамедтех KZ» — шовный хирургический материал в Казахстане (SOLUS-910 рассасывающийся)	Ультрамедтех KZ	company	2026	2026-09-01
`src-kz-22`	Evonik Health Care — RESOMER bioresorbable polymers	Evonik Industries AG	company	2026	2026-09-01
`src-kz-23`	Corbion PURASORB — polymers for medical devices	Corbion N.V.	company	2026	2026-09-01
`src-kz-24`	Resotech Polymer Solutions — Contact (UAE: FZ, The Meydan Hotel, Grandstand, 6th floor, Meydan Road, Nad Al Sheba, Dubai, +971 56 183 2814; USA: 251 Little Falls Drive, Wilmington, New Castle County, Delaware 19808; no Russian address or entity listed)	Resotech Polymer Solutions	company	2026	2026-09-01
`src-ru-01`	Регистрация медицинских изделий по национальным правилам завершится к 2028 году	Альта-Софт (EAEU news digest)	news	2025-12-30	2026-09-01
`src-ru-02`	Продлена возможность регистрации медицинских изделий по национальным правилам	Евразийская экономическая комиссия	news	2023-02	2026-09-01
`src-ru-03`	Биополимеры медицинского назначения PLGA, PGA, PLA от российского производителя НОВОХИМ	НПК «Новохим», Томск	company	unknown	2026-09-01
`src-ru-04`	Медицинские полимеры производства компании Resotech Polymer Solutions	Resotech Polymer Solutions	company	unknown	2026-09-01
`src-ru-05`	Resotech Polymer Solutions - bioresorbable polymers and forms	Resotech Polymer Solutions	company	unknown	2026-09-01
`src-ru-06`	ООО «ИНТЕХНОБИОМЕД» (ИНН 7326043718) - реквизиты, финансовая отчётность, руководство	Rusprofile	database	2026	2026-09-01
`src-ru-07`	Полилактид-ко-гликолид с полиэтиленгликолем (PEG-PLGA) - производитель ЭкоТек	НПО ЭкоТек	company	unknown	2026-09-01
`src-ru-08`	Поли-L-молочная кислота (полилактид) PLLA - производитель ЭкоТек	НПО ЭкоТек	company	unknown	2026-09-01
`src-ru-09`	ПОЛИГЛИКОЛИД (PGA) шовный материал, ПТО Медтехника, Россия - цены	Деалмед	company	unknown	2026-09-01
`src-ru-10`	Полилактид - производители и поставщики	ePolymer	database	unknown	2026-09-01
`src-ru-11`	Октреотид-лонг микросферы (Фармстандарт) - официальная инструкция по применению	Medi.ru	company	unknown	2026-09-01
`src-ru-12`	Октреотид-депо (Фарм-Синтез) - состав: сополимер DL-молочной и гликолевой кислот 560 мг	Аптека.ру	company	unknown	2026-09-01
`src-ru-13`	Октреотид-депо - цена от 28 600 руб., инструкция по применению	ASNA	database	unknown	2026-09-01
`src-ru-14`	Постановление Правительства РФ от 23.12.2024 № 1875 «О мерах по предоставлению национального режима при осуществлении закупок…»	Официальное опубликование правовых актов	other	2024-12-23	2026-09-01
`src-ru-15`	Постановление Правительства РФ от 30.04.2020 № 617 об ограничениях допуска отдельных видов промышленных товаров - разъяснения	ГАРАНТ.РУ	other	unknown	2026-09-01
`src-ru-16`	Materials firms pulling some business in Russia as Ukraine conflict continues	Plastics News	news	2022	2026-09-01
`src-ru-17`	Medical Sanctions Against Russia: Arresting Aggression or Abrogating Healthcare Rights?	The American Journal of Bioethics (Taylor & Francis)	academic	2024	2026-09-01
`src-ru-18`	Шовный материал «ЛИНТЕКС» / «ВОЛОТЬ» (Россия) - каталог	МедАМС	company	unknown	2026-09-01
`src-ru-19`	Bioresorbable Medical Material Global Market Report 2026 - Size, Forecast to 2030	The Business Research Company	industry report	2026	2026-09-01
`src-ru-20`	Analyst judgement: Russian resorbable-polymer demand base, qualification cycles, pricing structure, CAC and cost-base modelling	—	llm knowledge	—	2026-09-01
`src-ru-22`	Resotech Polymer Solutions - contact page listing UAE (Meydan Free Zone, Dubai) and US (Wilmington, Delaware) addresses	Resotech Polymer Solutions	company	unknown	2026-09-01
`src-ru-21`	Биорезорбируемые композиционные материалы для остеосинтеза: обзор современных исследований	КиберЛенинка	academic	unknown	2026-09-01
`src-tr-01`	Tibbi Cihaz Endustrisinde Yerlilesme Vizyonu ve Stratejik Ihtiyac Analizi (Localisation Vision and Strategic Needs Analysis in the Medical Device Industry)	TUSEB - Turkiye Saglik Enstituleri Baskanligi (Turkish Health Institutes Presidency)	official statistics	2025	2026-09-01
`src-tr-02`	Turkiye Ilac ve Tibbi Cihaz Kurumu Tibbi Cihaz Sektor Belgesi Yayinlandi (TITCK Medical Device Sector Report Published)	Gun + Partners	industry report	2024-04	2026-09-01
`src-tr-03`	Notice to Stakeholders: EU-Turkey Customs Union Agreement in the Field of Medical Devices	European Commission, DG SANTE and DG NEAR	official statistics	2022-03	2026-09-01
`src-tr-04`	Dogsan Tibbi Malzeme San. A.S. - Hakkimizda (About Us)	Dogsan	company	unknown	2026-09-01
`src-tr-05`	Katsan Tibbi Cihazlar - 2025 Urun Katalogu (2025 Product Catalogue)	Katsan Tibbi Cihazlar	company	2025-02	2026-09-01
`src-tr-06`	Boz Medical - Surgical Sutures (Absorbable Range)	Boz Medikal / Boz Tibbi	company	unknown	2026-09-01
`src-tr-07`	IMCD becomes new distributor for Evonik's RESOMER medical device polymers	Evonik Industries AG	company	2025-07	2026-09-01
`src-tr-08`	PURASORB bioresorbable polymers for medical devices	Corbion N.V.	company	unknown	2026-09-01
`src-tr-09`	Healthcare Resource Guide: Turkey	US Department of Commerce, International Trade Administration	official statistics	unknown	2026-09-01
`src-tr-10`	Exclusive: Turkish-Russian trade hit by fresh US sanctions threat	SWI swissinfo.ch / Reuters	news	2024	2026-09-01
`src-tr-11`	Russian Sanctions Compliance Guide 2024-2026	ComplyFactor	other	2026	2026-09-01
`src-tr-12`	Turkish Banks Close Russian Corporate Accounts Over Secondary Sanctions	The Moscow Times, citing Vedomosti	news	2024-02-01	2026-09-01
`src-tr-13`	Turkey TITCK Medical Device Registration Guide 2026: Process, Fees and Timeline	MedDeviceGuide	other	2026	2026-09-01
`src-tr-14`	PLGA supplier price listings (medical-grade and industrial-grade)	Made-in-China.com	database	2026	2026-09-01
`src-tr-15`	Turkish Lira Forecast 2026: Managed Depreciation Continues	NAGA	news	2026	2026-09-01
`src-tr-16`	TST Orthopedic Implants - company profile	TST Rakor Tibbi Aletler	company	unknown	2026-09-01
`src-tr-17`	Turkey Trade with Russia: Market Performance and Evaluation 2025	TradeInt	other	2025	2026-09-01
`src-tr-18`	LLM domain knowledge - bioresorbable polymer industry economics, medical device supplier qualification practice, and Turkish market structure	Claude (Anthropic)	llm knowledge	—	2026-09-01
`src-tr-19`	Turkey, Russia trade in national currencies, to similarly pay for gas	TASS	news	unknown	2026-09-01
`src-tr-20`	Turkey Medical Device Registration and Authorized Representative	Freyr Solutions	other	unknown	2026-09-01
`src-tr-21`	Resotech Polymer Solutions - Contact	Resotech Polymer Solutions (RPS)	company	unknown	2026-09-01
`src-us-01`	Bioresorbable Polymers Market Size & Share Report, 2030 - North America share 32.5% (2022)	Grand View Research	industry report	2023	2026-09-01
`src-us-02`	Bioresorbable Medical Material Global Market Report 2026 - Size, Forecast to 2030	The Business Research Company	industry report	2026-01	2026-09-01
`src-us-03`	Harmonized Tariff Schedule of the United States - line-level General and Column 2 rates queried for HTS 3907.70.00.00 (PLA: 6.5% general, 15.4c/kg + 45% Column 2), 3907.99.50 (other polyesters: 6.5% general, 15.4c/kg + 45% Column 2), 3006.10.01.00 (sterile absorbable suture materials and adhesion barriers: Free general, 40% Column 2), 5404.19.80 (monofilament: 6.9% general, 50% Column 2), 3920.99 (plastic film: 4.2-6% general, 25-35% Column 2)	United States International Trade Commission	official statistics	2026	2026-09-01
`src-us-04`	Russia Column 2 Rates of Duty	U.S. Customs and Border Protection	official statistics	2022	2026-09-01
`src-us-05`	Russia's Trade Status, Tariffs, and WTO Issues - Suspending Normal Trade Relations with Russia and Belarus Act (Pub. L. 117-110); Column 2 rates average ~32.3% versus ~3.3% MFN	Congressional Research Service	official statistics	2024	2026-09-01
`src-us-06`	Publication of Russian Harmful Foreign Activities Sanctions Regulations Web General Licenses 6D, 8J, 25D, 98, 99, and 100	Federal Register / U.S. Department of the Treasury, Office of Foreign Assets Control	official statistics	2024-08-14	2026-09-01
`src-us-07`	Selected General Licenses Issued by OFAC - GL 6D, Transactions Related to Agricultural Commodities, Medicine, Medical Devices, Replacement Parts and Components (12 June 2024, no expiration date)	U.S. Department of the Treasury, Office of Foreign Assets Control	official statistics	2024-06-12	2026-09-01
`src-us-08`	viatel ultrapure bioresorbable polymers - GMP compliant, FDA Drug Master File 33847; portfolio expanded June 2025	Ashland Inc.	company	2025	2026-09-01
`src-us-09`	Evonik commissions advanced biomaterials production facility in Birmingham, Alabama - 2,800 sq m, multiple cleanrooms (ISO 8), reactors, purification and micronization systems, for RESOMER bioresorbable polymers	Evonik Industries AG	company	2020	2026-09-01
`src-us-10`	PURASORB bioresorbable polymers for medical devices and controlled drug delivery	Corbion N.V.	company	2025	2026-09-01
`src-us-11`	Bioresorbable Medical Device Manufacturing - vertically integrated single source from bioresorbable polymer through finished device or component; standard and customized medical-grade resins produced on site (Anderson, South Carolina)	Poly-Med, Inc.	company	2025	2026-09-01
`src-us-12`	Foster - medical materials, implantable polymers, custom formulation and regulatory compliance across durable and bioresorbable grades (Putnam, Connecticut)	Foster, LLC / PolySource	company	2025	2026-09-01
`src-us-13`	Resorbable Polymers Market Size & Share Analysis - Growth Trends and Forecasts (2025-2030); market concentration characterised as medium	Mordor Intelligence	industry report	2025	2026-09-01
`src-us-14`	Bioresorbable Polymers Market to Reach USD 867.2 million by 2029, growing at a CAGR of 11.6%	MarketsandMarkets (via GlobeNewswire)	industry report	2026-08-17	2026-09-01
`src-us-15`	RESOMER and LACTEL bioresorbable polymers for parenteral controlled release	Evonik Industries AG	company	2025	2026-09-01
`src-us-16`	Evonik to acquire Birmingham-based LACTEL Absorbable Polymers from DURECT Corporation (USD 15m)	Evonik Industries AG	news	2016	2026-09-01
`src-us-17`	PolySciTech (Akina, Inc.) - research-scale PLGA, PLA, PCL and PEG copolymers, custom synthesis, West Lafayette, Indiana	Akina, Inc.	company	2025	2026-09-01
`src-us-18`	RESOMER RG 503 H, Poly(D,L-lactide-co-glycolide) acid terminated, lactide:glycolide 50:50, Mw 24,000-38,000 - catalogued in 5 g and 25 g pack sizes (research grade, price on sign-in)	MilliporeSigma / Merck KGaA	company	2026	2026-09-01
`src-us-19`	OFAC Issues Amended Russia-Related General Licenses and Related FAQs - GL 6D amended to cover the 12 June 2024 Tech Services Determination	Baker McKenzie, Global Sanctions and Export Controls Blog	news	2024	2026-09-01
`src-us-20`	General Licenses Applicable to the Russia Sanctions - status and scope of GL 6 series; EO 14024 and EO 14114 framework	ArentFox Schiff LLP	news	2025	2026-09-01
`src-us-21`	Analyst judgement: US merchant-versus-captive split for resorbable polymer, buyer-count build-up, FDA supplier change-control practice (21 CFR 807.81(a)(3), 814.39, 314.70), vendor-onboarding sanctions screening behaviour, CAC/LTV and entry-cost modelling, and keyword volume and CPC estimates. No keyword API connected; no public pricing exists for GMP bioresorbable resin - repeated searches for RESOMER and PURASORB per-kg pricing returned quotation-only responses.	Model knowledge	llm knowledge	2026-05	2026-09-01

Executive Summary

Markets ranked — best first

The market in four numbers

Global Market Overview

What counts as this market

What does not

Market state

Neighboring markets

What customers use it for

Problems this market exists to solve

Global Market Size & Growth

Total market worldwide

Part we could serve

Realistic 3-year target

What pushes the market up

What could hold it back

Country Ranking

Screening — all 30 candidates we considered

Country Deep Dives

The market here

Who buys

What hurts them today

What buyers search for — demand is Growing

Searches nobody answers well yet

Who we'd compete with — 6 companies est.[in-02] [in-03] [in-05] [in-06] [in-07] serious vendors, moderate market

Customers they leave behind

Rules & barriers to enter

Culture & language hurdles

How we'd win customers

The money math

What could go wrong here

The market here

Who buys

What hurts them today

What buyers search for — demand is Flat

Searches nobody answers well yet

Who we'd compete with — 4 competitors est.[kz-12] [kz-18] serious vendors, moderate market

Customers they leave behind

Rules & barriers to enter

Culture & language hurdles

How we'd win customers

The money math

What could go wrong here

The market here

Who buys

What hurts them today

What buyers search for — demand is Growing

Searches nobody answers well yet

Who we'd compete with — 6 competitors est.[ru-03] [ru-07] [ru-08] [ru-10] [ru-20] serious vendors, fragmented market

Customers they leave behind

Rules & barriers to enter

Culture & language hurdles

How we'd win customers

The money math

What could go wrong here

The market here

Who buys

What hurts them today

What buyers search for — demand is Growing

Searches nobody answers well yet

Who we'd compete with — 8 suppliers est.[us-08] [us-09] [us-10] [us-11] [us-12] [us-13] serious vendors, moderate market

Customers they leave behind

Rules & barriers to enter

Culture & language hurdles

How we'd win customers

The money math

What could go wrong here

The market here

Who buys

What hurts them today

What buyers search for — demand is Growing

Searches nobody answers well yet

Who we'd compete with — 6 vendors est.[ie-08] [ie-09] [ie-10] [ie-11] [ie-15] [ie-16] serious vendors, concentrated market

Customers they leave behind

Rules & barriers to enter

Culture & language hurdles

How we'd win customers

The money math

What could go wrong here

The market here

Who we'd compete with — 6 companies est.^{[in-02] [in-03] [in-05] [in-06] [in-07]} serious vendors, moderate market

Who we'd compete with — 4 competitors est.^{[kz-12] [kz-18]} serious vendors, moderate market

Who we'd compete with — 6 competitors est.^{[ru-03] [ru-07] [ru-08] [ru-10] [ru-20]} serious vendors, fragmented market

Who we'd compete with — 8 suppliers est.^{[us-08] [us-09] [us-10] [us-11] [us-12] [us-13]} serious vendors, moderate market

Who we'd compete with — 6 vendors est.^{[ie-08] [ie-09] [ie-10] [ie-11] [ie-15] [ie-16]} serious vendors, concentrated market

Who we'd compete with — 15 vendors est.^{[cn-14] [cn-15] [cn-16] [cn-17] [cn-18] [cn-19] [cn-04] [cn-05]} serious vendors, fragmented market